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Summary!Intravesical!drug!delivery!(IDD)!offers!a!unique!opportunity!to!target!pathology!of!the! lower!urinary! tract.!High! concentrations!of!drug! can!be!delivered!directly! to!the!bladder!with!minimal!systemic!absorption.!IDD!has!been!used!successfully!to!manage!a!range!of!conditions!such!as!bladder!cancer!and!overactive!bladder!and!continues!to!be!investigated!for!novel!indications.!Despite!this!the!majority!of!IDD!regimens!remain!empirically!driven!and!as!a!result!its!potential!largely!unfulfilled.!!!This! thesis! developed! and! validated! an! ex' vivo! porcine!model! to! investigate! the!transurothelial! delivery! and! bladder! wall! distribution! of! drugs! after! topical!application! to! the! urothelium.! Using! the! model,! transurothelial! permeability!coefficients!were!determined!and!tissue!layer!specific!bladder!wall!concentrations!calculated! for! a! range! of! clinically! relevant! drugs! including! ketorolac! and!oxybutynin.! The! results! of! these! studies!were! used! to! inform! on! the! viability! of!delivering! these! drugs! intravesically! in' vivo.! Additionally! a! computer! –! based!pharmacokinetic!model!of!IDD!was!developed!using!STELLA®!modelling!software.!The! model! was! used! to! investigate! the! key! variables! associated! with! IDD! and!suggest!novel!techniques!and!dosing!concepts!to!improve!its!efficacy.!For!the!first!time,! the! relative! permeability! of! the! upper! and! lower! urinary! tract! was!investigated!for!a!single!drug.!Ex'vivo!porcine!ureteral!urothelium!was!shown!to!be!significantly!more!permeable!to!mitomycin!C!than!that!of!the!bladder.!If!translated!into! human,! the! more! permeable! urothelium! may! provide! higher! target! tissue!concentrations!after!local!delivery!and!a!significant!opportunity!to!manage!upper!tract!urothelial!carcinoma!conservatively.!!This!project!developed!novel!ex'vivo!and!in'silico!methods!to!investigate!IDD.!These!techniques!can!be!used!to!rationally!inform!on!the!design!of!new,!or!optimisation!of!existing,!IDD!regimens.!! !
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1.1.! The$Urinary$Bladder# !!Located!behind! the!pubic!symphysis! in! the!pelvic!cavity,! the!bladder! is!a!hollow,!distensible!sac!that!provides!a!reservoir!for!urine!prior!to!micturition!(Figure!1.1).!Collapsed!when!empty,!it!expands!upon!filling!adopting!a!balloon!T!like!shape!as!its!capacity!increases.!The!bladder!is!highly!flexible!and!capable!of!stretching!to!hold!large!volumes!of!urine,!whilst!being!able!to!contract!and!expel!urine!once!a!certain!capacity! is! reached1.! When! fully! distended,! the! adult! human! bladder! has! a!maximum!capacity!of!~!800!mls2,!however!a!strong!urge!to!void!is!usually!initiated!at!25!T!50!%!of!maximum!capacity!beyond!which!voluntary!control!diminishes2,3.!!!
!!
Figure!1.1.!Anatomy!of!the!male!urinary!tract.!The!bladder!lies!in!the!pelvic!cavity!between!











1.1.1.#Structure#of#the#bladder#wall#The!bladder!wall! is!comprised!of!a!number!of!distinct! layers:!urothelium,! lamina!propria,!detrusor!muscle!and!adventitia!/!serosa!(Figure!1.3)7.!!!!The!urothelium!forms!the!inner!lining!of!the!organ,!separating!the!contents!of!the!bladder! lumen! from! the! underlying! bladder! wall.! It! covers! the! entire! luminal!surface,!transitioning!to!ureteral!and!proximal!urethral!urothelium!at!the!ureteral!and!internal!urethral!orifices!respectively8.!Owing!to!the!triangular!shape!formed!between! the! ureteral! and! urethral! openings,! this! region! of! the! bladder! base! is!known! as! the! trigone! (Figure! 1.2).! The! thickness! of! the! urothelium! varies!depending! on! the! extent! of! bladder! distension9.! In! the! contracted! bladder! the!human!urothelium!is!~!5!–!7!cells!thick,!whilst!in!the!distended!state!it!can!be!as!thin!as!2!–!3!cells10.!The!urothelium!is!a!highly!specialised!barrier!to!the!movement!of! substances! from! the! urine! back! into! systemic! circulation! and! is! discussed!further!in!section!1.1.2.!!!
!!
Figure!1.2.!Anatomically,! the! interior!of! the!bladder! lumen! is! separated! into! the!posterior!
wall,!anterior!wall!(not!shown),!lateral!walls,!dome!region!and!trigone11.!The!trigone!is!the!



















































1.1.2.#Structure#of#the#Urothelium#The! urothelium! is! the! principal! barrier! to! the! permeation! of!molecules! into! the!bladder!wall16.!It!is!a!highly!differentiated,!stratified!epithelial!layer!that!lines!not!only!the!bladder!but!also!the!apical!surface!of!the!renal!pelvis,!ureters!and!upper!urethra16.! The! urothelium! consists! of! three! distinct! layers;! umbrella! cells,!intermediate! cells! and! a! basal! layer17,18.! The! superficial! umbrella! cells! line! the!apical!surface!of!the!bladder;!they!are!the!largest!of!the!three!cell!types!(diameter!~!50!T!120!µm)!and!vary!in!diameter!depending!on!the!distension!of!the!bladder.!Below! lie! the! intermediate! cells! (diameter! ~! 20! µm)! whilst! the! basal! layer,!consisting!of!germinal!cells!(diameter!~!5!T!10!µm),!lines!the!basolateral!side!of!the!urothelium16.! Cell! recycling! involves! progenitor! basal! cells! migrating! and!differentiating! into! intermediate! cells! which! in! turn! are! partially! differentiated!forms! of! the! distinct! umbrella! cells19.! The! intermediate! and! basal! layers! are!unremarkable! in! morphology! and! investigations! have! shown! that! they! pose! no!significant!barrier!to!the!movement!of!substances!through!the!bladder!wall17,20,21.!Rather! it! is! the!umbrella! cells! that! are! responsible! for! the! impermeability! of! the!urothelium!and!they!are!highly!differentiated!to!fit!their!role!as!the!rate!T!limiting!permeation!barrier.!!








































































Figure! 1.8.! In! IC! /! PBS,! a! deficiency! in! the! protective! GAG! layer! results! in! an! increased!
exposure!of!irritant!solutes!such!as!potassium!(K+)!to!the!urothelium,!resulting!in!localised!
inflammation,!irritation!and!pain.!Figure!adapted!from!Pohl!Boskamp!Ltd67.!























































































Figure!1.10.!The!number!of! IDD! G! related!scientific!publications!published!between!2012!and!2014.!Data!was!obtained!by!searching!Pubmed!using! the!key!
words!‘intravesical’!+!‘drug’.!The!search!was!limited!to!articles!published!between!01/01/2012!and!31/12/2013.!The!search!yielded!371!articles,!of!which!109!
were! excluded! on! the! basis! of! relevance.! Articles!were! then! stratified! into! four! groups:! bladder! cancer! (‘Cancer’),! ‘Cystitis’,! overactive! bladder! (‘OAB’)! or!
‘Other’! depending! on! their! relevant! therapeutic! area.! Cancer,! cystitis! and! OAB! included! all! varieties! of! bladder! cancer,! cystitis! and! bladder! dysfunction!
respectively.!All!articles!outside!of!these!parameters!were!grouped!into!‘Other’!and!this!included!UTIs,!local!analgesia,!bladder!spasm!and!haematuria.!Articles!
were! then! further! stratified! into! ‘Pre! G! clinical! research’,! ‘Reviews’! or! ‘Clinical! studies’.! Pre! G! clinical! research! included!all! in#vivo! and! in#vitro! pre! G! human!
investigations.! Reviews! included! all! reviews,! round! G! table! discussions,! treatment! guidelines! and! patterns! of! practice.! Clinical! studies! included! all! clinical!
trials,!case!G!series,!case!reports,!cohort!studies!and!retrospective!analysis.! !



























Figure! 1.11.! A)! List! of! licensed! intravesical! therapies! currently! available! in! the! UK.! B)! Number! of! finished! consultant! episodes! (FCEs)!where! the! primary!
diagnosis!was!bladder!cancer,!IC!/!PBS!or!OAB!in!England!NHS!trusts!between!2012!and!2013121,122.!There!were!70,294!intravesical!treatments!administered!in!
England!NHS!trusts!between!2012!and!2013121,122.!*!Stratified!data!for!the!indication!of!treatment!was!not!available.!!






Pathology Product Active1agent Marketing1authorisation1holder
Cancer Mitomycin-C Kyowa® Mitomycin-C (MMC) ProStrakan Ltd
Cancer ImmuCyst® Bacillus Calmette-Guerin (BCG) Alliance Pharmaceuticals Ltd
Cancer Valstar® Valrubicin Endo Pharmaceuticals Ltd
Cancer Doxorubicin (generic) Doxorubicin Actavis Ltd
Cancer Thiotepa (generic) Thiotepa Boehringer Ingelheim Ltd
IC/PBS Uracyst® sodium chondroitin sulfate Stellar Pharmaceuticals Inc
IC/PBS Gepan® sodium chondroitin sulfate Pohl Boskamp Ltd
IC/PBS iAluril® sodium hyaluronate + chondroitin sulfate Aspire Pharmaceuticals Ltd
IC/PBS Hyacyst® sodium hyaluronate Syner-Med Ltd
IC/PBS Cystistat® sodium hyaluronate Bioniche Life Sciences Inc
OAB BOTOX® Onabotulinumtoxin-a Allergan Ltd
OAB Dysport® Abobotulinumtoxin-a Ipsen Ltd
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1.2.2.$Advantages$of$IDD$IDD! has! a! number! of! advantages,! the!most! significant! of!which! is! targeted! drug!delivery123.! High! concentrations! of! drug! can! be! delivered! directly! to! the! luminal!surface!of! the!bladder!wall7.! For! specific!pathologies,! such!as! superficial! bladder!cancer,!this!is!the!site!of!action!of!the!drug124.!For!other!indications!the!target!may!be! deeper! in! the! bladder! wall! within! the! lamina! propria! or! detrusor! muscle!layers125.!In!these!instances!the!topical!application!of!high!concentrations!of!drug!should! favour! transurothelial! permeation! and! the! subsequent! accumulation! of!drug! in! these! layers.! Compared! to! IDD,! the! bladder! wall! bioavailability! of!systemically!delivered!drugs!is!small!and!large!doses!are!often!required!to!deliver!effective! concentrations7.!Furthermore,! systemic!absorption!after! IDD! is!minimal!and! consequently! adverse! I! effect! profiles! are! highly! favourable! compared! to!systemic!therapy123.!Additional!advantages!relate!to!the!anatomy!and!accessibility!of! the!bladder126.! IDD!is!minimally! invasive;! the!bladder!can!be!accessed!directly!through! the! urethra! without! surgery.! Therapy! therefore! can! be! conducted! in!outpatient! clinics! minimising! morbidity! /! mortality! risks! to! the! patient! and!negating!the!need!for!overnight!hospital!admission.!Additionally,!an!instilled!dose!can!be!immediately!removed!if!necessary.!If!a!patient!has!a!local!allergic!reaction!to!an!instilled!drug!solution,!the!bladder!can!be!instantly!drained!and!subsequently!flushed!with!saline.!The!same!cannot!be!said!for!systemically!I!introduced!targeted!delivery! strategies127! or! even! organ! I! targeted! injections128.! IDD! is! also! highly!flexible;!instillation!volumes,!concentrations!and!durations!can!be!tailored!to!suit!a!particular!therapy,!indication!or!even!patient.!
1.2.3.$Disadvantages$of$IDD$Despite!its!advantages,!IDD!has!several!inherent!limitations.!Even!in!the!diseased!state,! the! urothelium! has! evolved! to! prevent! the! movement! of! small! molecules!back! into! the! bloodstream! and! hence! its! permeability! to! drugs! is! low7.!Subsequently,! although! high! concentrations! of! drug! may! be! introduced! to! the!bladder!surface,!concentrations!achievable!beyond!the!urothelium!are!usually!low!and! often! subtherapeutic126.! Several! normal! physiological! processes! associated!with! the! urinary! tract! hinder! IDD.! Urine! produced! by! the! kidneys! is! constantly!draining! into! the! bladder! diluting! the! instilled! drug! solution.! At! a! normal! urine!
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production!rate!(~1!ml!min91!129),!a!30!ml!instillation!of!drug!will!have!decreased!in!concentration! by! at! least! 50!%! after! only! 30!min.! Furthermore,! the! bladder! has!limited!capacity!and!voiding!excretes!the!entire!dose.!This!limited!residence!time!means!that!a!constant!concentration!gradient!across!the!bladder!wall!can!only!be!maintained!for!a!limited!period!of!time.!Because!it!requires!catheterization,!IDD!is!impractical!as!a! long!–! term!therapy.!Unless! the!patient!practices! intermittent!or!permanent! catheterization,! frequent! IDD! dosing! is! inconvenient.! This! is!highlighted! by! the! fact! that! with! the! exception! of! bladder! cancer,! IDD! is! a!secondary! treatment! option! initiated! only! subsequent! to! failed! oral!management130.!As!IDD!requires!catheterization,!it!also!increases!the!risk!of!UTIs!and! bleeding131,132.! Finally,! although! perhaps! not! an! inherent! limitation,! a!significant! pitfall! of! IDD! is! the! way! in! which! regimens! are! designed! and!implemented.!The!majority!of!IDD!regimens!are!empirically!driven,!with!minimal!scientific,! clinical!or!physiological!understanding!underpinning! treatment!design.!Examples! include! poor! choice! of! instillation! volume109,! arbitrary! instillation!times133!and!dosing!concentrations!derived!without!knowledge!of!resulting!target!bladder!wall! drug! concentrations109.! As! a! result! IDD! remains! poorly! understood!and!its!potential!unfulfilled.!
1.2.4.%Advancements%in%IDD%Considering!the!barrier!function!of!the!urothelium!restricts!the!penetration!of!drug!into!the!bladder!wall,!one!way!to!improve!IDD!is!to!minimize!TEER.!This!has!been!approached!in!two!ways:!physical!methods!to!perturb!barrier!function!and!the!use!of! chemical! permeation! enhancers7.! The! most! commonly! exploited! physical!method! is! iontophoresis! (also! referred! to! as! Electromotive! Drug! Administration!(EMDA)),! a! form! of! electrophoresis! that! describes! the! administration! of!water! 9!soluble! drugs! across! a! membrane! barrier! under! the! influence! of! an! electric!field134,135.!With!regard!to!the!bladder,!the!application!of!a!small!electrical!current!temporarily! disrupts! the! electrochemical! gradient! either! side! of! the! luminal!membrane! increasing! the! passive! diffusion! of! drug! molecules! through! the!urothelium!and!into!the!bladder!wall7.!Intravesical!EMDA!has!been!investigated!for!several! drugs! including!mitomycin! 9! C! (MMC)136,! oxybutynin137,! lidocaine138! and!hyaluronic! acid103! with! significantly! increased! permeation! rates! shown! versus!passive! diffusion.! Subsequently,! improved! clinical! outcomes! have! been! achieved!
! ! Chapter!One:!General!Introduction!!
! 18!




1.3.1.$Aims$The! overarching! aim! of! this! project! was! to! further! understanding! of! the! basic!science! underlying! the! IDD! process! and! in! doing! so! reduce! the! empiricism!preventing!this!drug!delivery!strategy!from!realising!its!potential.!!
1.3.2.$Objectives$The!main!objective!was!to!develop!an!ex#vivo!porcine!model!of!IDD!and!use!this!to!investigate! the! transurothelial! permeation! and! bladder! wall! distribution! of!clinically! relevant! drugs.! Investigating! the! transurothelial! permeation! of! existing!or! potential! intravesical! agents! reveals! crucial! information! about! the! target!concentrations! achievable! in! the! bladder! wall! and! subsequently! the! viability! of!delivering!drugs!in!this!manner.!This!bottom!I!up!approach!will!lead!to!the!design!of!more!rational!and!ultimately!efficient!intravesical!regimens.!
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2.1.1.$Relevant$Prologue:$Boston$Scientific$collaboration$Ureteral! stents! are! thin,! flexible,! hollow! tubes! that! are! placed! in! the! ureter!between! the! kidney! and! the! bladder1.! In! contemporary! urological! practice,! the!most! commonly!used! stent! is! the!double! I! J! or!double! I! pigtail! variety2! (the! two!names! are! used! interchangeably)! (Figure! 2.1A).! Double! I! J! stents! are! specially!designed!to!form!a!‘J’!shape!at!either!end!of!the!device.!Once!inserted,!these!ends!form!coils!in!the!kidney!and!bladder!preventing!displacement!of!the!stent3!(Figure!2.1B).!!!
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Figure!2.2.!Chemical!structure!of!ketorolac!tromethamine!!A!pre!I!clinical!safety!study!demonstrated!Lexington™!to!be!safe,!with!low!systemic!absorption! of! ketorolac! and! no! indication! of! local! urinary! tract! inflammation! or!ulceration!in!any!of!the!test!animals24.!Subsequently,!BSC!rolled!out!a!prospective,!double! I! blind,! randomised! controlled! trial! (RCT)! evaluating! the! efficacy! of!Lexington™!against!a!control!stent!after!uteroscopy21.!Surprisingly!the!Lexington™!stent! provided! no! clinical! benefit! over! the! control! group! with! suggestions! that!further!studies!with!higher!drug!concentrations!were!likely!required.!!!












line! pharmacotherapy! for!NMIBC30,! however! the! optimum!dose! is! unknown! and!the!mechanism!of!action!poorly!understood25.!!!So!despite!having!been!used! for!a!number!of!decades,! IDD!regimens,!such!as! the!one!BSC!used!to!identify!Ketorolac,!remain!largely!empirical.!Consequently!little!is!known! of! target! tissue! concentrations! achievable! or! ultimately! the! viability! of!delivering!drugs!locally!to!the!urinary!tract.!In#vivo!data!remains!limited!due!to!the!difficulty!in!obtaining!bladder!tissue!concentrations!in!human!and!animal!subjects.!Intravesical!pharmacokinetic!(PK)!studies!have!been!carried!out!for!several!drugs!including! MMC31,! doxorubicin32,! gemcitabine33! and! oxybutynin34.! While! such!investigations! reveal! valuable! information! concerning! systemic! drug! levels,! they!rarely! elucidate! concentrations! achieved! in! the! bladder! wall! or! urine.!Consequently! IDD! regimens! are! largely! based! on! clinical! outcomes! such! as!tolerability!or!perceived!benefit.!Although!such!qualitative!end!points!are!clinically!useful,! quantitative! data! on! urothelial! permeability! and! bladder! wall! tissue!distribution! is! equally! important! when! predicting! the! usefulness! of! local! drug!delivery! approaches.! BSC! believed! fundamental! research! investigating! the!transurothelial! permeability! of! ketorolac! would! help! ascertain! whether! bladder!wall! concentrations! achieved! after! local! delivery! are! sufficient! to! justify!incorporation!into!a!drug!I!eluting!ureteral!stent.!!
2.1.3.$Methods$to$investigate$transurothelial$delivery$Considering! what! has! been! discussed,! it! is! important! to! review! some! of! the!techniques! that! have! been! used! to! investigate! the! transurothelial! delivery! and!bladder!wall!distribution!of!drugs.!
2.1.3.1.$ In$vivo$studies$
In#vivo,!bladder!wall!penetration!after! IDD!has!been! investigated! in!mice35,!rats36!and! larger! animals! such! as! rabbits37,! dogs38,39! and! pigs40–43.! The! urinary! tract! of!larger!animals,!such!as!pigs,! is!anatomically!closer! in!structure!and!size!to!man44!and!subsequently!offers!significant!advantages!over!smaller!species!in!pre!I!clinical!studies.!Pig!bladders!can!hold!~!500!ml!of!urine45!(similar!to!the!human!bladder46)!whereas!the!maximum!capacity!of!the!mouse!and!rat!bladder!is!~!0.15!and!~1!ml!respectively47.!Accordingly!when!conducting!pre!I!clinical!studies!of!potential!IDD!regimens,! pharmaceutical! companies! generally! use! pigs43,48,49.! Studies! are!
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designed!to!mimic!human!IDD!regimens.!Animals!receive!instillations!(~!50!ml49)!through!a!urinary!catheter!and!the!drug!solution!is!maintained!in!the!bladder!for!the! desired! instillation! period! (usually! ~! 1! I! 2! h48,49)! prior! to! bladder! draining.!Note!only! female!pigs!are!used!as! the!shape!of! the!porcine!penis!makes!urethral!catheterisation! difficult! if! not! impossible50.! Blood! samples! are! usually! taken!periodically!after!instillation!and!urine!collected!upon!bladder!drainage48.!!!Interestingly,! two! studies! (from! the! same! research! group)! have! investigated!bladder! wall! concentrations! after! IDD! in! humans51,52.! Ethical! approval! was!obtained! to! give! intravesical! instillations! to! radical! cystectomy! patients! prior! to!the! start! of! their! surgery.! Radical! cystectomy! is! a! surgical! procedure! used! in!bladder! cancer! to! remove! the! whole! of! the! bladder! and! nearby! lymph! nodes53.!Such! studies! are! extremely! rare,! would! likely! be! impossible! to! obtain! ethical!approval!for!in!the!present!day!and!as!such!have!been!included!for!completeness!rather!than!relevance!to!current!in#vivo!techniques.!!By!their!nature,!in#vivo!studies!encompass!all!the!attributes!associated!with!a!living!animal.! For! IDD! the!major! advantages! are! dilution! of! the! instilled! dose! by! urine!and! systemic! clearance! of! drug! from! the! bladder! wall.! In# vivo! studies! in! large!animals!are! the!gold!standard!model!of! IDD!and! if!designed!correctly!can!yield!a!plethora! of! data! including! urine! pharmacokinetics,! bladder! wall! drug!concentrations!and!systemic! levels!of!drug!achieved!after! treatment40.!That! said,!bladder! wall! concentrations! are! often! neglected! in! favour! of! focusing! on! local!bladder!toxicology!and!systemic!PK48,49.!Furthermore!these!studies!are!extremely!costly!(~!$15,000!per!pig,!Tim!Harrah,!personal!communication,!June!20th,!2013)!and! as! such! are! typically! only! carried! out! when! phase! 1! human! studies! are!anticipated.! Consequently! the! majority! of! early! I! stage! research! into!transurothelial!delivery!is!investigated!in#vitro!or!ex#vivo.!
2.1.3.2.$ In$vitro$/$ex$vivo$studies$
2.1.3.2.a.! Cell!culture!systems!Although!not! used! to! investigate!delivery! across! the!urothelium,! cell! culture!has!been! used! to! investigate! the! uptake! of! chemotherapeutics! into! target! urothelial!cells54,55.!The!most!commonly!used!system! is! immortalised!human!urothelial! cell!
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cultures56,! although! normal! human! urothelial! cells! (NHU)! are! also! used57.! A!significant! limitation! from! a! drug! delivery! point! of! view! is! the! barrier! function!provided! by! these! systems.! The! immortalization! process! appears! to! prevent!normal!cellular!differentiation!and!subsequently!the!urothelial!cells!do!not!develop!a! functional! barrier58.! NHU! are! superior! to! immortalized! systems! and,! when!cultured!on!permeable!membrane!supports,!can!form!an!apparently!functional!or!‘biomimetic!urothelium’!exhibiting!significant!barrier!functionality!(TEER!values!of!>!3!kΩ!cm2)59.!Additionally,!seeding!onto!these!permeable!membranes!allows!the!modelling!of!systemic!and!intravesical!drug!exposure!by!addition!of!the!compound!the!basal!or!apical!chamber!respectively58.!Although!cell!culture!systems!provide!a!useful! tool! to! investigate! urothelial! V! drug! interactions,! they! are! less! valuable! in!terms!of!drug!delivery!studies.!Such!systems!represent!isolated!urothelium!and!do!not! therefore! permit! investigations! of! drug! distribution! into! other! layers! of! the!bladder!wall.!When!investigating!IDD,!distribution!of!drug!into!the!different!layers!of!the!bladder!wall!is!essential!as!bladder!wall!targets!may!reside!in!tissue!layers!below!the!urothelium!(Section!1.2.2).!
2.1.3.2.b.& Ex#vivo&bladder&tissue&
Ex#vivo,!bladder!wall!penetration!after!local!application!to!the!urothelium!has!been!investigated!using!rabbit60,!porcine61!and!human62!bladder!tissue.!Although!whole!bladder!models!have!been!reported63,64,!the!majority!of!studies!use!sections!of!ex#
vivo!bladder!tissue! loaded! into!diffusion!apparatus61,65–68.!Typically!drug!solution!is! applied! to! the! bladder! surface! and! removed! after! a! predefined!period! of! time!representative!of!the!intravesical!instillation!period67.!Unlike!urothelial!cell!culture!systems,! full! thickness! sections! of! bladder! tissue! allow! determination! of! drug!concentrations!throughout!the!bladder!wall.!An!established!technique!to!do!this!is!concentration!V!depth!profiling!where!bladder!tissue!exposed!to!drug!is!sectioned!parallel! to! the! urothelial! surface! all! the! way! down! to! the! serosal! side! of! the!tissue61.! This,! in! combination! with! knowledge! of! tissue! V! layer! depths,! allows!quantitation!of!drug!in!the!different!layers!of!the!bladder!wall!and!has!been!used!to!investigate!the!IDD!of!agents!such!as!paclitaxel66!and!docetaxel67.!!!
Ex#vivo!studies,!while!more!feasible!than!in#vivo!work,!are!inherently!limited!by!the!absence! of! systemic! drug! clearance! and! processes! such! as! urine! dilution! and!periodic! voiding! which! are! fundamental! to! IDD28! (Section! 1.2.3).! To! date,! no!
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studies! have! sought! to! incorporate! allowances! for! these! processes! into! ex# vivo!studies.!Furthermore!many!of!the!investigations!reported!have!done!little!to!verify!the! suitability! of! the! ex# vivo! urothelial! barrier! as! a! model! for! transurothelial!permeation61,65,69,70.! In! terms!of! apparatus,! examples! include! the!use!of! diffusion!cells! without! a! receiver! chamber! to! supply! the! tissue! with! buffer69,70,! whilst!experimentally! basic! histological! studies! are! often! relied! on! to! demonstrate!urothelial! barrier! function62.! A! recent! study! used! de! I! frosted! porcine! bladder!tissue! to! investigate! transurothelial! delivery;! histological! analysis! showed!abnormal!looking!tissue!with!minimal!evidence!of!an!intact!urothelium71.!
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2.2.1.$$ Materials$All! chemicals!were!purchased! from!Sigma! I!Aldrich,!Poole,!UK!and!were!used!as!received! unless! otherwise! stated.! All! organic! solvents! were! of! HPLC! grade! and!were!obtained!from!Fisher!Scientific,!Loughborough,!UK!unless!otherwise!stated.!
2.2.2.$Analysis$of$propranolol$hydrochloride$Propranolol! hydrochloride! was! analysed! by! high! –! performance! liquid!chromatography!(HPLC)!using!a!Thermo!Scientific!HPLC!automated!system!fitted!with!a!Kromasil,!5!µm,!C18,!250!mm!x!4.6!mm!i.d!column!(Sigma!I!Aldrich,!Poole,!UK).!The!mobile!phase!consisted!of!70!%!acetonitrile!(ACN)!:!30!%!sodium!dodecyl!sulfate!(10!mM),!disodium!hydrogen!phosphate!(10!mM)!adjusted!to!pH!2.3!with!phosphoric!acid.!UV!detection!was!set!at!290!nm.!The!injection!volume!was!20!µl!and!flow!rate!1!ml!minI1.!!
2.2.3.$Analysis$of$sodium$fluorescein$Sodium! fluorescein! was! analysed! by! fluorescence! (Fluostar! Optima! microplate!reader,! BMG! Labtech! GmbH,! Ortenburg,! Germany).! The! excitation! and! emission!wavelengths!were!set!at!485!nm!and!520!nm!respectively.!!
2.2.4.$Analysis$of$ketorolac$tromethamine$Ketorolac!was!analysed!by!HPLC!(2.2.2).!The!mobile!phase!consisted!of!60!%!0.02!M! phosphate! buffer! (adjusted! to! pH! 3.5! with! phosphoric! acid)! :! 40!%! ACN.! UV!detection!was!set!at!315!nm.!The! injection!volume!was!20!µl! and! flow!rate!1!ml!minI1.!
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Accurate! separation!of! the!bladder!mucosa! from! the!underlying!detrusor!muscle!was!confirmed!histologically.!The!mucosa!was!removed!from!one!half!of!a!bladder!section,!leaving!the!other!half!as!full!thickness!bladder!wall.!Tissue!samples!were!fixed! to! cork!mounts!with! optimal! cutting! temperature!medium! (OCT)! (Tissue! A!Tek™,! CRYO! A! OCT! Compound,! Fisher! Scientific! UK! Ltd,! Leicestershire,! England)!and! snap! frozen! between! two!metal! plates! using! liquid! nitrogen.! Samples! were!sectioned! at! 10! µm! using! a! cryostat! (Leica! CM3050! S,! Leica! Microsystems,!Buckinghamshire,!England).!Sections!were!then!stained!with!haematoxylin!A!eosin!(H!&!E)!and!examined!by!light!microscopy.!
2.2.6.2.$ Transepithelial$electrical$resistance$(TEER)$The! integrity! of! urothelial,! paracellular! tight! junctions! (TJs)!was! investigated! by!measuring!TEER!across!the!bladder!mucosa!over!2.5!h.!The!urothelium!and!lamina!propria! was! carefully! removed! and! a! 1! cm2! section! mounted! into! an! Ussing!chamber! (NaviCyte! vertical!multichannel! Ussing! chambers,!Warner! Instruments,!Hamden,! CT,! USA).! The!mucosal! chamber!was! filled!with! 4!ml! of! either! normal!saline!or!ketorolac!1.1!mg!mlA1!in!saline,!whilst!the!serosal!chamber!was!filled!with!4!ml!of!oxygenated!Krebs!buffer.!The!Ussing!chambers!were!maintained!at!37!°C!and!after!a!10!min!equilibration!period,!TEER!across!the!mucosa!measured!at!15!min!intervals.!TEER!was!measured!using!a!multi!A!channel!voltage!–!current!clamp!(EC! A! 800! single! channel,! Warner! Instruments,! Hamden,! CT,! USA).! The! Ussing!chambers!were! equipped!with! two! pairs! of! Ag! /! AgCl! electrodes,! for!measuring!potential! difference! (V)! and! for! passing! current! (I).! The! experiments! were!performed!under!open!circuit!conditions,!whereby!the!current!was!set!to!zero!and!the! natural! transepithelial! potential! difference! could! be! observed.! Electrical!resistance!was!determined!according!to!Ohm’s!law!(R!=!V!/!I).!The!TEER!value!at!time!zero!was!taken!to!be!the!baseline!reading,!from!which!the!percentage!change!was!calculated.!TEER!was!calculated!as!the!net!electrical!resistance!of!the!mucosa!multiplied!by!the!apparent!exposed!tissue!area!of!the!Ussing!chamber!(0.12!cm2).!Percentage!change!from!baseline!TEER!was!compared!for!the!saline!and!ketorolac!groups.!All!statistical!analysis!was!performed!using!GraphPad!Prism!version!6.0c!(GraphPad!Software,!Inc,!San!Diego,!California,!USA).!Unpaired!t!A!tests!were!used!for!all!comparisons.!
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2.2.6.3.$ Scanning$electron$microscopy$(SEM)$To! further! confirm! the! integrity! of! the! urothelial! barrier! under! experimental!conditions,!bladder!tissue!was!examined!by!scanning!electron!microscopy!(SEM).!Bladder!sections!were!loaded!into!Franz!A!type!diffusion!cells!and!500!µl!of!normal!saline!(negative!control),!ketorolac!1.1!mg!mlA1!in!saline!(test!agent)!or!protamine!sulfate!10!mg!mlA1!in!saline!(positive!control)!added!to!the!donor!chamber.!After!90!min! the! contents! of! the! donor! chamber! was! discarded,! the! urothelial! surface!subjected!to!3!x!1!ml!saline!rinses!and!the! tissue!sample!removed.!An!additional!sample,! fixed!on! A! site!at! the!abattoir! immediately!post!–!excision!of! the!bladder!(approximately! 5! min! after! slaughter),! was! examined! as! a! control.! Sections! of!tissue! (~! 2! cm2)!were! carefully! cut! without! touching! the! urothelial! surface! and!fixed! in! a! solution! of! 4! %! formaldehyde! and! 0.2! %! glutaraldehyde! in! 0.1! M!phosphate!buffer! for!24!h!at!room!temperature.!Following!washing!with!distilled!water!(2!x!60!min),!tissue!samples!were!dehydrated!in!isopropyl!alcohol!solutions!of! increasing!concentrations! (50!–!100!%)!before!undergoing!chemical!drying! in!100! %! hexamethyldisilazane.! Samples! were! then! sputter! A! coated! with! gold!(Emscope! sputter! coater,! Emscope,! Ashford,! Kent,! UK)! before! SEM! examination!(5!kV,!Jeol!JSM!840A,!Tokyo,!Japan).!Images!were!acquired!with!an!ADDA!2!image!grabber! and! processed! using! Scandium! analysis! software! (Soft! Imaging! System!GmbH,!Münster,!Germany).!
2.2.7.$Evaluation$of$the$delivery$of$ketorolac$to$the$bladder$wall!
2.2.7.1.$ Permeation$of$ketorolac$across$the$urothelium$$Franz!A!type!cells!were!assembled!as!described!(Section!2.2.5)!and!a!500!µl!aliquot!of! a! 1.1! mg! mlA1! ketorolac! solution! (in! normal! saline)! applied! to! the! donor!chamber.!At!fixed!time!points!(0.5,!1,!2,!3.5!and!5!h),!the!contents!of!the!receiver!and! donor! chambers! were! collected! and! the! tissue! sample! removed.! The! tissue!was! rinsed!3!x!1!ml!with! saline!and!ketorolac!extracted! in!1!ml!of!mobile!phase!!(Section!2.2.6.1).!Drug!was!quantified!using!HPLC!(Section!2.2.4).!
2.2.7.2.$ Distribution$of$ketorolac$into$the$bladder$wall$Franz!A!type!cells!were!assembled!as!described!(Section!2.2.5)!and!a!500!µl!aliquot!of! a! 1.1! mg! mlA1! ketorolac! solution! (in! normal! saline)! applied! to! the! donor!
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chamber.! After! 90! min! the! Franz! A! type! cells! were! dismantled,! the! donor! and!receiver! compartments! collected! and! the!urothelial! surface! rinsed!3! x!1!ml!with!saline.! The! area! of! drug! contact!was! isolated,! immediately! snap! frozen! between!two! metal! plates! using! liquid! nitrogen,! fixed! to! cork! mounts! with! OCT! and! the!tissue!sectioned!using!a!cryostat! (Section!2.2.6.1).!Care!was! taken! to!ensure!OCT!was!only!present!on!the!serosal!side!of!the!tissue.!!Samples!were!serially!sectioned!parallel!to!the!urothelial!surface!at!50!µm!thickness!and!sections!collected!in!pre!A!weighed! 1.5! ml! eppendorf! tubes.! Tissue! sections! between! 0! and! 200! µm!(urothelium)!were!collected!individually!for!analysis.!Groups!of!five!50!µm!tissue!sections! between! 200! and! 1,200! µm! (lamina! propria)! and! ten! tissue! sections!between!1,200!and!3,200!µm!(detrusor!muscle)!were!collected!and!pooled!prior!to!analysis.!For!pooled!samples,!tissue!depths!were!expressed!as!the!midpoint!depth!of! the! sections.! Tissue! sections! were! then! weighed,! extracted! in! 500! µl! mobile!phase! for! 24! h! and! drug! quantified! using! HPLC! (Section! 2.2.4).! Average! tissue!concentrations! achieved! in! the! urothelium,! lamina! propria,! detrusor!muscle! and!whole!bladder!wall!were!calculated!by!dividing!the!total!amount!of!drug!recovered!by!the!total!weight!of!tissue!in!that!layer.!!
2.3.! Results'and'Discussion! !
2.3.1.$Using$ex$vivo$porcine$bladder$tissue$When!designing!an!ex#vivo!model,! fresh!human! tissue! is! the!gold!standard! tissue!upon!which! to! carry! out! investigations.! For! certain! organs,! such! as! human! skin,!obtaining! fresh! samples! is! feasible!owing! to! the! steady! supply!of! surgical! excess!tissue72.! Unfortunately! the! same! is! not! true! for! human! bladder! tissue.! Statistics!published!by!the!British!Association!of!Urological!Surgeons!(BAUS)!reported!that!only! 743! cystectomies,! across! 45! health! centres! in! England,! Scotland! and!Wales!were!performed!in!201273.!Such!a!low!procedure!rate,!an!average!of!less!than!two!cystectomies!per!health!centre!per!month,!would!not!yield!an!adequate!supply!of!human! bladders! for! this! research! project.! Considering! this,! pig! bladders! were!chosen.!!
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Porcine!bladder!tissue!was!a!natural!choice!owing!to!the!long!history!of!pigs!being!used! as! animal! models! in! urology74–76.! A! number! of! studies! have! reported! the!physiology! of! the! porcine! urinary! tract! to! be! similar! to! that! of! humans45,77,78.!Anatomically,! the!porcine!urinary!tract! is!a!good!representation!of!man79!and!for!several! decades! anaesthetised! pigs! have! been,! and! continue! to! be,! used! for!urological!surgical!training44,80.!Histological!analysis!has!shown!parallels!between!the! structure! and! composition! of! the! porcine! and! human! bladder! wall;! both!comprise!an!ordered!layering!of!urothelium,!lamina!propria,!detrusor!muscle!and!adventitia81–83.! An! additional! advantage! of! procuring! abattoir! A! derived! porcine!tissue!concerns!ethical!approval.!As!none!of!the!animals!at!an!abattoir!are!killed!for!experimental!reasons,!ethical!approval!is!not!required.!!
2.3.2.$Confirmation$of$tissue$viability$
2.3.2.1.$ Tissue$procurement$and$transportation$The!ability!to!obtain!fresh!tissue!was!considered!essential!to!this!project.!Porcine!bladders! were! obtained! immediately! at! the! time! of! excision,! the! total! warm!ischemic! time! between! killing! the! animal! and! bladder! retrieval!was! consistently!under!10 min.!Bladders!were! transported! from!the!abattoir! in!oxygenated!Krebs!buffer84.!Krebs!is!a!balanced!salt!solution!used!to!maintain!tissue!at!a!physiological!pH! and! ensure! intracellular! and! extracellular! osmotic! balance85.! It!was! a! logical!choice!based!on! its! extensive!use! in!ex#vivo! full! bladder86,87! and! isolated!bladder!tissue!studies66,67,88,89.!!!Buffer! was! made! fresh! for! each! experiment! and! was! cooled! such! that! the!temperature!during!bladder!transportation!was!~!4!°C.!Cooling!prevents!hypoxic!injury!by!reducing!cellular!metabolism!and!therefore!the!oxygen!requirements!of!the! organ90.! The! van't!Hoff! A! Arrhenius! law! states! that! the! rate! of! a! biochemical!reaction!is!halved!for!each!10!°C!decrease!in!temperature91!and!data!obtained!from!perfused!rat!livers!has!shown!oxygen!requirements!to!be!significantly!reduced!at!lower! temperatures! compared! to! 37! °C90.! Such! cooling! techniques! are! used! in!organ! transplantation,! where! hypothermia! remains! the! principal! method! of!maintaining!organ!viability!during!ischaemic!transfer!from!donor!to!recipient90.!In!addition! to! cooling,! the!Krebs! buffer!was! bubbled!with! carbogen! (95!%!O2,! 5!%!CO2)!to!provide!oxygen!for!the!bladder!tissue.!Prior!to!oxygenation!the!buffer!was!
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chilled,! as! oxygen! solubility! is! higher! at! lower!water! temperatures92.! Consistent!with!other!reported!Krebs!recipes86,89,93,!the!buffer!was!modified!by!the!addition!of!glucose!to!provide!an!energy!source!for!cell!maintenance.!!
2.3.2.2.$ Investigating$markers$of$permeability$Whilst! the! literature!suggested! that!gross!bladder!viability!should!be!maintained!under! the! conditions!described66,86! (Section!2.3.2.1),! there!was!uncertainty! as! to!how! the! urothelial! barrier! function! would! be! affected! by! bladder! excision,!transport! and! experimentation.! In! addition! to! preventing! the! significant!permeation!of!molecules,! a! functional! barrier!would!be! expected! to!differentiate!between! molecules! that! permeate! paracellularly! and! those! that! permeate!transcellularly94.! Sodium! fluorescein! and! propranolol! hydrochloride! are!recognised! paracellular! and! transcellular! markers! respectively95,96.! In! this! study!the! two! compounds!were!used! to! evaluate! the! integrity! of! the!urothelial! barrier!over!6.5!h.!!






2.3.2.2.b.! Permeation! of! sodium! fluorescein! and! propranolol!
hydrochloride!into!the!bladder!wall!Figure!2.6A!shows!the!amount!of!each!marker!permeated!across!the!mucosa!over!time,! normalised! to! the! surface! area! of! the! urothelium.! This! was! calculated! by!summing! the! amount! of! drug! extracted! from! the! detrusor!muscle! and! any! drug!recovered! from! the! receiver! compartment.! Figure! 2.6B! shows! the! successful!removal! of! the!mucosa! (urothelium! and! lamina! propria! (U! and! LP))! leaving! the!underlying! detrusor! muscle! (M).! Apparent! permeability! coefficients! (Kp),!calculated! by! normalising! the! transurothelial! flux! to! the! concentration! of! drug!applied!to!the!urothelium!at!time!zero,!were!5.1!x!10A6!cm!sA1!and!1.3!x!10A6!cm!sA1!for!propranolol!hydrochloride!and!sodium!fluorescein!respectively.!Over!6.5!h!the!permeation!rate!of!both!molecules!was!constant,! indicative!of! little!change!in!the!tissue’s! behaviour.! Furthermore! the! calculated! Kp! values! were! distinct! and,!although!there!are!no!directly!comparable!figures!available!in!the!literature,!in!the!same!range!as!those!reported!for!other!small!molecules!such!as!urea!(5.1!x!10A05!cm!sA1)97!and!ammonia!(6.4!x!10A05!cm!sA1)97.!!
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Propranolol hydrochloride (left Y-axis)
Sodium fluorescein (right Y-axis)  
Kp = 1.33 x 10
-6 cm s-1








































2.3.2.3.$ Transepithelial$electrical$resistance$(TEER)$TEER!is!an!established!method!of!investigating!the!paracellular!permeability!of!the!urothelium98–100.! By! assessing! the! resistance! across! bladder! mucosa,! the!maintenance!of!umbrella!cell!TJs!crucial!to!the!barrier!function!of!the!urothelium!can! be! evaluated.! Absolute! TEER! and! deviation! from! baseline! TEER! across! the!bladder!mucosa!was!investigated!after!the!application!of!saline!(negative!control)!and!ketorolac! to! the!urothelium! (Figure!2.7).!At! time! zero,! average!TEER!values!were! 8.3! and! 7.8! kΩ! cm2! for! the! saline! and! ketorolac! samples! respectively;!indicative!of!tight!epithelia101.!Although!not!previously!reported!for!ex#vivo!porcine!bladder,!these!values!are!comparable!to!those!in!the!literature!for!fully!functional!






























































































































Figure!2.9.!A! closer! look!at! SEM!micrographs!of!ex%vivo! porcine!bladder! tissue! loaded! into!
Franz! <! type! diffusion! cells! and! treated! with! 1.1! mg! ml<1! ketorolac! (A)! and! 10! mg! ml<1!
protamine! sulfate! (B)! for! 90! min.! Tissue! exposed! to! ketorolac! displayed! normal! tissue!
morphology!with!exemplar!polygonal!umbrella!cells!(traced!blue!for!clarity).!Umbrella!cell!
membrane! shedding! (red! arrow)! and! whole! cell! lysis! (red! circle)! was! evident! in! the!
protamine!group.!







about! a! therapeutic! effect.! We! chose! therefore! to! use! a! 1.1! mg! mlM1! ketorolac!solution!in!our!ex#vivo!studies.!!
2.3.3.1% Analysis%of%ketorolac%tromethamine%%HPLC!analysis!of!ketorolac!produced!narrow,!near!symmetrical!peaks!eluting!at!a!stable!retention!time!(Figure!2.11).!Analyte!quantitation!(based!on!peak!area)!was!calculated! using! an! external! standard! solution! ranging! in! concentration! from!0.0011! to! 11! µg! mlM1! (Figure! 2.10).! Calibration! curves! were! run! in! triplicate! to!ensure! reproducibility! and! showed! high! linearity! across! the! expected! analyte!concentration! range.! The! LLOD! and! LLOQ! was! 0.0173! and! 0.0575! µg! mlM1!respectively.! There! was! minimal! analyte! peak! interference! in! the! homogenised!bladder!tissue!and!background!noise!was!low!enabling!good!precision!around!the!LLOQ!(Figure!2.11C).!! !!!!!!!!!!!!!
Figure!2.10.!External!standard!calibration!curve!used!in!the!HPLC!analysis!of!ketorolac.!!
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Ketorolac 0.5 µg ml-1 (standard)










































ml!aliquot!of!1.1!mg!ml=1!ketorolac!solution!according! to! the!methods!described! in!section!
2.2.7.1.!(n!=!10!tissue!samples!from!2!bladders!± !SD).!
!Figure! 2.13A! shows! that! ketorolac! was! capable! of! permeating! across! the!urothelium.!Drug!permeated!in!a!linear!fashion!and!after!5!h!approximately!60!µg!cmJ2!of!ketorolac!had!permeated!into!the!bladder!wall.!An!apparent!transurothelial!Kp! value! of! 2.63! x! 10J6! cm! sJ1! was! calculated! by! normalising! the! flux! to! the!concentration!applied!to!the!donor!chamber!at!time!zero.!Results!of!mass!balance!analysis! showed! good! recovery! of! drug! from! the! Franz! J! cell! apparatus!with! an!average!95.2!%!of!the!applied!ketorolac!dose!recovered!per!sample!(Figure!2.13B).!Over! the! 5! h! experiment! the! majority! of! drug! remained! in! the! donor! chamber,!whilst!the!amount!accumulating!in!the!bladder!tissue!increased!steadily!with!time.!Drug! was! only! present! in! the! receiver! compartment! for! the! 5! h! time! point,!constituting!~!0.2!%!of!the!applied!ketorolac!dose.!



































Figure! 2.13.! (A)! Permeation! profile! of! 1.1! mg!ml81!ketorolac! across! porcine! bladder! urothelium,! permeability! coefficients! (Kp,! cm! s81)! were! calculated! by!
normalising! the! flux! (J,!µg!cm82!s81)! to! the!dosing!concentration.! (B)!Mass!balance!analysis!of! the!recovery!of!ketorolac! from!the!Franz! 8! type!cell! setup!per!
sampling!timepoint.!(n!=!4!tissue!samples!from!2!bladders!±!SD).!
































































2.3.3.2$ Distribution$of$ketorolac$into$the$bladder$wall$According! to! the! mean! urination! time! reported! in! the! BSC! intravesical! study22,!ketorolac!would!have!been!voided!from!the!bladder!after!~!90!min.!Given!this,!an!endpoint! of! 90!min!was! chosen! in! this! study.! To! understand! the! distribution! of!ketorolac! into! the! different! layers! of! the! bladder! wall,! a! concentration! K! depth!profile!was!constructed!(Figure!2.14A).! !Tissue!K!layer!depths!for!porcine!bladder!wall! were! based! on! those! reported! in! the! literature66.! Drug! concentrations!declined!with!tissue!depth!with!average!concentrations!of!400,!141!and!21!µg!gK1!achieved! in! the! urothelium,! lamina! propria! and! detrusor! muscle! respectively!(Figure!2.14B).! In!agreement!with!others!who!have!performed!similar!studies!on!








midpoint! depth! of! the! sections.! IC50! represents! the! top! 5! end! value! reported! at! COX! 5! 1! and! COX! 5! 2! for! ketorolac110.! (B)! Corresponding! average! ketorolac!
concentrations!achieved!in!the!urothelium!(0!5!200!µm),!lamina!propria!(200!–!1,200!µm),!detrusor!muscle!(1,200!–!3,200!µm)!and!whole!bladder!wall!(0!–!
3,200!µm)!after!90!min!(B).!(n!=!5!bladders!±!SD).!













































































The!production!of!prostaglandins!within!the!bladder!wall!is!well!established!with!synthesis!occurring!not!only!in!the!detrusor!muscle!but!also!within!the!urothelium!and!lamina!propria117–119,!all!of!these!regions!can!therefore!be!taken!to!be!targets!for! the! IDD! of! ketorolac.! After! 90! min! the! total! concentration! in! these! target!regions!was!87!µg!gL1.!The!reported!potency!of!ketorolac,! in! terms!of! IC50!values,!varies!widely!with! top! end! values! of! 31.5! and! 60.5!µM! for! COX! L! 1! and! COX! L! 2!respectively110.! Taking! the! average! bladder! wall! concentration! of! 87! µg! gL1! and!making!the!assumption!that!1!g!of!bladder!tissue!has!a!volume!of!~!1!cm3,!a!target!bladder!wall!concentration!of!231.1!µM!was!achieved!after!90!min.!This!equates!to!a!predictive!ketorolac!concentration!of!at!least!seven!times!the!IC50!for!COX!L!1!and!three! and! a! half! times! the! IC50! for! COX! L! 2! at! the! site! of! action! (Figure! 2.14B),!suggesting!that!levels!of!ketorolac!in!the!bladder!wall!could!indeed!be!sufficient!to!provide!an!anti!L!inflammatory!effect.!!!It! is! important! to!point!out!however! that! these! studies!are!ex#vivo! and! therefore!have! inherent! limitations.! Systemic! clearance! and! dilution! of! the! intravesical!instillation!by!urine!are!notably!absent!in!our!model.!As!shall!be!discussed!later!in!this!thesis,!these!processes!can!have!significant!effects!on!the!delivery!of!drug!into!the! bladder!wall.! Subsequently,! concentrations! achieved! in! these! ex# vivo! studies!likely!overestimate!the!in#vivo!situation.!!
2.4.! Conclusions! !!This!chapter!described!and!validated!an!ex#vivo!porcine!bladder! tissue!model! for!studying!the!barrier!properties!of!the!urothelium!and!investigating,!in!quantitative!terms,! drug! delivery! into! the! bladder! wall.! Using! this! model! the! transurothelial!permeation!of!the!NSAID!ketorolac!was!studied!and!its!delivery!into!the!different!layers!of!the!bladder!wall!investigated.!Fundamental!studies!such!as!these!can!be!used!to! inform!on!the!viability!of!delivering!drugs! intravesically! in#vivo.!The!data!suggest!that,!in!the!ex#vivo!setting,!the!levels!of!ketorolac!delivered!to!the!bladder!wall!following!local!application!to!the!urothelium!would!be!pharmacodynamically!appropriate! to! provide! an! anti! L! inflammatory! effect.! In! practice! local! delivery!strategies! to! the! urinary! tract! are! largely! guided! by! clinical! outcome,! with! little!
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outcome,! with! little! information! available! on! target! drug! concentrations.!Investigations!such!as!those!described!here!yield!quantitative!ex#vivo!data!that!can!be! used! to! rationally! design! new! transurothelial! drug! delivery! strategies! and!optimise!existing!intravesical!drug!regimens.!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 75!
2.5.! Reference'List! !!1.!! Yachia! D,! Paterson! PJ.! Stenting! the! Urinary! System.! 2nd! ed.! London;! New!York:!CRC!Press;!2004.!!2.!! Chew! BH,! Knudsen! BE,! Denstedt! JD.! The! use! of! stents! in! contemporary!urology.!Curr!Opin!Urol.!2004!Mar;14(2):111–5.!!3.!! Finney!RP.!Experience!with!new!double!J!ureteral!catheter!stent.!J!Urol.!1978!Dec;120(6):678–81.!!4.!! Hegde! P,! Giridhar! V,! Natarajan! K.! Migration! of! forgotten! stent! into! renal!pelvis.!Indian!J!Urol.!2011;27(2):282.!!5.!! Siggers!JH,!Waters!S,!Wattis!J,!Cummings!L.!Flow!dynamics!in!a!stented!ureter.!Math!Med!Biol.!2009!Mar;26(1):1–24.!!6.!! Joshi!HB,!Keeley!Jr!FX,!Timoney!AG.!Having!a!Ureteric!Stent!c!What!to!Expect!and!How!to!Manage![Internet].!Bristol!Urological! Institute.!2000![cited!2014!Aug!28].!Available!from:!http://www.bui.ac.uk/PatientInfo/ureterstent.html!7.!! Joshi!HB,! Stainthorpe!A,!MacDonagh!R,!Keeley!F,! others.! Indwelling!ureteral!stents:! evaluation! of! symptoms,! quality! of! life! and! utility.! J! Urol.!2003;169(3):1065–9.!!8.!! Uthappa! MC,! Cowan! NC.! Retrograde! or! antegrade! doublecpigtail! stent!placement! for! malignant! ureteric! obstruction?! Clin! Radiol.! 2005!May;60(5):608–12.!!9.!! Lennon!G,!Thornhill!J,!Sweeney!P,!Grainger!R,!McDermott!T,!Butler!M.!“Firm”!versus! “soft”!double!pigtail!ureteric! stents:! a! randomised!blind!comparative!trial.!Eur!Urol.!1995;28(1):1–5.!!10.!! Joshi! HB,! Chitale! S,! Nagarajan! M,! Irving! S,! Browning! A,! Biyani! C,! et! al.! A!prospective!randomized!singlecblind!comparison!of!ureteral!stents!composed!of!firm!and!soft!polymer.!J!Urol.!2005;174(6):2303–6.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 76!
11.!! Erturk! E,! Sessions! A,! Joseph! JV.! Impact! of! ureteral! stent! diameter! on!symptoms!and!tolerability.!J!Endourol.!2003;17(2):59–62.!!12.!! Dunn!MD,!Portis!AJ,!Kahn!SA,!Yan!Y,!Shalhav!AL,!Elbahnasy!AM,!et!al.!Clinical!effectiveness!of!new!stent!design:!randomized!singlecblind!comparison!of!tail!and!doublecpigtail!stents.!J!Endourol.!2000;14(2):195–202.!!13.!! Chew!BH,!Lange!D,!Paterson!RF,!Hendlin!K,!Monga!M,!Clinkscales!KW,!et! al.!Next!generation!biodegradable!ureteral!stent! in!a!Yucatan!pig!model.! J!Urol.!2010;183(2):765–71.!!14.!! Pengfei!S,!Yutao!L,! Jie!Y,!Wuran!W,!Yi!D,!Hao!Z,!et!al.!The!results!of!ureteral!stenting! after! ureteroscopic! lithotripsy! for! ureteral! calculi:! a! systematic!review!and!metacanalysis.!J!Urol.!2011!Nov;186(5):1904–9.!!15.!! Leibovici!D,!Cooper!A,!Lindner!A,!Ostrowsky!R,!Kleinmann!J,!Velikanov!S,!et!al.!Ureteral!stents:!morbidity!and!impact!on!quality!of!life.!Isr!Med!Assoc!J.!2005!Aug;7(8):491–4.!!16.!! Joshi! HB,! Okeke! A,! Newns! N,! Keeley! Jr! F,! Timoney! A.! Characterization! of!urinary!symptoms!in!patients!with!ureteral!stents.!Urology.!2002;59(4):511–6.!!17.!! Dyer! RB,! Chen! MY,! Zagoria! RJ,! Regan! JD,! Hood! CG,! Kavanagh! PV.!Complications! of! Ureteral! Stent! Placement.! RadioGraphics.! 2002! Sep!1;22(5):1005–22.!!18.!! Saltzman! B.! Ureteral! stents.! Indications,! variations,! and! complications.! Urol!Clin!North!Am.!1988!Aug;15(3):481–91.!!19.!! Miyaoka! R,!Monga!M.! Ureteral! stent! discomfort:! Etiology! and!management.!Indian!J!Urol.!2009;25(4):455–60.!!20.!! Life!Science!Intelligence.!U.S.!Markets!for!noncvascular!stents:!Market!analysis!for!2011c2014![Internet].!Huntington!Beach,!CA;!2011![cited!2014!Jul!20]!p.!140.! Available! from:! https://www.lifescienceintelligence.com/marketcreportscpage.php?id=A255!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 77!
21.!! Krambeck!AE,!Walsh!RS,!Denstedt! JD,! Preminger!GM,! Li! J,! Evans! JC,! et! al.! A!novel! drug! eluting! ureteral! stent:! a! prospective,! randomized,! multicenter!clinical! trial! to! evaluate! the! safety! and! effectiveness! of! a! ketorolac! loaded!ureteral!stent.!J!Urol.!2010;183(3):1037–43.!!22.!! Beiko! D,! Watterson! J,! Knudsen! B,! others.! A! doublecblinded! prospective!randomized! controlled! trial! assessing! the! safety! and! efficacy! of! intravesical!agents! for! ureteral! stent! symptoms! following! extracorporeal! shockwave!lithotripsy.!J!Endourol.!2004;18(8):723–30.!!23.!! Buckley!MM,!Brogden!RN.!Ketorolac.! A! review!of! its! pharmacodynamic! and!pharmacokinetic! properties,! and! therapeutic! potential.! Drugs.! 1990!Jan;39(1):86–109.!!24.!! Chew!BH,!Davoudi!H,!Li! J,!Denstedt! JD.!An! In!Vivo!Porcine!Evaluation!of! the!Safety,! Bioavailability,! and! Tissue! Penetration! of! a! Ketorolac! DrugcEluting!Ureteral!Stent!Designed!to!Improve!Comfort.!J!Endourol.!2010;24(6):1023–9.!!25.!! Madbouly!K.!Intravesical!bacillus!CalmettecGuerin!for!bladder!cancer:!What!is!known?!What!is!not?!What!is!next?!Urol!Ann.!2013;5(2):108–9.!!26.!! Zargar!H,!Aning!J,!Ischia!J,!So!A,!Black!P.!Optimizing!intravesical!mitomycin!C!therapy! in! noncmusclecinvasive! bladder! cancer.! Nat! Rev! Urol.! 2014!Apr;11(4):220–30.!!27.!! Colombo! R,! Rocchini! L,! Suardi! N,! Benigni! F,! Colciago! G,! Bettiga! A,! et! al.!Neoadjuvant! shortcterm! intensive! intravesical! mitomycin! C! regimen!compared!with!weekly!schedule!for!lowcgrade!recurrent!noncmusclecinvasive!bladder!cancer:!preliminary!results!of!a!randomised!phase!2!study.!Eur!Urol.!2012!Nov;62(5):797–802.!!28.!! Wientjes!MG,!Badalament!RA,!Au!JL.!Use!of!pharmacologic!data!and!computer!simulations!to!design!an!efficacy!trial!of!intravesical!mitomycin!C!therapy!for!superficial! bladder! cancer.! Cancer! Chemother! Pharmacol.! 1993;32(4):255–62.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 78!
29.!! Morales! A,! Eidinger! D,! Bruce! AW.! Intracavitary! Bacillus! CalmettecGuerin! in!the!treatment!of!superficial!bladder!tumors.!J!Urol.!1976!Aug;116(2):180–3.!!30.!! Babjuk!M,!Burger!M,!Zigeuner!R,!Shariat!SF,!van!Rhijn!BWG,!Compérat!E,!et!al.!EAU!guidelines!on!noncmusclecinvasive!urothelial! carcinoma!of! the!bladder:!update!2013.!Eur!Urol.!2013!Oct;64(4):639–53.!!31.!! Maffezzini!M,!Campodonico!F,!Manuputty!EE,!Puntoni!M,!Martelli!A,!Marini!V,!et! al.! Systemic! absorption! and! pharmacokinetics! of! singlecdose! early!intravesical!mitomycin!C!after!transurethral!resection!of!noncmusclecinvasive!bladder!cancer.!Urology.!2013!Aug;82(2):400–4.!!32.!! Chai!M,!Wientjes!MG,!Badalament!RA,!Burgers!JK,!Au!JL.!Pharmacokinetics!of!intravesical! doxorubicin! in! superficial! bladder! cancer! patients.! J! Urol.!1994;152(2):374–8.!!33.!! Witjes! JA,! van!der!Heijden!AG,! Vriesema! JLJ,! Peters!GJ,! Laan!A,! Schalken! JA.!Intravesical! gemcitabine:! a! phase! 1! and! pharmacokinetic! study.! Eur! Urol.!2004!Feb;45(2):182–6.!!34.!! Krause! P,! Fuhr! U,! Schnitker! J,! Albrecht! U,! Stein! R,! Rubenwolf! P.!Pharmacokinetics! of! intravesical! versus! oral! oxybutynin! in! healthy! adults:!results!of!an!open! label,!randomized,!prospective!clinical!study.! J!Urol.!2013!Nov;190(5):1791–7.!!35.!! Hsieh!JcT,!Zhou!J,!Gore!C,!Zimmern!P.!R11,!a!novel!cellcpermeable!peptide,!as!an!intravesical!delivery!vehicle.!BJU!Int.!2011!Nov;108(10):1666–71.!!36.!! Hwang! TcL,! Fang! CcL,! Chen! CcH,! Fang! JcY.! Permeation! enhancerccontaining!watercincoil! nanoemulsions! as! carriers! for! intravesical! cisplatin! delivery.!Pharm!Res.!2009!Oct;26(10):2314–23.!!37.!! Lee!H,!Cima!MJ.!An!intravesical!device!for!the!sustained!delivery!of!lidocaine!to!the!bladder.!J!Control!Release.!2011!Jan!20;149(2):133–9.!!38.!! Song!D,!Wientjes!MG,!Au! JL.!Bladder! tissue!pharmacokinetics!of! intravesical!taxol.!Cancer!Chemother!Pharmacol.!1997;40(4):285–92.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 79!
39.!! Lu! Z,! Yeh! TcK,! Wang! J,! Chen! L,! Lyness! G,! Xin! Y,! et! al.! Paclitaxel! gelatin!nanoparticles! for! intravesical! bladder! cancer! therapy.! J! Urol.! 2011!Apr;185(4):1478–83.!!40.!! Leakakos!T,!Ji!C,!Lawson!G,!Peterson!C,!Goodwin!S.!Intravesical!administration!of!doxorubicin!to!swine!bladder!using!magnetically!targeted!carriers.!Cancer!Chemother!Pharmacol.!2003!Jun;51(6):445–50.!!41.!! BaranowskacKortylewicz! J,!Dalrymple!GV,!Harrison!KA,!Holdeman!KP,!Sharp!JG,!Cohen!SM,!et!al.!On!the!safety!of!5c[125I]iodoc2’cdeoxyuridineccPreclinical!evaluation!in!swine.!Acta!Oncol.!1996;35(7):925–33.!!42.!! Harrison! KA,! Dalrymple! GV,! BaranowskacKortylewicz! J,! Holdeman! KP,!Schneiderman! MH,! Lieberman! RP,! et! al.! Radiolabeled! iododeoxyuridine:!safety!evaluation.!J!Nucl!Med.!1996!Apr;37(4!Suppl):13S!–!16S.!!43.!! Arentsen! HC,! HulsbergencVan! de! Kaa! CA,! Jansen! CFJ,! Maj! R,! Leoni! LM,!Oosterwijk!E,!et!al.!Pharmacokinetics!and!toxicity!of! intravesical!TMXc101:!a!preclinical!study!in!pigs.!BJU!Int.!2011!Oct;108(7):1210–4.!!44.!! Tunc! L,! Resorlu! B,! Unsal! A,! Oguz!U,! Diri! A,! Gozen! AS,! et! al.! In! vivo! porcine!model!for!practicing!retrograde!intrarenal!surgery.!Urol!Int.!2014;92(1):64–7.!!45.!! Sibley!G.!An!experimental!model!of!detrusor!instability!in!the!obstructed!pig.!Br!J!Urol.!1985;57(3):292–8.!!46.!! Tortora! GJ,! Derrickson! BH.! Principles! of! Anatomy! and! Physiology.! 12th! ed.!John!Wiley!&!Sons;!2008.!!47.!! Andersson! KcE,! Arner! A.! Urinary! bladder! contraction! and! relaxation:!physiology!and!pathophysiology.!Physiol!Rev.!2004!Jul;84(3):935–86.!!48.!! Hendricksen! K,! Moonen! PMJ,! van! der! Heijden! AG,! MolkenboercKuenen! J,!Hulsbergencvan! de! Kaa! CA,! Witjes! JA.! Potential! and! toxicity! of! intravesical!pemetrexed:! a! preclinical! study! in! pigs.! Clin! Cancer! Res.! 2006! Apr!15;12(8):2597–601.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 80!
49.!! Witjes! JA,! Vriesema! JLJ,! van! der! Heijden! AG,! Peters! GJ,! Schalken! JA.!Pharmacokinetics!of!intravesical!gemcitabine:!a!preclinical!study!in!pigs.!Eur!Urol.!2003!Nov;44(5):615–9.!!50.!! Swindle!MM.! Urinary! System! and!Adrenal! Glands.! Swine! in! the! Laboratory:!surgery,! anesthesia,! imaging,! and! experimental! techniques.! 2nd! ed.! Florida:!CRC!Press;!2007.!!51.!! Wientjes!MG,!Badalament!RA,!Au!JL.!Penetration!of!intravesical!doxorubicin!in!human!bladders.!Cancer!Chemother!Pharmacol.!1996;37(6):539–46.!!52.!! Wientjes! MG,! Badalament! RA,! Wang! RC,! Hassan! F,! Au! JL.! Penetration! of!mitomycin!C!in!human!bladder.!Cancer!Res.!1993;53(14):3314.!!53.!! Steinberg! PL,! Ghavamian! R.! Roboticcassisted! radical! cystectomy:! current!technique!and!outcomes.!Expert!Rev!Anticancer!Ther.!2012!Jul;12(7):913–7.!!54.!! Bolenz! C,! Trojan! L,! Gabriel! U,! Honeck! P,! WendtcNordahl! G,! Schaaf! A,! et! al.!Cellular!uptake! and!ex! vivo!urothelial! penetration!by!oligodeoxynucleotides!for! optimizing! treatment! of! transitional! cell! carcinoma.! Anal! Quant! Cytol.!2008!Oct;30(5):265–73.!!55.!! Bilensoy! E,! Sarisozen! C,! Esendağlı! G,! Doğan! AL,! Aktaş! Y,! Şen! M,! et! al.!Intravesical! cationic! nanoparticles! of! chitosan! and! polycaprolactone! for! the!delivery!of!Mitomycin!C!to!bladder!tumors.!Int!J!Pharm.!2009!Apr!17;371(1–2):170–6.!!56.!! Perrone!RD,!Johns!C,!Grubman!SA,!Moy!E,!Lee!DW,!Alroy!J,!et!al.!Immortalized!human!bladder!cell!line!exhibits!amiloridecsensitive!sodium!absorption.!Am!J!Physiol.!1996!Jan;270(1!Pt!2):F148–53.!!57.!! Huygens!A,!Kamuhabwa!AR,!Roskams!T,!van!Cleynenbreugel!B,!van!Poppel!H,!de!Witte! PAM.! Permeation! of! hypericin! in! spheroids! composed! of! different!grade!transitional!cell!carcinoma!cell!lines!and!normal!human!urothelial!cells.!J!Urol.!2005!Jul;174(1):69–72.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 81!
58.!! Baker!SC,!Shabir!S,!Southgate!J.!Biomimetic!urothelial!tissue!models!for!the!in!vitro!evaluation!of!barrier!physiology!and!bladder!drug!efficacy.!Mol!Pharm.!2014!Jul!7;11(7):1964–70.!!59.!! Cross!WR,!Eardley!I,!Leese!HJ,!Southgate!J.!A!biomimetic!tissue!from!cultured!normal!human!urothelial!cells:!analysis!of!physiological!function.!Am!J!Physiol!Renal!Physiol.!2005!Aug;289(2):F459–68.!!60.!! Negrete!HO,!Lavelle!JP,!Berg!J,!Lewis!SA,!Zeidel!ML.!Permeability!properties!of!the! intact! mammalian! bladder! epithelium.! Am! J! Physiol! Renal! Physiol.!1996;271(4):F886.!!61.!! Kerec!M,! Švigelj! V,!Bogataj!M,!Mrhar!A.!The! enhancement! of! pipemidic! acid!permeation!into!the!pig!urinary!bladder!wall.!Int!J!Pharm.!2002!Jun!20;240(1c2):33–6.!!62.!! Di! Stasi! SM,! Giannantoni! A,! Massoud! R,! Cortese! C,! Vespasiani! G,! Micali! F.!Electromotive! administration! of! oxybutynin! into! the! human! bladder! wall.! J!Urol.!1997!Jul;158(1):228–33.!!63.!! Tammela! T,! Wein! AJ,! Monson! FC,! Levin! RM.! Urothelial! permeability! of! the!isolated!whole!bladder.!Neurourol!Urodyn.!1993;12(1):39–47.!!64.!! Tringali! G,! Lisi! L,! Bettella! F,! Renier! D,! Di! Stasi! SM,! Navarra! P.! The! in! vitro!rabbit! whole! bladder! as! a! model! to! investigate! the! urothelial! transport! of!anticancer!agents!The!ONCOFIDcP!paradigm.!Pharmacol!Res.!2008!Dec;58(5c6):340–3.!!65.!! Grabnar! I,! Bogataj! M,! Mrhar! A.! Influence! of! chitosan! and! polycarbophil! on!permeation! of! a!model! hydrophilic! drug! into! the!urinary!bladder!wall.! Int! J!Pharm.!2003;256(1c2):167–73.!!66.!! Tsallas!A,!Jackson!J,!Burt!H.!The!uptake!of!paclitaxel!and!docetaxel!into!ex!vivo!porcine! bladder! tissue! from! polymeric! micelle! formulations.! Cancer!Chemother!Pharmacol.!2011!Aug;68(2):431–44.!!67.!! Mugabe!C,!Raven!PA,!Fazli!L,!Baker! JHE,! Jackson! JK,!Liggins!RT,!et!al.!Tissue!uptake! of! docetaxel! loaded! hydrophobically! derivatized! hyperbranched!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 82!
polyglycerols!and!their!effects!on!the!morphology!of!the!bladder!urothelium.!Biomaterials.!2012!Jan;33(2):692–703.!!68.!! Stasi!SMD,!Giannantoni!A,!Navarra!P,!Massoud!R,!Zavaglia!D,!Bertucci!P,!et!al.!The! stability! of! lidocaine! and! epinephrine! solutions! exposed! to! electric!current! and! comparative! administration! rates! of! the! two! drugs! into! pig!bladder!wall.!Urol!Res.!2003!Jul!1;31(3):169–76.!!69.!! Kerec!M,!Bogataj!M,!Veranic!P,!Mrhar!A.!Permeability!of!pig!urinary!bladder!wall:! the! effect! of! chitosan! and! the! role! of! calcium.! Eur! J! Pharm.! 2005!May;25(1):113–21.!!70.!! Kos!MK,!Bogataj!M,!Veranic!P,!Mrhar!A.!Permeability!of!pig!urinary!bladder!wall:! time! and! concentration! dependent! effect! of! chitosan.! Biol! Pharm!Bull.!2006!Aug;29(8):1685–91.!!71.!! Moch!C,!Salmon!D,!Rodríguez!Armesto!L,!Colombel!M,!Pivot!C,!Pirot!F.!Bladder!tissue! permeability! and! transport! modelling! of! intravesical! alum,! lidocaine!hydrochloride,! methylprednisolone! hemisuccinate! and! mitomycin! C.! Int! J!Pharm.!2014!Apr!10;464(1c2):91–103.!!72.!! Tissue! Solutions! Ltd.! Fresh! Human! Tissues! [Internet].! Tissue! Solutions! Ltd.!2012! [cited! 2014! Aug! 29].! Available! from:! http://www.tissuecsolutions.com/prod_fresh.html!73.!! Fowler! S.! Analyses! of! Cystectomy! Dataset! for! 2012.! Section! of! Oncology.!London:!BAUS;!2013.!!74.!! Tscholl!R,!Tettamanti!F,!Zingg!E.!Ileal!substitute!of!ureter!with!refluxcplasty!by!terminal! intussusception! of! bowel:! animal! experiments! and! clinical!experience.!Urology.!1977!Apr;9(4):385–9.!!75.!! Coolsaet! BL,! van! Mastrigt! R,! van! Duyl! WA,! van! Rees! Vellinga! F.! Some!influences!of!the!contractile!element!on!the!viscocelastic!properties!of!bladder!wall!strips.!Eur!Urol.!1978;4(6):450–6.!!76.!! Van! Mastrigt! R,! Griffiths! DJ.! Contractility! of! the! urinary! bladder.! Urol! Int.!1979;34(6):410–20.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 83!
77.!! Crowe!R,!Burnstock!G.!A!histochemical!and!immunohistochemical!study!of!the!autonomic!innervation!of!the!lower!urinary!tract!of!the!female!pig.!Is!the!pig!a!good!model!for!the!human!bladder!and!urethra?!J!Urol.!1989!Feb;141(2):414–22.!!78.!! Bridgewater! M,! MacNeil! H,! Brading! A.! Regulation! of! tone! in! pig! urethral!smooth!muscle.!J!Urol.!1993;150(1):223–8.!!79.!! Ciprian!P,!Bogdan!F,!Ona!V,!Costin!N.!Training!Model!in!Laparoscopic!Urologic!Surgery! c! Laparoscopic! Cure! of! Bladder! Injuries! in! Pig! Animal!Models.!Med!Connect.!2012!Mar;25(1):1–11.!!80.!! Escobar!PF,!Haber!GcP,!Kaouk!J,!Kroh!M,!Chalikonda!S,!Falcone!T.!Singlecport!surgery:! laboratory! experience! with! the! daVinci! singlecsite! platform.! JSLS.!2011!Jun;15(2):136–41.!!81.!! Dixon!JS,!Gosling!JA.!Histology!and!fine!structure!of!the!muscularis!mucosae!of!the!human!urinary!bladder.!J!Anat.!1983!Mar;136(Pt!2):265–71.!!82.!! Teufl! F,! Dammann! F,! Wehrmann! M.! In! vitro! study! of! morphology! of! the!bladder!wall! using!MR! tomography! at! 1.0! Tesla:! correlation!with! histology.!RöFo.!1997!May;166(5):406–10.!!83.!! Narumi!Y,!Kadota!T,!Inoue!E,!Kuriyama!K,!Horinouchi!T,!Kasai!K,!et!al.!Bladder!wall!morphology:!in!vitro!MR!imagingchistopathologic!correlation.!Radiology.!1993!Apr;187(1):151–5.!!84.!! Krebs! HA,! Henseleit! K.! Untersuchungen! uber! die! Harnstoffbildung! im!Tierkörper.!HoppecSeyler´s!Z!Für!Physiol!Chem.!1932!Jan;210(1c2):33–66.!!85.!! HiMedia! Laboratories! Ltd.! KrebscRinger! Bicarbonate! Buffer,! Product! Code!TS1097![Internet].!Mumbai,!India;!2013![cited!2013!Aug!20].!Available!from:!http://himedialabs.com/TD/TS1097.pdf!86.!! Dittrich!R,!Beckmann!MW,!Maake!C,!Oppelt!PG,!Mueller!A,!Mueller!S,!et!al.!The!extracorporeal!perfusion!of!the!female!pig!detrusor!as!an!experimental!model!for!the!study!of!bladder!contractility.!Neurourol!Urodyn.!2007;26(7):1024–9.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 84!
87.!! Parsons! BA,! Drake! MJ,! Gammie! A,! Fry! CH,! Vahabi! B.! The! validation! of! a!functional,! isolated! pig! bladder! model! for! physiological! experimentation.!Front!Pharmacol.!2012;3(52):1–8.!!88.!! Pick! DL,! Shelkovnikov! S,! Canvasser! N,! Louie! MK,! TongsoncIgnacio! J,!McDougall!EM,!et!al.!First!prize:!Chitosan!and!the!urothelial!barrier:!effects!on!ureteral! intraluminal! drug! penetration! and! peristalsis.! J! Endourol! Endourol!Soc.!2011!Mar;25(3):385–90.!!89.!! Rivera!L,!Brading!AF.!The!role!of!Ca2+!influx!and!intracellular!Ca2+!release!in!the!muscariniccmediated!contraction!of!mammalian!urinary!bladder!smooth!muscle.!BJU!Int.!2006!Oct;98(4):868–75.!!90.!! Guibert! EE,! Petrenko! AY,! Balaban! CL,! Somov! AY,! Rodriguez! JV,! Fuller! BJ.!Organ! Preservation:! Current! Concepts! and! New! Strategies! for! the! Next!Decade.!Transfus!Med!Hemotherapy.!2011!Apr;38(2):125–42.!!91.!! Scaravilli! V,! Bonacina! D,! Citerio! G.! Rewarming:! facts! and! myths! from! the!systemic!perspective.!Crit!Care.!2012!Jun!7;16(Suppl!2):A25.!!92.!! Wise! DL,! Houghton! G.! Solubilities! and! diffusivities! of! oxygen! in! hemolyzed!human!blood!solutions.!Biophys!J.!1969!Jan;9(1):36–53.!!93.!! SigmacAldrich!Company!Ltd.!KrebscHenseleit!Buffer,!Product!Number!K3753![Internet].! Dorset,! England;! 2007! [cited! 2013! Aug! 20].! Available! from:!http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/1/k3753pis.Par.0001.File.tmp/k3753pis.pdf!94.!! Lewis! SA.! Epithelial! electrophysiology.! In:! Wills! NK,! Reuss! L,! Lewis! SA,!editors.! Epithelial! transport:! a! guide! to!methods! and! experimental! analysis.!London:!Chapman!&!Hall;!1996.!p.!93–117.!!95.!! Hermanns!MI,!Unger!RE,!Kehe!K,!Peters!K,!Kirkpatrick!CJ.!Lung!epithelial!cell!lines! in! coculture! with! human! pulmonary! microvascular! endothelial! cells:!development! of! an! alveoloccapillary! barrier! in! vitro.! Lab! Invest.!2004;84(6):736–52.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 85!
96.!! Walgren! RA,! Walle! UK,! Walle! T.! Transport! of! quercetin! and! its! glucosides!across! human! intestinal! epithelial! Cacoc2! cells.! Biochem! Pharmacol.!1998;55(10):1721–7.!!97.!! Sugasi!S,!Lesbros!Y,!Bisson!I,!Zhang!YY,!Kucera!P,!Frey!P.!In!vitro!engineering!of! human! stratified! urothelium:! analysis! of! its! morphology! and! function.! J!Urol.!2000;164(3):951–7.!!98.!! Janssen! DAW,! van! Wijk! XMR,! Jansen! KCFJ,! van! Kuppevelt! TH,! Heesakkers!JPFA,! Schalken! JA.! The! distribution! and! function! of! chondroitin! sulfate! and!other! sulfated! glycosaminoglycans! in! the! human! bladder! and! their!contribution! to! the!protective!bladder!barrier.! J!Urol.! 2013! Jan;189(1):336–42.!!99.!! Erman! A,! Kerec! Kos!M,! Žakelj! S,! Resnik! N,! Romih! R,! Veranič! P.! Correlative!study!of!functional!and!structural!regeneration!of!urothelium!after!chitosancinduced!injury.!Histochem!Cell!Biol.!2013!Nov;140(5):521–31.!!100.!!Lewis! SA,! Berg! JR,! Kleine! TJ.! Modulation! of! epithelial! permeability! by!extracellular!macromolecules.!Physiol!Rev.!1995!Jul;75(3):561–89.!!101.!!Fromter!E,!Diamond! J.!Route!of!passive! ion!permeation! in!epithelia.!Nature.!1972;235(53):9–13.!!102.!!Turner! AM,! Subramaniam! R,! Thomas! DFM,! Southgate! J.! Generation! of! a!functional,! differentiated! porcine! urothelial! tissue! in! vitro.! Eur! Urol.! 2008!Dec;54(6):1423–32.!!103.!!Lavelle! J,!Meyers!S,!Ramage!R,!Bastacky!S,!Doty!D,!Apodaca!G,!et!al.!Bladder!permeability!barrier:!recovery!from!selective!injury!of!surface!epithelial!cells.!Am!J!Physiol!Renal!Physiol.!2002!Aug!1;283(2):F242–53.!!104.!!Lavelle! JP,! Meyers! SA,! Ruiz! WG,! Buffington! CAT,! Zeidel! ML,! Apodaca! G.!Urothelial! pathophysiological! changes! in! feline! interstitial! cystitis:! a! human!model.!Am!J!Physiol!Renal!Physiol.!2000!Apr!1;278(4):F540–53.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 86!
105.!!Sun! TcT.! Altered! phenotype! of! cultured! urothelial! and! other! stratified!epithelial! cells:! implications! for!wound! healing.! Am! J! Physiol! Renal! Physiol.!2006!Jul!1;291(1):F9–21.!!106.!!Redden! RJ.! Ketorolac! tromethamine:! an! oral! /! injectable! nonsteroidal! anticinflammatory! for! postoperative! pain! control.! J! Oral! Maxillofac! Surg.! 1992!Dec;50(12):1310–3.!!107.!!Miller! OF,! Bloom! TL,! Smith! LJ,! Mc! Aleer! IM,! Kaplan! GW,! Kolon! TF.! Early!hospital! discharge! for! intravesical! ureteroneocystostomy.! J! Urol.!2002;167(6):2556–9.!!108.!!Routh! JC,! Graham! DA,! Nelson! CP.! Ketorolac! is! underutilized! after! ureteral!reimplantation! despite! reduced! hospital! cost! and! reduced! length! of! stay.!Urology.!2010;76(1):9–13.!!109.!!Stein!A,!Dov!DB,!Finkel!B,!Mecz!Y,!Kitzes!R,!Lurie!A.!Singlecdose!intramuscular!ketorolac!versus!diclofenac! for!pain!management! in!renal!colic.!Am!J!Emerg!Med.!1996;14(4):385–7.!!110.!!Laneuville! O,! Breuer!DK,! Dewitt! DL,! Hla! T,! Funk! CD,! Smith!WL.! Differential!inhibition! of! human! prostaglandin! endoperoxide! H! synthasesc1! and! c2! by!nonsteroidal! anticinflammatory! drugs.! J! Pharmacol! Exp! Ther.! 1994!Nov;271(2):927–34.!!111.!!ElcNahas!AR,! ElcAssmy!AM,! Shoma!AM,! Eraky! I,! ElcKenawy!MR,! ElcKappany!HA.!Selfcretaining!ureteral!stents:!analysis!of!factors!responsible!for!patients’!discomfort.!J!Endourol.!2006!Jan;20(1):33–7.!!112.!!Bultitude!MI,!Hills!NH,!Shuttleworth!KE.!Clinical!and!experimental!studies!on!the!action!of!prostaglandins!and!their!synthesis!inhibitors!on!detrusor!muscle!in!vitro!and!in!vivo.!Br!J!Urol.!1976;48(7):631–7.!!113.!!Rahnama’i!MS,!van!Koeveringe!GA,!Essers!PB,!de!Wachter!SGG,!de!Vente!J,!van!Kerrebroeck!PE,!et!al.!Prostaglandin!Receptor!EP1!and!EP2!Site!in!Guinea!Pig!Bladder!Urothelium!and!Lamina!Propria.!J!Urol.!2010!Mar;183(3):1241–7.!!
! Chapter!Two:!Development!of!an!Ex!Vivo!Model!!!
! 87!
114.!!Rahnama’i! MS,! van! Koeveringe! GA,! van! Kerrebroeck! PEV,! de!Wachter! SGG.!The! effect! of! indomethacin! on! the! muscarinic! induced! contractions! in! the!isolated!normal!guinea!pig!urinary!bladder.!BMC!Urol.!2013;13:8.!!115.!!Birder!LA.!Nervous!network!for!lower!urinary!tract!function.!Int!J!Urol.!2013!Jan;20(1):4–12.!!116.!!Wen!CC,!Coyle!TLC,!Jerde!TJ,!Nakada!SY.!Ketorolac!effectively!inhibits!ureteral!contractility!in!vitro.!J!Endourol.!2008!Apr;22(4):739–42.!!117.!!Abrams! PH,! Sykes! JA,! Rose! AJ,! Rogers! AF.! The! synthesis! and! release! of!prostaglandins!by!human!urinary!bladder!muscle! in!vitro.! Invest!Urol.!1979!Mar;16(5):346–8.!!118.!!Kasakov! LN,! Vlaskovska! MV.! Profile! of! prostaglandins! generated! in! the!detrusor!muscle!of!rat!urinary!bladder:!effects!of!adenosine!triphosphate!and!adenosine.!Eur!J!Pharmacol.!1985!Jul!31;113(3):431–6.!!119.!!Jeremy! JY,! Mikhailidis! DP,! Dandona! P.! The! rat! urinary! bladder! produces!prostacyclin! as! well! as! other! prostaglandins.! Prostaglandins! Leukot! Med.!1984!Nov;16(2):235–48.!!
! Chapter!Three:!Oxybutynin!!!
! 88!







3.1.1.$Oxybutynin$Oxybutynin!is!an!antispasmodic,!non!L!specific!antimuscarinic!agent!which!exhibits!local! anaesthetic!properties!on! the!bladder!wall1.!Administered!as! a! racemate!of!the!R!L!and!S!L!isomers,!oxybutynin!is!a!tertiary!amine!with!a!molecular!weight!of!357!g!molL1!2,3!(Figure!3.1).!Pharmacologically!it!competitively!antagonises!the!M1,!M2!and!M3!subtypes!of!the!muscarinic!acetylcholine!(ACh)!receptor4.!Oxybutynin’s!primary! indication! is! the! treatment! of! overactive! bladder! (OAB),! for! which! it!remains!the!most!widely!prescribed!drug!worldwide5.!!!! !!!!!
Figure!3.1.!Chemical!structure!of!oxybutynin!!






mechanism!of!action!(MOA)!by!which!antimuscarinics! improve!OAB!symptoms12.!Traditional!dogma!was!based!on!the!understanding!of!nervous!control!of!detrusor!muscle! contraction13.! Accordingly,! an! overview! of! bladder! detrusor! neurology! is!necessary.!
3.1.3.$Neural$control$of$the$detrusor$muscle$
3.1.3.1.$ Parasympathetic$control$Bladder! voiding! is! initiated! by! contraction! of! the! detrusor! muscle,! a! process!mediated! by! the! parasympathetic! system.! Preganglionic! neurons! originating! in!sacral! spinal! cord! segments! S2! L! S4! travel! in! the! pelvic! nerve! and! synapse!with!postganglionic! fibres! in! the! pelvic! plexus! and! bladder! wall14.! Transmission! to!postganglionic! fibres! is! cholinergic! and! mediated! through! nicotinic! receptors14.!Postganglionic! fibres,! if! not! already! present,! travel! to! the! bladder! wall! where!excitatory! parasympathetic! innervation! causes! the! detrusor! to! contract.!Cholinergic!transmission!is!mediated!through!M3!muscarinic!receptors,!whilst!non!L! cholinergic! transmission! is! mediated! by! adenosine! triphosphate! (ATP)! at! P2X!purinergic! receptors.! It! is! ACh! however! that! is! the! principal! parasympathetic!neurotransmitter!in!the!detrusor14.!!
3.1.3.2.$ Sympathetic$control$Relaxation! of! the! bladder! detrusor! muscle,! which! is! essential! during! filling,! is!regulated! by! the! sympathetic! system.! Sympathetic! innervation! of! the! bladder!originates! in! the! lower! thoracic! and! upper! lumbar! segments! of! the! spinal! cord!(T10!L!L2)14.!Preganglionic!axons!synapse!with!postganglionic!fibres!in!the!inferior!mesenteric! ganglia! and! pelvic! plexus.! Postganglionic! neurons! travel! in! the!hypogastric! and! pelvic! nerves! to! the! detrusor!muscle,!where! innervation! causes!relaxation! mediated! predominantly! through! β3! L! adrenoceptors! and! to! a! lesser!extent!β2!L!adrenoceptors15.!!
3.1.3.3.$ Afferent$pathways$The! afferent! division! of! the! peripheral! nervous! system! is! responsible! for!transmitting! sensory! information.! Bladder! afferent! pathways! initiate! the!micturition! reflex! and! are! essential! to! the! normal! functioning! of! the! organ.! In!response! to! filling,! afferent! fibres! are! excited! by! mechanical! (e.g.! bladder! wall!
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stretch,! torsion,! increased! intravesical! pressure)! and! chemical! (e.g.! ATP,! ACh)!stimuli16.!Afferent! fibres! in! the!urinary! tract! travel! in! three! sets!of!nerves! to! the!central! nervous! system,! the! most! important! for! micturition! being! the! pelvic!nerve17.! ! Myelinated! Aδ! and! unmyelinated! C! L! fibres! are! activated! by!mechanoreceptors! in! the!bladder!wall! that!relay!sensory! information!to!second!L!order! neurons! in! the! dorsal! horn! of! the! spinal! cord14.! Aδ! fibres! are! involved! in!normal! micturition,! whilst! C! L! fibres! are! typically! associated! with! painful!sensations18.! From! the! spinal! cord,! sensory! information! is! conveyed! to! higher!centres!in!the!periaqueductal!gray!area!of!the!midbrain,!which!itself!receives!input!from! several! forebrain! structures! (hypothalamus,! amygdala! and! orbital! L!medial!prefrontal!cortex)14.!These!structures!participate!in!limbic!networks!that!evaluate!certain!risks!and!emotional!significance.!In!the!context!of!bladder!voiding!this!may!include!whether!it!is!safe!and!socially!appropriate!for!an!individual!to!urinate15.!
3.1.3.4.$ Bladder$filling$and$voiding$The!neural!pathways!controlling!bladder! filling!and!voiding!operate!according! to!an! on! L! off! switch! mechanism.! When! bladder! volume! is! low! or! moderate,!micturition! is! inhibited! because! sympathetic! activity! is! greater! than!parasympathetic!activity,!i.e.,!the!‘switch’!is!off19.!!!This! voiding! ‘switch’! can! be! turned! on! involuntarily! (autonomic,! referred! to! as!reflexly)!or!voluntarily! (somatic)14.! In! the!autonomic!pathway! increased!afferent!firing! from! mechanoreceptors! in! the! bladder! wall! at! the! micturition! threshold!reverses! the! overall! efferent! signal;! parasympathetic! activity! increases,! while!sympathetic!decreases.!This!results!in!relaxation!of!the!internal!urethral!sphincter!followed! shortly! by! contraction! of! the! bladder! detrusor,! an! increase! in! bladder!luminal!pressure!and!urination14.!!
3.1.4.$Signalling$in$the$urothelium$and$lamina$propria$Nervous! innervation! extends! beyond! the! detrusor! muscle! with! evidence! of!unmyelinated! C! L! fibres! located! in! the! lamina! propria! at! close! proximity! to! the!urothelium20–23.!These!nerve!fibres!can!synthesise!a!number!of!neurotransmitters!and! express! a! wide! range! of! receptors! including! muscarinic! and! purinergic!receptors24–26.!In!addition,!they!are!known!to!respond!to!mediators!released!from!
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cells! in!response! to! inflammation,! injury!and! ischaemia! including!prostaglandins,!serotonin!and!ATP23.!!!There! is! now! considerable! evidence! that! cells! in! the! urothelium! and! lamina!propria!can!modulate,!and!be!modulated!by!these!sensory!pathways23,27.!Urothelial!cells! express! a! variety! of! receptors! and! ion! channels! allowing! them! to! be!modulated! by!mechanical! and! chemical! inputs! from! a! variety! of! sources27–31.! In!addition!to!muscarinic!receptors!(Section!3.1.5.3)32–36,!examples! include!nicotinic!receptors37,! purinergic! receptors38–40! and! adrenoceptors41,42.! Suggested!mechanical!inputs!include!changes!in!intravesical!pressure!and!tension!/!torsion!in!the!bladder!wall!during!filling.!Chemical! inputs!include!factors!found!in!the!urine!such! as! epidermal! growth! factor! or! mediators! such! as! ACh,! adenosine! and!noradrenaline!released!from!sympathetic!nerve!terminals,!inflammatory!cells!and!blood! vessels23,27.! These! inputs! can! cause! various! outputs! from! the! urothelium!such! as! the! secretion! of! ATP,! ACh,! prostaglandins,! prostacyclin,! nitric! oxide! and!cytokines23.! It! is! believed! that! through! paracrine! signalling! these! outputs! allow!functional! processes! to! occur! in! nearby! and! underlying! cells! and! that! this!propagation! can! be! enhanced! by! a! number! of! stimuli! including! stretch! of! the!bladder!wall!and!states!of!pathological!disease23,43–45.!
3.1.5.$Distribution$of$muscarinic$receptors$in$the$bladder$wall$Five! subtypes! of! muscarinic! receptors! (M1! L! M5)! have! been! cloned! and!pharmacologically! characterised46! and! although! all! are! expressed! in! the! bladder!wall,! population! density! and! subtype! varies! depending! of! the! tissue! layer! in!question.!
3.1.5.1.$ Detrusor$muscle$At! the! protein! level,! immunoprecipitation! and! radioligand! binding! studies! have!shown! the! human! detrusor! to! express! the!M1,!M2! and!M3! but! not! the!M4! or!M5!subtypes35,47–49.!In!terms!of!population!density!the!M2!subtype!predominates!over!the! M3! and! M1! subtypes! representing! ~! 70! %,! 20! –! 30! %! and! 10! %! of! the!muscarinic! receptor! population! respectively35,47.! However,! in! all! species!investigated,! it! is! the! relatively! minor! population! of! M3! receptors! that! mediate!direct!detrusor!contractile!responses49.!!
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3.1.5.2.$ Lamina$propria$The!lamina!propria!contains!a!population!of!cells!with!similar!morphology!to!the!interstitial! cells! of! Cajal! (ICC)! of! the! gastrointestinal! tract50.! ICCs! are! found!throughout!the!lamina!propria,!including!just!below!the!urothelium,!and!have!been!shown!to!form!connections!with!afferent!nerves51.!The!function!of!the!ICCs!in!the!bladder! is! unclear.! It! has! been! suggested! that! they! may! play! a! role! in! sensory!pathways,! acting! to! regulate! the! contractile! activity! of! detrusor49.! There! is! also!evidence! that! ICC! cell! expression! is! up! L! regulated! in! bladder! pathology! such! as!OAB50.!Immunostaining!has!shown!ICCs!of!the!human!bladder!to!express!both!M2!and!M3!receptors36.!
3.1.5.3.$ Urothelium$All! five! subtypes! of! the! muscarinic! receptor! are! expressed! by! the! human!urothelium32,33,35,52.!Like!the!detrusor,!at!the!protein!level!the!M2!subtype!appears!to!be!the!most!highly!expressed33,35.!Expression!is!urothelial!cell!layer!dependent.!In! human! urothelium! M2! receptors! are! found! exclusively! in! the! umbrella! cells,!whilst!M1! receptors! are! located! solely! in! the! lower!basal! layer33.! Conversely,! the!M3,!M4!and!M5!subtypes!are!expressed!throughout!the!urothelium33.!
3.1.6.$The$mechanism$of$action$of$antimuscarinics$in$OAB$Traditionally,! storage! LUTS! were! believed! to! result! from! abnormal,! involuntary!detrusor! contractions! during! the! bladder! filling! (detrusor! overactivity)53.! Since!antimuscarinics!are!effective!in!treating!such!symptoms!and!are!established!to!be!beneficial!in!OAB54,!their!MOA!was!believed!to!be!antagonism!of!the!M3!muscarinic!receptors! in! the!detrusor!muscle! and! subsequent! inhibition!of! these! involuntary!contractions13,55.!!!However!significant!evidence!now!suggests!this!may!not!be!the!case!and!the!MOA!of! antimuscarinics! has! come! under! scrutiny56–58.! Although! it! is! well! established!that!antimuscarinics!reduce!the!symptoms!associated!with!OAB59,!whether!this!is!brought!about!by!an!inhibition!in!parasympathetic!mediated!detrusor!contraction!is!unclear56,57.!Finney!et#al!conducted!a!review!of!all!articles!containing!cystometric!data! for! both! storage! and! voiding! phases! in! OAB! patients! before! and! after!antimuscarinic! therapy57.! They! found! that! although! antimuscarinics! significantly!
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improved! the! storage! symptoms! associated! with! OAB,! they! did! not! cause! a!significant! reduction! in! detrusor! muscle! contraction.! In! agreement,! although! at!high!doses!antimuscarinics!can!inhibit!detrusor!contraction!during!voiding!and!as!such! cause! retention,! the! likelihood!of! this! occurring! at! clinical! doses! is! low12,60.!Some!have!made! the!point! that! the!common!antimuscarinics!prescribed! for!OAB!such! as! oxybutynin,! tolteradine! and! solifenacin! are! competitive! antagonists! and!therefore! their! effectiveness! should! be! reduced! during! times! of! significant! ACh!release,! such!as!during!micturition57.! !During!bladder! filling! the!parasympathetic!switch!is!off!(there!is!no!parasympathetic!outflow!form!spinal!cord!/!no!activity!in!the! parasympathetic! nerves! innervating! the! detrusor)! and! post! L! junctional!muscarinic! receptors! in! the! detrusor! are! presumably! inactive17.! Therefore! the!ability!of!antimuscarinics!to!improve!storage!symptoms!is!unlikely!to!be!explained!exclusively!by!antagonism!of!the!parasympathetic!L!controlled,!ACh!L!activated!M3!receptors!of!the!detrusor61.!!
3.1.6.1.$ Afferent$mechanisms$of$antimuscarinic$drugs$Kim! et# al! investigated! the! possibility! that! antimuscarinic! agents! improve! OAB!symptoms! by! inhibiting! sensory! pathways62.! When! instilled! intravesically! at! a!concentration! of! 0.167! mg! mlL1,! oxybutynin! significantly! increased! bladder!capacity,! intercontraction! interval! and! pressure! threshold! (indicators! of! bladder!storage! function)! without! decreasing! detrusor! contractility! in! the! normal! rat!bladder62.! Instillations! were! retained! for! short! periods! of! time! (~! 30! min)! and!cystometric! effects! observed! immediately! after! emptying.! The! authors! therefore!attributed!the!effects!of!oxybutynin!to!a!local!action!on!muscarinic!receptors!in!the!urothelium!or! lamina!propria! rather! than! the!underlying!detrusor!muscle62.! The!MOA!was! suggested! to! be! desensitisation! of! afferent! C! L! fibres.! This! agrees!with!previous!work!showing!that!intravesical!oxybutynin!desensitises!C!L!fibre!afferents!in! the! rat! bladder1. In! a! different! study! Iijima! et# al! showed! that! systemic!administration!of!the!M3!antagonist!darifenacin!reduced!afferent!activity! induced!by!bladder!filling!in!the!normal!bladder63.!!!There! is! evidence! that! in! patients! with! OAB,! the! M2! and! M3! receptors! on! the!suburothelial! ICCs! exhibit! increased! immunoreactivity36,50.! This! increased!immunoreactivity!has!been!correlated!with!patient!urgency,!suggesting!a!role! for!these! receptors! in! the! underlying! aetiology! of! urgency13,36.! Although! the!
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parasympathetic! switch! is! off! during! filling,! the! bladder! exhibits! spontaneous!(myogenic)! contractions! of! the! detrusor12.! This! is! believed! to! be! reinforced! by!neuronal!and!non!L!neuronal!mediators!and!helps!the!bladder!exhibit!tone!during!filling64–66.! It! is! suggested! that! this! myogenic! activity! can! modulate! afferent!signals65! and! that! in! OAB! these! signals!may! be! enhanced12,67.! In! addition! to! the!detrusor,! it! has! recently! been! shown! that! isolated! porcine! mucosa! exhibits!spontaneous! phasic! contractile! activity! that! is! increased! during! stretch68.!Contractions! appear! to! be! ACh! mediated! through! M3! muscarinic! receptors! and!clinically!used!antimuscarinics!were!shown!to!depress!this!activity68.!!!Evidence!suggests!therefore!that!in!OAB,!antimuscarinics!might!elicit!their!effects!not! by! decreasing! direct! contractility! of! the! detrusor! muscle,! but! rather! by!modifying!afferent!mechanisms!in!the!storage!phase12,69.!!
3.1.6.2.$ Pharmacology$underlying$bladder$afferent$pathways$$The!pharmacology!underlying!afferent!modulation!in!OAB!is!thought!to!centre!on!two!intertwined!mediators;!ATP!and!ACh!(Figure!3.2).!During!filling,!stretch!of!the!bladder!wall!results!in!ATP!release!from!urothelial!cells70–72.!The!concentration!of!ATP! in! voided! urine! correlates! strongly! with! voided! volume,! suggesting! ATP! is!released! in! an! incremental! fashion! in! response! to! bladder! wall! stretch73.! In!comparison! to! the! normal! bladder,! ATP! release! is! significantly! increased! in!detrusor! overactivity74! and! interstitial! cystitis! /! painful! bladder! syndrome75,76!suggesting! a! functional! role! in! bladder! pathology.! ATP! released! from! the!urothelium!can!directly!activate!afferents! in!the!mucosa!through!P2X3!receptors,!resulting! in! the! increased! firing! associated!with! bladder! filling16,72,77,78.! ATP! can!also! activate! purinergic! receptors! (P2X79! or! P2Y80)! on! ICCs,! indirectly! activating!closely!associated!afferent!nerves81–83!and!subsequently!amplifying!afferent!firing!during!bladder!filling84,85.!!!The! urothelium! is! also! capable! of! synthesising! ACh86,87! and! bladder! stretch! is!associated!with!non!L!neuronal!ACh!release!from!the!urothelium88,89.!OAB!seems!to!be!associated!with!an!increased!release!of!ACh!during!the!storage!phase!suggesting!the!mediator! contributes! to! the! pathophysiology! of! the! disorder12.! Interestingly!basal! and! stretch! L! induced! urothelial! ACh! release! increases! with! age! and! is!significantly! higher! in! those! aged! >! 65! years86.! It! is! unclear!whether!muscarinic!
! Chapter!Three:!Oxybutynin!!!
! 96!















Figure! 3.2.! The! suggested! mechanism! of! cholinergic! signalling! in! the! bladder! wall! and!



































































Intravesical! administration! of! muscarinic! agonists! has! been! shown! to! increase!afferent! excitability! in# vivo62,94,95.! These! effects! were! attributed! to! muscarinic!receptor! activation! and! the! subsequent! ATP! H! mediated! activation! of! purinergic!receptors! on! afferent! nerves.! The! location! of! these! muscarinic! receptors! was!believed! to! be! the! urothelium! or! underlying! lamina! propria62,95.! In! agreement,!antimuscarinics! have! been! shown! to! inhibit! bladder! afferent! excitation.!Systemically! administered! oxybutynin! inhibits! Aδ! and! C! H! fibre! afferent! firing!during!bladder!filling72!and!long!term!administration!is!associated!with!decreased!afferent!nerve!activity96.!Antimuscarinics!are!thought!to!improve!bladder!capacity!by!inhibiting!C!H!fibre!afferents;!intravesical!tolteradine!increased!bladder!capacity!in! non! H! resiniferatoxin! pre! H! treated! rats,! but! had! no! effect! in! those! that! had!received! the! C! H! fibre! desensitising! toxin97.! In! addition! intravesical! oxybutynin!significantly! reduced!bladder! C! H! fibre! afferent! response! to! intravesical! pressure!and! volume1.! Kullmann! et#al! found! activation! of!muscarinic! receptors! located! in!the!apical!cells!of!the!urothelium!leads!to!modulation!of!afferent!C!H!fibres!which!in!turn!alters!the!frequency!of!reflex!voiding95.!Yokoyama!showed!that!intravesically!induced! hydrodistention! of! the! bladder! leads! to! increased! intravesical!concentrations! of! urothelialHreleased! ATP! and! that! antimuscarinics! significantly!suppressed!this!increase98.!Indeed!it!has!recently!been!confirmed!that!M2!and!M3!muscarinic! receptor! antagonism! inhibits! stretch! H! induced! ATP! release! from! the!bladder!mucosa,!further!suggesting!urothelial!muscarinic!receptor!involvement!in!the!MOA!of!antimuscarinics!in!bladder!pathology99.!In!addition!to!the!urothelium,!the! M2! H! M4! subtypes! of! muscarinic! receptor! are! found! on! bladder! afferent!nerves100;!raising!the!possibility!that!ACh!(like!ATP)!may!directly!activate!afferent!nerves! in! the!mucosa101.! Interestingly,! activation! of!M2! receptors! in! the! bladder!urothelium! by! the! muscarinic! agonist! carbachol! leads! to! release! of! ‘urothelial!derived! inhibitory! factor’! (UDIF),! which! directly! inhibits! detrusor! muscle!contractions102–105.!!!!The!exact!MOA!through!which!antimuscarinics!inhibit!afferent!firing!in!the!bladder!wall!is!still!uncertain.!However!the!evidence!strongly!suggests!mucosal!muscarinic!receptors!are! integral! to!the!process.!Based!on!the!pharmacology!elicited,!a!MOA!has! been! suggested! (Figure! 3.2)12,13,101.! During! filling! the! bladder!wall! stretches!and! releases! ATP! and! ACh.! ACh! may! activate! muscarinic! receptors! in! the!
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urothelium! leading! to! the! release! of! more! ATP95,99.! ATP! and! ACh! can! modulate!afferents! indirectly! through!activation!of!purinergic!and!muscarinic! receptors!on!ICCs.!In!addition!ATP!and!ACh!can!activate!afferent!nerves!directly!through!P2X3!and!M2!/!M3!receptors!located!on!afferent!nerves.!Afferent!firing!then!initiates!the!micturition! reflex! and! /! or! enhances! the! spontaneous! (myogenic)! contractile!activity! of! the! detrusor! which! occurs! during! filling13.! Therefore! the! MOA! of!antimuscarinics! in! OAB! is! believed! to! be! the! competitive! antagonism! of! the!mucosal! muscarinic! receptors,! although! the! exact! location! of! these! targets!(urothelium,! suburothelial! ICCs,! suburothelial! afferent! nerves)! is! unknown.! It! is!postulated! that! after! oral! administration,! antimuscarinics! reach! the! mucosa!through! the! plexus! of! blood! vessels! located! in! the! lamina! propria! or! via! drug!excreted!in!the!active!form!in!the!urine13,106.!!Therefore! on! the! basis! of! growing! evidence! suggesting! the! antagonism! of!muscarinic! receptors! in! the! bladder! mucosa! is! the! MOA! for! antimuscarinics! in!OAB,! it!would! seem!probable! that! locally!delivered!drug!might! lead! to! improved!clinical!outcomes.!
3.1.7.$Clinical$use$of$Intravesical$oxybutynin$Although!oral!antimuscarinics!are!first!L! line!pharmacotherapy!for!OAB,!for!some!patients! they! are! unsuitable! either! due! to! insufficient! suppression! of! detrusor!overactivity12! (up! to! 45!%! of! patients! discontinue! treatment! owing! to! a! lack! of!efficacy107)! or! the! experience! of! significant! adverse! effects! such! as! dry! mouth,!constipation! and! blurred! vision108–110.! For! such! patients,! conservative!management!with!intravesical!oxybutynin!is!an!option108.!In!the!late!1980’s!Kato!et#
al!documented!the!first! investigation!into!the!IDD!of!oxybutynin!using!an! in#vitro!rabbit!bladder!model111.!They!suggested!that!the!local!delivery!of!antimuscarinics!might! be! advantageous! in! the! treatment! of! neurogenic! bladder,! especially! for!patients! already! managed! by! clean! intermittent! catheterisation.! Since! then! a!wealth!of!evidence!has!documented!intravesical!oxybutynin!to!be!not!only!highly!efficacious! in! increasing!mean! bladder! capacity! and! decreasing!mean!maximum!filling! pressure,! but! also! to! be! well! tolerated! and! associated! with! less! adverse!effects! than! its! oral! counterpart112–124.! Although! more! commonly! reported! in!neurogenic!patients,!the!efficacy!of!intravesical!oxybutynin!extends!also!to!the!non!
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3.2.1.$$ Materials$All! chemicals!were!purchased! from!Sigma! L!Aldrich,!Poole,!UK!and!were!used!as!received! unless! otherwise! stated.! All! organic! solvents! were! of! HPLC! grade! and!were!obtained!from!Fisher!Scientific,!Loughborough,!UK!unless!otherwise!stated.!
3.2.2.$Analysis$of$oxybutynin$chloride$Oxybutynin!was!quantified!using!a!Quattro!liquid!chromatography!L!tandem!mass!spectrometer! (Waters,! Elstree,! Herts,! UK)! coupled! to! a! Thermo! Spectra! System!using!a!HPLC!column!(Section!2.2.2).!The!mobile!phase!consisted!of!50!%!aqueous!formic!acid!(0.1!%)!:!50!%!ACN.!The!injection!volume!was!10!µl!and!flow!rate!0.4!ml!minL1.!Positive! ion!mass! spectrometry!was!used! for! the!detection,!with! single!ion!monitoring!for!the!parent!ion!between!357.5!and!358.5!m!/!z.!!
3.2.3.$Bladder$tissue$preparation$Porcine! bladder! tissue!was! prepared! as! previously! described! (Section! 2.2.5).! To!one!group!of!bladder!tissue!samples!the!urothelium!was!removed!prior!to!loading!in! the! Franz! L! type!diffusion! cells! (urothelium!denuded! group).! The! other! group!were!untreated!(intact!urothelium!group).!
3.2.3.1.$ Removal$of$the$urothelium$After!cutting!the!bladder!tissue!into!sections,!a!cotton!swab!was!rolled!across!the!entire! surface! of! the! urothelium.! Following! this! an! additional! cotton! swab,! this!time!dipped! in!Krebs,!was!used! to! gently!wipe! the!urothelial! surface.! The! tissue!was!then!gently!rinsed!with!Krebs!to!remove!any!debrided!urothelial!cells.!
3.2.4.$Permeation$of$oxybutynin$across$the$urothelium$Bladder!tissue!sections!were!loaded!in!Franz!L!type!cells!(Section!2.2.5)!and!a!750!
µl!aliquot!of!oxybutynin!chloride!(0.167!mg!mlL1!in!deionised!water)!applied!to!the!donor! chamber.! At! fixed! time! points! (20,! 40! and! 60!min)! the! Franz! L! type! cells!were! disassembled! (Section! 2.2.7.1).! Tissue! samples! were! immediately! snap!frozen,! fixed! with! OCT! and! sectioned! using! a! cryostat! (Section! 2.2.7.2).! Tissue!
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sections! between! 0! and! 250! µm! (urothelium)! were! collected! individually! for!analysis.!Four!tissue!sections!between!250!and!1,050!µm!(upper! lamina!propria)!and! 10! sections! between! 1,050! and! 1,550! µm! (lower! lamina! propria)! were!collected!and!pooled!for!analysis.!Similarly!ten!tissue!sections!between!1,550!and!3,550! µm! (detrusor! muscle)! were! collected! and! pooled! for! analysis.! The! slight!difference!between! tissue! layer!depths!compared! to! the!ketorolac! study! (Section!2.2.7.2)! was! based! on! histological! analysis! of! the! bladder! samples! used! in! this!study! (Section! 3.2.6).! The! decision! to! collate! 10! sections! for! the! lower! lamina!propria! was! the! result! of! preliminary! experiments! (in! rare! cases! drug!concentrations!approached!the!LLOD!when!collating!only!four!sections).!!!Drug!was!extracted! in!0.75!ml!mobile!phase! (Section!2.2.6.1)! and! the!amount!of!oxybutynin! in! the! bladder! wall! at! each! time! point! quantified! using! HPLC! L! MS!(Section!3.2.2).!Average!tissue!concentrations!achieved! in! the!urothelium,! lamina!propria!and!detrusor!muscle!were!determined!as!described!(Section!2.2.7.2).!
3.2.5.$Intravesical$instillation$of$oxybutynin$




















3.2.7.%Statistical%analysis%All! statistical! analysis! was! performed! using! GraphPad! Prism! version! 6.0c!(GraphPad!Software,!Inc,!San!Diego,!California,!USA).!Unpaired!t!K!tests!were!used!for!all!comparisons.!!
3.3.! Results%and%Discussion! !!It!is!well!established!that!intravesical!oxybutynin!is!beneficial!for!the!treatment!of!OAB! in! patients! refractory! to! oral! treatment112–124,! although! the! MOA! remains!unclear12.! Furthermore,! the! last! decade! has! seen! significant! advancement,! and! a!major! change! in! direction,! regarding! our! understanding! of! the! MOA! of!antimuscarincs!as!a!whole.!Originally!believed! to!act!by! inhibiting!M3!muscarinic!receptors!in!the!detrusor!muscle!and!subsequently!preventing!involuntary!bladder!contractions!during! filling,! there! is!now!significant!evidence! that!antimuscarinics!activate! muscarinic! receptors! at! the! urothelial! and! /! or! suburothelial! level! to!modulate! the! afferent! arc! of! the! micturition! cycle12,13,57.! This! hypothesis! may!explain! the! increased! effectiveness! of! intravesical! oxybutynin! considering!relatively! high! concentrations! of! drug! are! presented! to! the! urothelium! in!comparison! to! the! low!bladder!bioavailability!after!oral!dosing.!Considering! this,!bladder!wall!concentrations!achieved!after!intravesical!delivery!of!oxybutynin!are!valuable! in! ascertaining! target! concentrations! necessary! to! modulate! sensory!pathways.!Additionally,!quantifying!drug!concentrations! in! the!different! layers!of!the! bladder! wall! may! provide! more! information! regarding! the! site! of! action! of!antimuscarinics.!A!recurring!limitation!to!understanding!the!pharmacological!site!of!action!of!antimuscarinics!has!been!not!knowing!the!depth!of!penetration!of!drug!after!direct!application!to!the!urothelium58,62,133,135.!This!is!particularly!relevant!to!antimuscarinics! as! studies! have! shown!muscarinic! receptor! subtype!distribution!to! vary! depending! on! the! cell! layer! of! the! urothelium! (Section! 3.5.1.3)33.!Concentration! K! depth! profiling! (Section! 2.3.3.2)! is! becoming! an! established!technique! to!quantify! drug!disposition! in! the!bladder!wall! and!has!been!used! to!investigate! the! local! delivery! of! chemotherapeutics136,137.! Such! studies! have! not!been! carried! out! for! antimuscarinics.! This! chapter! aimed! to! quantify!
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Dose!(mg!kg<1)! Dose!(mg)! Vehicle! Volume!(ml)! Concentration!(mg!ml<1)! Reference!
NR# 5! Saline! 20,!30! 0.25,!0.167! 112!0.1,!0.2,!0.3! 5,!10,!15! Saline! 20! 0.25,!0.5,!0.75! 124!0.1!<!0.2! NR# Water! 10! NR# 143!
NR# 5,!15! Saline! 100! 0.05,!0.15! 131,139!
NR# 5! Water! 30! 0.167! 130!0.2! 5! Water! 10! 0.5! 138!
NR# 10! Saline! 10! 1! 128!
NR# 5! 1!%!HPC! 10! 0.5! 145!
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min.!An!apparent!Kp!of!1.36!x!10D05!cm!sD1!was!calculated!by!normalising! the! flux!(J,!µg!cmD2!sD1)! to! the!dosing!concentration!(167!µg!mlD1).!B)!Mass!balance!
analysis!showing!the!percentage!recovery!of!oxybutynin!from!the!Franz!D!type!cell!apparatus!per!sampling!timepoint.!(n!=!4!bladders!±!SD).! !






































































































































































Figure! 3.9.! Predicted! transurothelial! permeation! profiles! of! oxybutynin! chloride! over! 60!
min.! Dosing! concentration! at! time! zero! is! assumed! to! be! 0.167!mg!mlB1! for! both! studies.!
Apparent! transurothelial! KP! values! were! calculated! experimentally! for! this! work! (Figure!
3.7A)!and!extracted!from!the!literature!for!Di!Stasi!et!al133.!!A! possible! explanation! for! the! disparity! in! the! values! reported! concerns! the!integrity! of! the! urothelial! barrier.! Histological! analysis! of! their! ex# vivo! bladder!tissue!shows!an!eroded!urothelium!consisting!of!only!basal!cells!and!an!absence!of!the! superficial! umbrella! cells! fundamental! to! barrier! function! (Figure! 3.10).!Although!the!value!extracted!from!the!Di!Stasi!study!is!>!4! fold!greater!than!that!determined!in!this!study,!they!are! ‘similar’! in!that!they!are!both!markedly!higher!than!that!calculated!for!ketorolac!(2.63!x!10G6!cm!sG1,!Section!2.3.3.2).!Interestingly!in! guinea! pigs,! oxybutynin! has! been! shown! to! significantly! increase! bladder!permeability! to! technetium! compared! to! phosphate! buffered! saline! (~! 5! fold!increase! in! permeability)150.! It! is! suggested! that! oxybutynin,! a! tertiary! amine,!increases! permeability! by! inactivating! the! GAG! layer! in! a! similar! fashion! to! the!mechanism!of!the!quaternary!amine!protamine.!Disruption!of!the!GAG!layer!could!explain! the! high! Kp! value! although! it! should! be! noted! that! the! concentration! of!oxybutynin!used! in! that! study! (5!mg!mlG1)!was!~!30! fold!greater! than! this! study!(0.167!mg!mlG1).!!





































Figure! 3.10.! Photomicrographs! adapted! from!Di! Stasi! et#al133.! Images! show!H!&! E! stained!
mucosa! of! ex# vivo# human! bladder! tissue! before! (A)! and! after! (B)! 15! min! exposure! to!
oxybutynin!chloride!solution!(45!µg!mlB1).!The!lack!of!an!integral!urothelium!is!evident!even!




























(A)!and!after!(B)!removal!of! the!urothelium.! Images!A!and!B!taken! from!the!same!bladder!
with!50!x!magnification!(scale!bar!represents!500!µm).!C)!Average'oxybutynin'concentrations'
achieved( in( the(detrusor(muscle(of!bladder' tissue'with' and'without' the'presence'of' an' intact'
urothelium.( D)# Permeation# of# oxybutynin# into# the# detrusor# muscle# after# application# to# the#
surface!of#bladder#tissue#with#and#without#the#presence#of#an#intact#urothelium.#(n#=#4#bladders#±#












































































The! advantage! of! the! conservative! technique! used! here! is! that! an! intact! lamina!propria!remains!(Figure!3.11B).!






































Figure! 3.12.! A)! Representative! photograph! of! the! cryostat! in! use.! In! this! example! porcine!
bladder! tissue! is! being! sectioned! at! the! detrusor! muscle! level.! B)! Mean% total% weights% of%
bladder' wall' tissue' layers' sectioned' from' bladders" instilled" with" standard" and$ continually!
diluted'with'artificial'urine'oxybutynin)solution.%(n#=#10#tissue#samples#from#2"bladders"±!SD)."! !
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Figure!3.15.!Average'oxybutynin!concentrations*achieved* in* the*different* layers*of*the$bladder$wall$ following!60!min! instillation!with!undiluted!or! continually!
diluted!with!artificial!urine!oxybutynin!solution.!(*p$<$0.05,$calculated$by$unpaired$t$–!test,%n"="10"tissue"samples"from"2"bladders"±"SD).!
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3.3.2.3.$ Histology$Landau!et#al!investigated!the!effects!of!intravesical!oxybutynin!on!the!morphology!of! the! bladder!wall! using! an! in#vivo! rabbit!model157.! Oxybutynin! (3.5!mg!mlD1! in!saline)!was!instilled!daily!and!animals!sacrificed!at!1,!10!and!30!days.!The!authors!did!not!specify!how!long!instillations!were!retained!in!the!bladder.!Post!D!sacrifice,!bladder! tissue! was! examined! under! light! microscopy! and! assessed! for!inflammation!by!a!blinded!pathologist.!Intravesical!oxybutynin!caused!no!harmful!local!effects!to!the!bladder!tissue,!with!the!mild!inflammation!observed!attributed!to! the! effects! of! daily! catheterisation! (as! the! same! was! observed! in! the! control!group).!!!To!assess!any!effects!oxybutynin!may!have!had!on!the!gross!morphology!of!the!ex#








from! bladders! excised! immediately! post! ?! sacrifice! (A),! following! 60!min! instillation!with!
standard! (undiluted)! oxybutynin! solution! (B)! and! following! 60! min! instillation! with!
oxybutynin! solution! continually! diluted! with! artificial! urine! (C).! All! images! 50! x!
magnification!(scale!bar!represents!500!µm).!
 In!agreement!with!the!aforementioned!studies157,!the!histological!results!of!the!ex#









reported!by!Di! Stasi!et#al#(Figure!3.10)133,! the!ex#vivo! bladder! tissue!used! in! this!work! displays! a! normal! morphology! with! a! complete,! multi! D! cell! layered!urothelium.!
3.4.! Conclusions! !This! chapter! aimed! to! increase! our! understanding! of! the! concentrations! of!oxybutynin! achieved! in! the! bladder! wall! after! intravesical! delivery.! A! detailed!analysis! of! drug! concentrations! achieved! in! the! urothelium,! lamina! propria! and!detrusor!muscle!is!provided.!Oxybutynin!permeated!the!bladder!wall!more!readily!than!other!drugs!previously! investigated.!Abrading! the!urothelium!with!a! cotton!swab!has!been!shown!an!effective!way!of!selectively!removing!porcine!urothelium!and!one!that!may!be!beneficial!for!future!studies.!For!the!first!time,!urine!dilution!has! been! incorporated! into! ex# vivo! permeability! studies! and! its! effect! on!concentrations!achieved!in!the!bladder!wall!shown.!Concentration!D!depth!profiles!suggest! oxybutynin! concentrations! achieved! in! the! detrusor! muscle! after!application! of! a! clinically! relevant! intravesical! dose! are! insufficient! to! directly!inhibit! bladder! wall! contraction.! Consequently,! these! drug! delivery! studies! add!more!weight! to! the! growing! argument! that! antimuscarincs! exert! their! effects! on!the! bladder! wall! through! mechanisms! other! than! direct! detrusor! inhibition.! An!inherent! limitation! of! this! study! is! that! it! did! not! concomitantly! investigate!detrusor! muscle! contractility! with! drug! concentrations! achieved! in! the! bladder!wall.!We!cannot!therefore!directly!state!that!these!concentrations!are!insufficient!to! inhibit! detrusor! muscle! contraction.! Ideally! pharmacology! groups! will! work!hand! in! hand! with! drug! delivery! groups! to! achieve! real! time,! functional!concentration! D! depth! profiles.! This! would! elicit! knowledge! of! in# vivo! tissue!concentrations,! and! therefore! information! regarding! site! of! action,! necessary! to!modulate!afferent!activity!in!the!bladder!wall.!! !
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Chapter# Four:# Development# of# a#







4.1.1.$Introduction$to$STELLA®$modelling$software$STELLA®!(Structural!Thinking!Experimental!Learning!Laboratory!with!Animation,!Isee!systems!Inc,!New!Hampshire,!USA)!is!a!computer!program!that!facilitates!the!mapping,! modelling,! simulation,! and! communication!of! dynamic! processes1.! It!allows! users! to! build! dynamic! models! of! complex! systems.! A! system! can! be!interpreted! as! a! process! or! mechanism,! the! functioning! of! which! depends! on!multiple! parts! working! together.! As! these! parts! change! over! time,! so! does! the!functioning!of!the!system.!By!embedding!advanced!mathematical!equations!behind!simple,! diagrammatical! building! blocks,! STELLA®!offers! a! practical!way! to! study!the!underlying!processes! of! complex! systems.!Once!built,!models! can!be!used! to!investigate! the! contribution! of! different! variables! to! the! system! as! a!whole.! The!human!body! is! arguably! the!most! complex! system!of! all! and!certainly!one!about!which!a!great!deal!remains!unknown.!It!follows!that!STELLA®!is!well!suited!to!PK!modelling! and! has! become! a! valuable! resource! for! doing! so2.! Examples! include!investigating! the!effect!of!antibacterial!doses!on!bacterial! resistance3,!developing!PK!profiles! of! enteric! coated! tablets4! and!modelling! ocular! permeation5,6.! In! this!chapter!STELLA®!was!used!to!create!a!PK!model!of!IDD.!!












4.2.1.$STELLA®$$STELLA®!models! are!built!diagrammatically!using!building!blocks,! each!having!a!specific! purpose.! ‘Stocks’! represent! accumulation.! For! example,! a! stock! may!calculate!the!collection#of#urine!in!the!bladder.!Stock!levels!are!controlled!by!‘flows’.!Flows!control!the!movement!in!and!out!of!stocks,!such!as!the!passage#of#urine!from!the! kidneys! to! the! bladder.! ‘Converters’! determine! the! rate! at!which! flows! alter!stocks.!Converters!allow!you!to!control!how!building!blocks!interact!with!one!and!other.!They!contain!algebraic!equations,!input!by!the!user,!which!allow!variables!to!be!calculated! for!a!single!point! in! time.!For!example,!a!converter!will!control! the!
rate#at#which#urine#collects! in! the! bladder.! The! frequency! at!which! variables! are!calculated,!known!as!the!time!D!step!(DT),!is!specified!by!the!user.!Changing!the!DT!from! 2! to! 1!will! double! the! rate! at!which! calculations! are! performed.! All!model!simulations!in!this!work!were!performed!with!a!DT!value!of!1!second.!
4.2.2.$Model$construction$The! PK!model! was! constructed! in! a! stepwise! manner,! with! each! step! validated!(Section!4.3)!before!advancing!to!the!next.!For!clarity,!STELLA®!model!schematics!have!been!redrawn!using!Microsoft!PowerPoint.!! $
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4.2.2.1.$ Step$ 1:$ Transfer$ of$ drug$ from$ bladder$ lumen$ into$ the$





Figure! 4.1.! Schematic! overview! of! the! multilayered! diffusion! model.! Drug! is! transferred!
between! compartments! according! to! equations! 1! ?! 6.! Drug! is! free! to! diffuse! in! both!




































































































(i)$ Bladder$lumen$At!T!=!0,!all!drug!resides!in!the!bladder!lumen!compartment!(CBL).!Drug!movement!out!of!the!bladder!lumen!and!into!the!first!compartment!of!the!urothelium!(C1)!is!described!by!the!equation!!!!",! = !!!×! !ℎ!" ℎ!!! !!
where,! !!ℎ!" = !!"!!"! (1)!
where!kBL,1!is!the!transfer!coefficient!of!drug!into!compartment!C1!(sN1),!Km1!is!the!partition! coefficient! of! the! drug! between! the! urothelium! and! the! bladder! lumen!(unitless),!D1!is!the!drug!diffusion!coefficient!in!the!urothelium!(cm2!sN1),!hBL!is!the!effective! thickness! of! the! bladder! contents! (cm),! h1! is! the! thickness! of! the!urothelium!(cm),!n1!the!number!of!compartments!in!the!urothelium,!VBL!is!bladder!lumen!volume!(cm3)!and!ABL!is!the!surface!area!of!the!bladder!lumen!(cm2).!
(ii)$ Urothelium$Drug! transfer! between! compartments! of! the! urothelium! (C1! N! C5,! C5! N! CBL,!bidirectional)!is!described!by!the!equation!!!!!,!!!!"!!!!!,! = ! !ℎ!!! !! (2)!!where! ki,i+1! is! the! transfer! coefficient! between! adjacent! urothelial! compartments!down! the! concentration! gradient! (e.g.! C2! to! C3)! (sN1)! and! ki+1,i! is! the! transfer!coefficient!against!the!concentration!gradient!(e.g.!C3!to!C2,!C1!to!CBL)!(sN1).!! !
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At!the!urothelium!/!lamina!propria!boundary!(C5!to!C6),!drug!transfer!into!the!first!compartment!of!the!lamina!propria!(C6)!is!described!by!the!equation!!!!!,! = !!!!!!× ! !ℎ!!! × ℎ!!! ! (3)!!where! k5,6! is! the! transfer! coefficient! of! drug! from! C5! into! C6! (sN1),! Km2! is! the!partition! coefficient! of! the! drug! between! the! lamina! propria! and! the! urothelium!(unitless),!D2!is!the!drug!diffusion!coefficient!in!the!lamina!propria!(cm2!sN1),!h2!is!the!thickness!of!the!lamina!propria!(cm)!and!n2!is!the!number!of!compartments!in!the!lamina!propria.!
(iii)$ Lamina$propria$$Drug! transfer! between! compartments! of! the! lamina! propria! (C6! N! C10,! C10! N! C5,!bidirectional)!is!described!by!the!equation!!!!,!!!!"!!!!!,! = ! !ℎ!!! !! (4)!!At! the! lamina!propria!/!detrusor!muscle!boundary!(C10!to!C11),!drug! transfer! into!the!first!compartment!of!the!detrusor!muscle!(C11)!is!described!by!the!equation!!!!",!! = !!!!!!× ! !ℎ!!! × ℎ!!! + 1 ! (5)!!
*where! k10,11! is! the! transfer! coefficient! of! drug! from! C10! into! C11! (sN1),! Km3! is! the!partition! coefficient! of! the! drug! between! the! detrusor! muscle! and! the! lamina!propria!(unitless),!D3!is!the!drug!diffusion!coefficient!in!the!detrusor!muscle!(cm2!sN1),! h3! is! the! thickness! of! the! detrusor! muscle! (cm)! and! n3! is! the! number! of!compartments!in!the!detrusor!muscle.!
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(iv)$ Detrusor$muscle$Drug! transfer! between! compartments! of! the! detrusor!muscle! (C11!N! C16,! C16!N! C10!bidirectional)!is!described!by!the!equation!!!!,!!!!"!!!!!,! = ! !ℎ!!! + 1 !! (6)!!Drug!transfer!into!the!peritoneum!at!the!detrusor!muscle!/!peritoneum!boundary!(C16!to!CPerit)!is!also!described!by!equation!(6).!In!the!peritoneum!there!is!no!drug!transfer!back!into!the!detrusor!muscle!as!sink!conditions!are!assumed.!
Geometric*assumption*The!bladder! exists! in!pseudo! spherical! geometry.!The!outer! layer! of! the!bladder!wall!(represented!by!C16)!is!further!from!the!bladder!lumen!than!the!inner!surface!(represented!by!C1)!and!as!such!has!a!greater!surface!area!(Figure!4.3A).!To!allow!easier!modelling,!the!model!treats!the!bladder!as!if!it!were!in!flat!geometry!(Figure!4.3B).!Although!the!model!allows!the!thickness!of!each! layer!(urothelium,! lamina!propria!and!detrusor!muscle)!to!be!varied!(h1!N!h3),!the!surface!area!of!the!different!layers! (ABL)! is! assumed! constant.! The! switch! from! spherical! to! flat! geometry!assumes!bladder!wall! thickness!to!be!small!relative!to!the!bladder! lumen!surface!area.!Consequently!any!differences!between!the!surface!area!of!the!inner!and!outer!bladder! wall! will! be! small,! allowing! easier! modelling! of! the! bladder.! This!assumption!was!investigated:!!!Consider!a!bladder!with!a!maximum!volume!of!400!ml!(a!reasonable!assumption!seeing! as! the! urge! to! void! is! usually! initiated! at!~300! –! 400!ml8).! Assuming! the!bladder!to!be!spherical,!the!internal!surface!area!can!be!calculated!by!the!equation!!
where! A! is! the! luminal! surface! area! of! the! bladder! (cm2),! r! is! the! radius! of! the!bladder!lumen!(cm)!and!V!is!the!volume!of!the!bladder!lumen!(cm3).!!!
!! = 4!!!!!
!where,! ! = 3 !4! !!! !(7)!
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Figure!4.3.!Comparing! the!spherical!geometry!of! the!bladder! (A)!with! the! flat!geometry!assumed! in! the!multi! >! compartment!PK!model! (B).!With!a! luminal!





























































Figure! 4.4.! Schematic! overview! of! the! multilayered! diffusion! model! with! drug! clearance!




























!Blood! flow! to! the! human! bladder! during! filling! has! been! investigated! using!Doppler! ultrasound11.! As! the! bladder! fills,! blood! flow! steadily! increases! before!slightly!dropping!once!100!%!capacity!is!achieved.!An!average!blood!flow!rate!over!the!0!–!100!%!capacity!range!was!used!in!the!model!(0.00102!ml!sP1!gP1)11.!!
4.2.2.3.$ Step$3:$Incorporating$urine$dilution$To!closer!mimic!the!IDD!process,!urine!production!by!the!kidneys!and!subsequent!dilution!of!the!instilled!dose!was!incorporated!into!the!PK!model.!Urine!moves!into!the!bladder!lumen!at!a!specified!urine!production!rate!(UR).!Urine!accumulation!in!the!bladder!is!described!by!the!equation!!!!" = !!"0+ !!×!! ! (9)!!where! VBL! is! the! volume! in! the! bladder! lumen! (ml)! at! time! t! (min),! VBL0! is! the!volume!in!the!bladder!lumen!at!time!zero!(ml)!and!UR!is!the!urine!production!rate!(ml!minP1).! A! constant! urine! production! rate! of! 1!ml!minP1! (an! accepted! normal!rate12)!was!used!in!the!model.!
4.2.2.4.$ Step$ 4:$ Moving$ from$ a$ ‘mass’$ to$ ‘concentration’$ @$ based$
model$To!aid!the!design!process,!the!STELLA®!model!was!originally!built!to!describe!drug!movement! in! terms! of! mass.! However! drug! concentrations! are! more! valuable!when!investigating!the!efficiency!of!intravesical!regimens.!Given!tissue!layer!depth!was!already! incorporated!within!the!model,! the!switch! from!mass!terms!enabled!the! generation! of! predictive! concentration! P! depth! profiles.! Concentration! terms!were!generated!by!normalising!the!mass!of!drug!in!each!compartment!to!the!tissue!weight!of!that!compartment.!!! !
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Patient!#2!!!Patient!2!receives!a!single!instillation!of!50!ml!drug!solution!(20!mg!mlP1).!In!this!case!the!patient!is!instructed!to!hold!their!bladder!for!1!h!after!which!the!dose!is!voided.! Following! a! two! P! minute! interlude! to! allow! for! dose! reconstitution,! a!second!50!ml!dose!is!instilled!(20!mg!mlP1).!Again!the!patient!is!instructed!to!hold!their! bladder! for! 1! h! completing! the! 2! h! intravesical! treatment.! Patient! 2! has!received!two!50!ml!doses!over!the!2!h!treatment!period.!
4.2.2.6.$ Step$6:$Incorporating$post$@$void$residual$(PVR)$volume$$Post!P!void!residual!(PVR)!volume!describes!the!volume!of!urine!remaining!in!the!bladder!immediately!post!P!micturition.!PVR!volume!can!vary!greatly;!generally!in!adults!it!is!close!to!zero!(0.09!P!2.24!ml)13,!however!for!diagnostic!purposes!<!50!ml!and!<!100!ml!is!considered!normal!when!assessing!urinary!retention!in!young!and!elderly!patients! respectively14.!Patients!with! lower!urinary! tract! symptoms!often!
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exhibit!higher!PVR!values,!sometimes!>!100!ml15–17.!Draining!post!P!void!residual!urine!with!a!catheter!has!been!suggested!to!improve!the!efficacy!of!IDD18.!However!the! technique! is! not! commonplace! and! even!when! performed!may! only! reduce,!rather! than! completely! remove,! residual! urine18.!Multiple! catheter! drains!whilst!repositioning!the!catheter!and!patient!are!usually!required18.!!!To!account!for!PVR!volume!in!the!bladder!lumen,!equation!9!was!extended!to!the!equation!!!!" = !!"0+ !!×!! !!!
where,! !!"0 = !!"#$ + !!"# ! (11)!
where!VDrug!is!the!volume!of!drug!solution!instilled!in!the!bladder!(ml)!and!VPVR!is!the!PVR!volume!in!the!bladder!at!the!point!of!drug!instillation!(ml).!!
4.3.! Results'and'Discussion! !Two! PK! models! of! IDD! have! previously! been! reported.! Wientjes! et# al! used!computer!P!based!PK!simulations19!to!suggest!an!improved!dosing!strategy!for!the!IDD! of! MMC18.! Their! model! is! based! on! MMC! urine! PK20! and! bladder! wall!concentrations21! determined! from! in# vivo! IDD! studies.! Suggested! regimen!improvements! included! minimising! PVR! volume,! reducing! the! urine! production!rate! and! increasing! the! dose! from! 20! mg! to! 40! mg.! Their! model! was! designed!specifically!to!investigate!the!IDD!of!MMC!and!used!a!multitude!of!experimentally!determined!values!specific! to! the!drug!(e.g.!absorption!rate!constant,!elimination!rate!constant!and!relationships!between!the!concentration!of!drug!in!the!urine!and!urothelium).! More! recently! Grabnar! et# al# developed! a! kinetic! model! of! IDD! to!simulate! the! permeability! enhancing! effects! of! chitosan! and! polycarbophil! on!pipemidic! acid! concentrations! achieved! in! the! bladder! wall22.! Their! model! was!constructed! as! an! advanced! compartmental! diffusion! model! similar! to! the! one!described!here! (Section!4.2.2.1,! Figure!4.2),! but!does!not! take! into! consideration!the!differing!partition!of!the!drug!between!the!various!tissue!layers!(Km,!equations!3!and!5).!!
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In! contrast! to! these! previous! approaches,! which! were! built! using! high! –! level!coding! language,! the! user! C! friendly! STELLA®!model! delivers! high! resolution! PK!predictions!with!a!far!higher!degree!of!flexibility.!This!allows!the!rapid!generation!of!a!wide!range!of!PK!simulations!by!varying!determinants!such!as!the!rate!of!urine!production,!PVR!volume!and!volume!of!instillation!etc.!The!graphical!capabilities!of!STELLA®!allow!simulations!to!be!explored!in!‘real%time’,!simultaneously!displaying!how!each!part!of!the!model!(e.g.!bladder!lumen!volume,!drug!concentrations!in!the!urothelium)! changes! with! time.! This! allows! for! a! faster! and! more! thorough!understanding! of! the! dynamic! processes! underlying! IDD.! Subsequently! the!STELLA®! model! allows! for! the! realisation! of! novel! and! often! counterintuitive!dosing! strategies,! which! would! not! have! been! elicited! using! other! approaches.!Furthermore! previously! described! models! have! sought! to! investigate! a! specific!hypothesis! for!a!particular!drug.!This!model!was!designed!to! investigate! the! IDD!process! as! a! whole! and! to! be! applicable! to! any! drug! solution! instilled! into! the!bladder.!!
4.3.1.%Validating%the%model%with%PYTHON®%To!validate!the!outputs!generated!by!STELLA®,!the!PK!model!was!simultaneously!built! using! PYTHON™.! This! was! done! in! collaboration! with! Yuri! Anissimov,! an!associate! professor! in! mathematical! modelling! at! Griffith! University,! Brisbane!Australia.! Dr! Anissimov! has! published! extensively! in! the! field! of! mathematical!modelling!of!biological!processes23–26!and!has!used!multi!–!compartment!diffusion!models,! such!as! the!one!described!here,! to!model! the! transdermal!permeation!of!drugs7,27.! PYTHON™! is! a!widely! used,! scripting! programming! language. Whereas!STELLA®! allows! users! to! design! models! visually,! PYTHON™! uses! code! to!incorporate! the! many! layers! of! equations! necessary! to! build! the! model.!Considering! the! different! methodology! used! by! these! packages! to! construct! the!same! model,! similar! outcomes! would! validate! the! appropriateness! of! the!underlying!approach.!To!be!clear,!outputs!generated!by!PYTHON™!do!not!validate!the!‘accuracy’!of!the!model!in!terms!of!clinical!results!predicted!in%vivo;!this!would!require! clinical! studies.! It! does! however! validate! that! the! model! has! been!constructed! correctly! using! the! STELLA®! software.! Steps! 1! –! 3! of! the! PK!model!development! were! validated! with! PYTHON™.! Further! steps! represented!
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interpretations! (rather! than!new!coding)!of! the!existing!model!and!subsequently!were!analysed!with!STELLA®!only.!
4.3.1.1.$ Validating$Step$1:$Transfer$of$drug$from$bladder$lumen$into$






outputs!were! identical! to! 2! decimal! places.! The! increase! between! compartments! 5! and! 6!
does!not! represent! a! decrease! in! concentration! gradient! as! values! represent!mass,! rather!
than!concentration,!of!drug.!



































































Table! 4.2.! Example! outputs! generated! with! the! STELLA®! (red)! and! PYTHON™! (green)! model! over! 30! min.! Data! shows! drug! accumulated! (mg)! in! each!
compartment!over!30!min.!STELLA®!and!PYTHON™!model!outputs!were!identical!to!2!decimal!places.!
(CBL%1) (C1%5,*5%BL) (C5%6) (C6%10,*10%5) (C10%11) (C11%16,*16%10) (C16*%*CPerit)
MBL 1000&mg Km1 1 Km1 1 Km2 1.5 Km2 1.5 Km3 1.5 Km3 1.5
VBL 50&ml D1 1E207&cm2&s21 Km2 1.5 D2 1E206&cm2&s21 Km3 1.5 D3 1.5E206&cm2&s21 D3 1.5E206&cm2&s21
SABL 30&cm2 hBL 1.67&cm km2&/&km1 1.5 h2 0.02&cm km3&/&km2 1 h3 0.035&cm h3 0.035&cm
Km1 1 h1 0.01&cm D2 1E206&cm2&s21 n2 5 D3 1.5E206&cm2&s21 n3 6 n3 6
D1 1E207&cm2&s21 n1 5 h1 0.01&cm h2&/&n2 0.004&cm h2 0.02&cm h3&/&(n3+1) 0.005&cm h3&/&(n3+1) 0.005&cm
hBL 1.67&cm h1&/&n1 0.002&cm n1 5 Ki,i+1&or&Ki+1,i 0.0625&s21 n2 5 Ki,i+1&or&Ki+1,i 0.06&s21 Ki,i+1 0.06&s21
h1 0.01&cm Ki,i+1&or&Ki+1,i 0.025&s21 h1&/&n1 0.002&cm h2&/&n2 0.004&cm
n1 5 h2 0.02&cm h3 0.035&cm
h1&/&n1 0.002&cm n2 5 n3 6
KBL 3E205&s21 h2&/&n2 0.004&cm h3&/&(n3+1) 0.005&cm
Ki,i+1 0.1875&s21 Ki,i+1 0.075&s21
DM&/&Perit&boundaryBladder&lumen Uro Uro&/&LP&boundary LP LP&/&DM&boundary DM
STELLA PYTHON
Time.(min) CBL C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 CPerit
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 996.846 0.941 0.697 0.473 0.272 0.090 0.202 0.148 0.105 0.072 0.048 0.040 0.026 0.016 0.010 0.006 0.003 0.008
5 996.847 0.940 0.696 0.472 0.271 0.090 0.202 0.148 0.105 0.073 0.048 0.040 0.026 0.017 0.010 0.006 0.003 0.008
10 995.121 0.979 0.766 0.557 0.354 0.157 0.395 0.326 0.265 0.211 0.164 0.161 0.124 0.093 0.065 0.042 0.020 0.198
10 995.121 0.979 0.766 0.557 0.354 0.157 0.395 0.326 0.265 0.211 0.164 0.161 0.124 0.093 0.066 0.042 0.020 0.199
15 993.558 0.989 0.787 0.587 0.389 0.195 0.510 0.439 0.373 0.311 0.254 0.261 0.210 0.163 0.119 0.078 0.039 0.736
15 993.558 0.989 0.787 0.587 0.389 0.195 0.510 0.439 0.373 0.311 0.254 0.261 0.210 0.163 0.119 0.078 0.039 0.737
20 992.062 0.994 0.798 0.604 0.411 0.220 0.584 0.512 0.443 0.377 0.314 0.330 0.270 0.212 0.157 0.104 0.052 1.556
20 992.062 0.994 0.798 0.604 0.411 0.220 0.584 0.512 0.443 0.377 0.314 0.330 0.270 0.212 0.157 0.104 0.052 1.557
25 990.607 0.997 0.805 0.614 0.424 0.236 0.633 0.560 0.489 0.421 0.354 0.375 0.309 0.245 0.182 0.121 0.060 2.569
25 990.607 0.997 0.805 0.614 0.424 0.236 0.632 0.560 0.489 0.421 0.354 0.375 0.309 0.245 0.182 0.121 0.060 2.570
30 989.179 0.998 0.809 0.621 0.433 0.246 0.664 0.591 0.519 0.449 0.380 0.404 0.335 0.266 0.199 0.132 0.066 3.708
30 989.179 0.998 0.809 0.621 0.433 0.246 0.664 0.591 0.519 0.449 0.380 0.404 0.335 0.266 0.199 0.132 0.066 3.709
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4.3.1.2.& Validating& Step& 2:& Incorporating& drug& clearance& from& the&































































Figure' 4.7.' Mass' balance' analysis' of' the' STELLA®' model' showing' 100' %' of' drug' is'
accountable'throughout'a'100'min'simulation.'Input'parameters'are'the'same'as'for'figure'
4.6.'CBL'is'mass'of'drug'in'the'bladder'lumen'and'C(1'R'16)'+'(Blood)'+'(Perit)'is'the'sum'of'the'mass'of'
drug' in' the' bladder' wall' compartments' (C1' R' 16),' the' blood' compartment' (CBlood)' and' the'
peritoneum'compartment'(CPerit).'










CBL C(1 - 16) + (Blood) + (Perit)
























Table! 4.3.! Example! outputs! generated! with! the! STELLA®! (red)! and! PYTHON™! (green)! model! over! 30! min.! Data! shows! drug! accumulated! (mg)! in! each!
compartment.!STELLA®!and!PYTHON™!model!outputs!were!identical!to!2!decimal!places.!
STELLA PYTHON
Time.(min) CBL C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 CPerit
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 996.847 0.940 0.696 0.471 0.270 0.087 0.191 0.137 0.097 0.066 0.043 0.035 0.023 0.014 0.009 0.005 0.002 0.007
5 996.845 0.941 0.696 0.472 0.270 0.087 0.191 0.138 0.097 0.066 0.043 0.035 0.023 0.014 0.009 0.005 0.002 0.007
10 995.115 0.977 0.762 0.551 0.344 0.142 0.348 0.281 0.223 0.174 0.132 0.127 0.097 0.071 0.050 0.031 0.015 0.157
10 995.115 0.977 0.762 0.551 0.344 0.142 0.349 0.281 0.223 0.174 0.132 0.127 0.097 0.071 0.050 0.031 0.015 0.156
15 993.531 0.985 0.778 0.573 0.369 0.167 0.422 0.351 0.290 0.235 0.186 0.188 0.148 0.113 0.082 0.053 0.026 0.536
15 993.530 0.985 0.778 0.573 0.369 0.167 0.422 0.352 0.290 0.235 0.186 0.188 0.148 0.113 0.082 0.053 0.026 0.535
20 991.993 0.987 0.784 0.582 0.380 0.179 0.458 0.387 0.323 0.266 0.215 0.219 0.176 0.136 0.099 0.065 0.032 1.063
20 991.993 0.987 0.784 0.582 0.380 0.179 0.458 0.387 0.323 0.266 0.215 0.220 0.176 0.136 0.099 0.065 0.032 1.063
25 990.478 0.988 0.787 0.586 0.385 0.185 0.475 0.404 0.340 0.282 0.229 0.235 0.189 0.147 0.108 0.071 0.035 1.669
25 990.478 0.988 0.787 0.586 0.385 0.185 0.475 0.404 0.340 0.282 0.229 0.235 0.189 0.147 0.108 0.071 0.035 1.669
30 988.976 0.987 0.787 0.587 0.388 0.188 0.484 0.412 0.348 0.289 0.236 0.243 0.196 0.153 0.112 0.074 0.037 2.314
30 988.976 0.987 0.787 0.587 0.387 0.188 0.484 0.412 0.348 0.289 0.236 0.243 0.196 0.153 0.112 0.074 0.037 2.314
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Figure! 4.8.! Results! of! STELLA®!simulations! showing! the!mass! of! drug! accumulating! in! the!
peritoneum! compartment! over! 100! min! with! and! without! the! incorporation! of! urine!
production.!



































Table! 4.4.! Example! outputs! generated! with! the! STELLA®! (red)! and! PYTHON™! (green)! model! over! 30! min.! Data! shows! drug! accumulated! (mg)! in! each!
compartment.!STELLA®!and!PYTHON™!model!outputs!were!identical!to!2!decimal!places.!
STELLA PYTHON
Time.(min) CBL C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 CPerit
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5 974.639 7.382 5.544 3.797 2.188 0.711 1.575 1.139 0.802 0.548 0.356 0.295 0.191 0.120 0.073 0.041 0.018 0.058
5 974.627 7.385 5.549 3.802 2.192 0.712 1.578 1.140 0.803 0.548 0.356 0.294 0.190 0.120 0.072 0.041 0.018 0.056
10 963.036 6.981 5.543 4.064 2.573 1.090 2.688 2.182 1.744 1.368 1.044 1.014 0.772 0.570 0.400 0.254 0.123 1.291
10 963.028 6.981 5.544 4.065 2.574 1.091 2.690 2.184 1.746 1.370 1.045 1.015 0.773 0.570 0.400 0.254 0.123 1.285
15 953.527 6.441 5.185 3.878 2.540 1.190 3.031 2.549 2.118 1.732 1.385 1.404 1.114 0.855 0.620 0.403 0.198 4.264
15 953.520 6.441 5.185 3.879 2.541 1.190 3.032 2.551 2.120 1.734 1.386 1.406 1.115 0.856 0.620 0.403 0.199 4.259
20 945.080 5.949 4.815 3.633 2.418 1.184 3.057 2.609 2.201 1.830 1.489 1.534 1.235 0.960 0.703 0.461 0.228 8.156
20 945.072 5.949 4.815 3.633 2.418 1.184 3.058 2.610 2.202 1.831 1.490 1.535 1.236 0.960 0.704 0.461 0.228 8.154
25 937.374 5.513 4.472 3.388 2.272 1.136 2.951 2.534 2.153 1.803 1.478 1.533 1.242 0.970 0.714 0.470 0.233 12.331
25 937.366 5.513 4.472 3.388 2.272 1.136 2.952 2.535 2.154 1.803 1.479 1.533 1.242 0.970 0.714 0.470 0.233 12.332
30 930.244 5.129 4.164 3.159 2.126 1.073 2.795 2.407 2.052 1.723 1.418 1.475 1.198 0.938 0.692 0.456 0.226 16.474
30 930.235 5.129 4.164 3.159 2.126 1.073 2.795 2.408 2.052 1.723 1.418 1.475 1.198 0.938 0.692 0.456 0.226 16.476
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4.3.1.4.% Validating%Step%4:%Moving%from%a% ‘mass’%to% ‘concentration’% <%







(CBL%1) (C1%5,*5%BL) (C5%6) (C6%10,*10%5) (C10%11) (C11%16,*16%10) (C16*%*CPerit)
MBL 1000 Km1 1 Km1 1 Km2 1.5 Km2 1.5 Km3 1.5 Km3 1.5
VBL 50 D1 1E/07 Km2 1.5 D2 1E/06 Km3 1.5 D3 2E/06 D3 2E/06
SABL 260 hBL 0.192 km27/7km1 1.5 h2 0.10 km37/7km2 1 h3 2.0E/01 h3 0.20
UR 1 h1 0.02 D2 1E/06 n2 5 D3 2E/06 n3 6 n3 6
Km1 1 n1 5 h1 0.02 h27/7n2 0.02 h2 0.10 h37/7(n3+1) 0.0286 h37/7(n3+1) 0.0286
D1 1E/07 h17/7n1 0.004 n1 5 Ki,i+17or7Ki+1,i 0.0625 n2 5 Ki,i+17or7Ki+1,i 1.84E/03 Ki,i+1 1.84E/03
hBL 0.19 Ki,i+17or7Ki+1,i 6.25E/03 h17/7n1 0.004 KElim 1.02E/03 h27/7n2 0.02 KElim 1.02E/03
h1 0.02 W1/5 0.53 h2 0.1 W6/10 2.63 h3 0.2 W11/16 4.38
n1 5 n2 5 n3 6
h17/7n1 0.004 h27/7n2 0.02 h37/7(n3+1) 0.029
KBL 1E/04 Ki,i+1 1.88E/02 Ki,i+1 2.63E/03
KElim 1.02E/03
























































































4.3.1.5.& Validating&Step&5:&Allowing&for&multiple&intravesical&doses&To!validate!the!introduction!of!multiple!=!dose!functionality,!the!volume!and!drug!concentration! in! the!bladder! lumen! throughout! an! example! intravesical! regimen!was! investigated! (Section! 4.2.2.5,! Figure! 4.10A! =! B).! With! the! exception! of! the!double! dosing! technique,! all! other! model! inputs! were! unchanged! (Table! 4.5).!Bladder!volume!at!the!end!of!the!2!h!treatment!(VBL2h)!is!described!by!equation!11!(PVR!volume!is!assumed!to!be!0!ml!for!both!patients).!!!
Patient'#1'(single'50'ml'drug'instillation'for'2'h)'!!!"2ℎ = 50+ 1!×!120 = 170!ml! !!
Patient'#2'(two'50'ml'drug'instillations'over'the'2'h'period)'For! patient! 2,! VBL0! is! replaced! with! VBL62! min,! representing! the! volume! in! the!bladder! at! the! time! of! the! second! dose! (50! ml! drug! solution! plus! 2! ml! urine!production!since!voiding!of!the!first!dose).!!!!"2ℎ = 52+ 1!×!60 = 112!ml! !!Simulations! show! the!model! is!working!with! respect! to! final!bladder!volumes!of!170!ml!and!112!ml!predicted!for!patient!1!and!2!respectively!(Figure!4.10A).!This!variation! in! bladder! volume! translates! into! higher! bladder! lumen! drug!concentrations!from!62!min!onwards!for!patient!2!(Figure!4.10B).!Bladder!lumen!drug!concentration!is!described!by!the!equation!!!"#$%!"#$ = !"#$%!"##!!" ! (13)!!where!LumenConc!is!the!concentration!of!drug!in!the!bladder!lumen!(mg!ml=1)!and!LumenMass!is!the!mass!of!drug!in!the!bladder!lumen!(mg).!! !
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Second dose (62 min)
Second void (120 min)
Changeover period (2 min)

































































First Void (60 min)
Second dose (62 min)
Second void (120 min)
Changeover period (2 min)







































































4.3.1.6.& Validating& Step&6:& Incorporating&post& 8& void& residual& (PVR)&






of&intravesical&drug&delivery&The!validated!PK!model!was!used!to! investigate! the!effect!of! individual!variables!on!the!efficacy!of!the!IDD!process.!The!major!limitation!cited!for!IDD!is!the!inability!to!achieve!sufficient!drug!concentrations!in!the!bladder!wall32.!For!the!purpose!of!this! exercise,! efficacy! will! be! measured! on! bladder! wall! drug! concentrations!achieved! and! bladder! wall! drug! exposure! (AUC).! The! greater! the! tissue! drug!concentration!and!AUC!achieved,!the!more!effective!the!intravesical!regimen.!It!is!however!acknowledged!that!higher!drug!tissue!concentrations!may!not!always!be!the!aim!of!optimised!intravesical!regimens.!!!The!range!of!values!considered!clinically!relevant!for!the!variables!associated!with!an!intravesical!regimen!can!vary!significantly.!A!high!urine!production!rate!may!be!


































































an!order!of!magnitude!higher! than! that!of! a! low!one,!however!a! long! instillation!time! is! unlikely! to! be!more! than! 2! or! 3! times! that! of! a! short! one.! An! approach!which! multiples! all! variables! by! a! common! factor! and! then! assess! individual!contribution!to!the!efficacy!of!the!delivery!process!is!unsuitable.!Instead!variables!were!investigated!within!a!clinically!relevant!range.!Apart!from!the!variable!under!investigation,! all! other! variables! (model! inputs)! were! kept! constant.! These!baseline! variables! represent! physiologically! relevant! values! as! introduced! in!section!4.3.1.4.!!The!following!variables!were!investigated:!drug!diffusion!coefficient,!concentration!of!drug!instillation,!volume!of!drug!instillation,! instillation!time,!urine!production!rate,!and!dosing!regimen!(single!versus!double!dosing).!!
4.3.2.1.& Drug&diffusion&coefficient&(D)&The!transurothelial!diffusion!coefficient!(D,!cm2!sW1)!represents!the!ability!of!a!drug!to! permeate! across! the! urothelium! and! penetrate! into! the! bladder! wall.! For! an!infinite!dose!(when!approximately!≥!90!–!95!%!of!the!applied!dose!remains!in!the!donor! chamber! of! the! diffusion! apparatus! during! the! steady! W! state! period! of!permeability! studies! (Section! 2.2.5)),! transurothelial! permeation! is! described! by!Fick’s!first!law33!and!the!equation!!! = −! ∆!∆ℎ! (14)!!where!J!is!diffusive!flux!(mg!cmW2!sW1),!D!is!the!transurothelial!diffusion!coefficient!(cm2!sW1),!ΔC!is!the!concentration!gradient!across!the!urothelium!(mg!cmW3)!and!Δh!is!the!linear!distance!travelled!(thickness!of!urothelium,!(cm)).!D!is!independent!of!drug!concentration!and!unique!to!the!drug!in!question.!In!contrast!to!other!fields!of! pharmaceutics! such! as! transdermal! delivery,! mathematical! modelling! and! in#
vitro# /# ex# vivo! transurothelial! permeability! data! is! scarce! with! only! two! studies!reporting! D! values! (both! for! pipemidic! acid)22,34.! Ex# vivo! transurothelial!permeability! coefficients! (kP)! have! been! determined! for! several! drugs! (Section!2.3.3.2!and!3.3.2.1)35,36.!! !
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!kP!is!related!to!D!by!the!equation!!!! = !!!∆ℎ ! rearranged!to! ! = !!∆ℎ!! ! (15)!!where!kP!is!the!transurothelial!permeability!coefficient!(cm!sW1),!Δh!is!the!thickness!of!the!urothelium!(cm),!and!Km!is!the!partition!coefficient!of!the!drug!between!the!urothelium!and!the!donor!chamber!of!the!diffusion!apparatus27.!!Using! equation! 15,! D! values! were! derived! from! experimentally! determined! kP!values!(Table!4.6).!Owing!to!the!lack!of!data!in!the!literature,!diffusion!coefficients!for!the!lamina!propria!and!detrusor!muscle!were!derived!from!urothelial!D!values!(Table!4.8).!The!urothelium!is!the!rate!W!limiting!barrier!to!the!movement!of!drug!into!the!bladder!wall37–39.!It!is!assumed!therefore!that!diffusion!coefficients!in!the!lamina! propria! and! detrusor! muscle! layers! will! be! greater! than! that! in! the!urothelium.!These!assumptions!are!consistent!with!results!presented!by!Grabnar!
et#al!who!reported!a! large! increase! in!diffusion!coefficient! in! the!sub! W!urothelial!layers! compared! to! the! urothelium22.! Although!not! available! for! all! layers! of! the!bladder! wall,! there! are! detrusor! muscle29,35! and! combined! lamina! propria! /!detrusor! muscle22! Km! values! for! a! range! of! drugs! in! the! literature.! These! in!combination!with!literature!sourced!Km!values!for!similar!tissue!matrixes,!such!as!the!dermis7!for!the!lamina!propria,!allowed!good!estimation!of!suitable!values!for!the! different! layers! of! the! bladder! wall! (Table! 4.8).! Based! on! experimentally!determined!values!(Table!4.6),!the!effect!of!varying!D!values!in!the!range!0.1!–!5.0!x!10W07!cm2!sW1!was!investigated.!An!overview!of!the!intravesical!regimen!is!provided!in!table!4.7!and!a!complete!list!of!inputs!used!in!the!model!detailed!in!table!4.8.!!From! a! clinical! standpoint,! investigating! the! ability! of! a! drug! to! diffuse! into! the!bladder!wall! is!highly!relevant.! It! is! common!knowledge! that! the!urothelium! is!a!significant! barrier! to! IDD40.! Additionally! clinicians! are! aware! that! a! drug’s!physiochemical! properties! are! important! to! the! attainment! of! therapeutic! drug!concentrations!in!target!tissues41.!Early!stage!screening!of!drug!W!like!properties!is!routine! in! the! development! of! candidate! drug! molecules42.! For! these! reasons! a!
! Chapter!Four:!Development!of!a!PK!Model!of!IDD!!!
! 177!




Table! 4.6.! Transurothelial! diffusion! coefficients! (D)! derived! from! experimentally!
determined!transurothelial!permeability!coefficients!(kP)! for!a!range!of!drugs!according!to!
equation! 15.! Values! of! 0.02! cm19! and! 122,29! were! used! for! urothelium! thickness! (h)! and!
urothelium!partition!coefficient!(Km)!respectively.!! Intravesical!regimen!Concentration!of!drug!instillation! 1!mg!mlW1!Volume!of!drug!instillation! 50!ml!Instillation!time! 60!min!Urine!production!rate! 1!ml!minW1!Dosing!pattern! Standard,!single!instillation!Transurothelial!diffusion!coefficient,!D! 0.1!–!5.0!x!10W07!cm2!sW1!
!
Table! 4.7.! Overview! of! the! dosing! regimen! used! to! investigate! the! effect! transurothelial!
diffusion!coefficient!has!on!the!efficacy!of!the!intravesical!delivery!process.!








(CBL%1) ((C1%5,(5%BL) ((C5%6) ((C6%10,(10%5) ((C10%11) ((C11%16,(16%10) ((C16%CPerit)
MBL 50 Km1 1 Km1 1 Km2 1.5 Km2 1.5 Km3 1.5 Km3 1.5
VBL 50 D1 Variable Km2 1.5 D2 D14x410 Km3 1.5 D3 D14x410 D3 D14x410
PVR 0 hBL 0.19 Km2/Km1 1.5 h2 0.1 Km3/Km2 1 h3 0.2 h3 0.2
ABL 260 h1 0.02 D2 D14x410 n2 5 D3 D14x410 n3 6 n3 6
UR 1 n1 5 h1 0.02 h24/4n2 0.02 h2 0.1 h3/(n3+1) 0.0286 h3/(n3+1) 0.0286
Km1 1 h14/4n1 0.004 n1 5 ki,i+14or4ki+1,i Variable n2 5 ki,i+14or4ki+1,i Variable ki,i+1 Variable
D1 Variable ki,i+14or4ki+1,i Variable h14/4n1 0.004 KElim 1.02EH03 h24/4n2 0.020 kElim 1.02EH03
hBL 0.19 W1H5 0.53 h2 0.1 W6H10 2.63 h3 0.2 W11H16 4.38
h1 0.02 n2 5 n3 6
n1 5 h24/4n2 0.02 h3/(n3+1) 0.029
h14/4n1 0.004 ki,i+1 Variable ki,i+1 Variable
kBL Variable kElim 1.02EH03









































































Uro Detrusor muscleLamina propria
0.1 x 10-07 cm2 s-1
1.0 x 10-07 cm2 s-1





































0.1 x 10-07 cm2 s-1, AUC - 12.3 mg min g-1
1.0 x 10-07 cm2 s-1, AUC - 31.3 mg min g-1































0.1 x 10-07 cm2 s-1, AUC - 1.12e-08 mg min g-1
1.0 x 10-07 cm2 s-1, AUC - 0.02 mg min g-1
5.0 x 10-07 cm2 s-1, AUC - 0.86 mg min g-1



























0.1 x 10-07 cm2 s-1, AUC - 0.01 mg min g-1
1.0 x 10-07 cm2 s-1, AUC - 1.88 mg min g-1






























0.1 x 10-07 cm2 s-1
1.0 x 10-07 cm2 s-1
5.0 x 10-07 cm2 s-1




































Figure& 4.14.& Results& of& PK&model& simulations& showing& average& drug& concentrations& in& the&
different&layers&of&the&bladder&wall&(A)&and&full&concentration&C&depth&profiles&(B)&following&
60&min& intravesical& instillation&with&different&concentrations&of&drug&solution& (0.1& C&10&mg&
mlC1).&







































Uro Detrusor muscleLamina propria

















































0.1 mg ml-1, AUC - 3.13 mg min g-1
1 mg ml-1, AUC - 31.32 mg min g-1
10 mg ml-1, AUC - 313.2 mg min g-1
































0.1 mg ml-1, AUC - 0.19 mg min g-1
1 mg ml-1, AUC - 1.88 mg min g-1
10 mg ml-1, AUC - 18.78 mg min g-1































0.1 mg ml-1, AUC - 1.62e-03 mg min g-1
1 mg ml-1, AUC - 0.016 mg min g-1
10 mg ml-1, AUC - 0.16 mg min g-1



























4.3.2.3.% Volume%of%drug%instillation%Although! drug! is! normally! instilled! in! volumes! of! 40! B! 50! ml49,50,! the! literature!provides! examples! from! 10! to! 100! ml51,52! and! therefore! this! range! was!investigated.!The!human!bladder!has!a!maximum!capacity!of!~800!mls!when!fully!distended! although! an! urge! to! void! initiated! at! ~300! –! 400! mls8.! ! A! 100! ml!instillation!may!seem!like!a!large!volume,!however!given!a!urine!production!rate!of!1ml!minB1!the!final!bladder!volume!is!well!below!the!normal!micturition!threshold!after! 60!min.! An! overview! of! the! intravesical! regimen! is! provided! in! table! 4.10.!With! the! exception! of! volume! of! drug! instillation,! all! other! model! inputs! were!consistent!with!table!4.8.!!The!volume!of!drug!instillation!is!often!dictated!by!the!solubility!of!the!drug!and!/!or!the!volume!capacity!of!the!bladder.!Little!consideration!is!given!to!the!dilution!effect!urine!will!have!on!different!volumes!of!drug!instillation.!Figure!4.17D!shows!that!despite!starting!at!the!same!intravesical!concentration!(1!mg!mlB1),!the!luminal!concentration! of! drug! decreases! at! different! rates! according! the! volume! of! drug!solution!instilled.!The!lower!the!instillation!volume,!the!greater!the!urine!dilution!effect! and! the! faster! the! luminal! drug! concentration! decreases.! Drug!concentrations!achieved!in!the!bladder!wall!are!proportional!to!the!concentration!of!the!drug!in!the!bladder!lumen!(Figure!4.14!B!15).!Consequently!the!greater!the!initial! volume! of! drug! instillation,! or! more! accurately! the! wider! the! differential!between!the!volume!of!instillation!and!the!rate!of!urine!production,!the!higher!the!drug! concentration! achieved! at! each! depth! of! the! bladder! wall! (Figure! 4.16B).!Increasing!the!volume!of!drug!instillation!from!10!ml!to!50!ml!resulted!in!a!216.3!%!increase!in!the!final!urothelial!drug!concentration!after!60!min!(Figure!4.16A).!Once!the!drug!instillation!exceeds!a!certain!volume,!further!increases!have!a!lesser!effect!on!bladder!wall!drug!concentrations!as!the!dilution!effect!of!urine!is!negated.!Increasing!the!volume!of!instilled!drug!solution!from!50!ml!to!100!ml!resulted!in!a!much!lower!35.9!%!increase!in!the!final!urothelial!concentration!of!drug!after!60!min!(Figure!4.16A).!! !
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!! Intravesical!regimen!Concentration!of!drug!instillation! 1!mg!mlB1!Volume!of!drug!instillation! 10!B!100!ml!Instillation!time! 60!min!Urine!production!rate! 1!ml!minB1!Dosing!pattern! Standard,!single!instillation!Transurothelial!diffusion!coefficient,!D! 1.0!x!10B07!cm2!sB1!





Figure& 4.16.& Results& of& PK&model& simulations& showing& average& drug& concentrations& in& the&
different&layers&of&the&bladder&wall&(A)&and&full&concentration&D&depth&profiles&(B)&following&
60&min& intravesical& instillation&with&different& volumes& of& instilled&drug& solution& (10& D& 100&
ml).&








































Uro Detrusor muscleLamina propria

























































10ml, AUC - 15.04 mg min g-1
50ml, AUC - 31.31 mg min g-1
100ml, AUC - 37.42 mg min g-1




























10ml, AUC - 0.010 mg min g-1
50ml, AUC - 0.016 mg min g-1
100ml, AUC - 0.018 mg min g-1



























10ml, AUC - 0.99 mg min g-1
50ml, AUC - 1.88 mg min g-1
100ml, AUC - 2.17 mg min g-1






























































4.3.2.3.a.& Solving&the&ideal&volume&of&intravesical&instillation&It! follows! that! for! any! given! urine! production! rate,! micturition! threshold! and!suggested! intravesical! treatment! length,! there!must! be! an! ideal! volume! of! drug!instillation! for! the! drug! in! question! (VIdeal)! that! maximises! the! concentration! of!drug! achieved! in! the! bladder!wall.! A! volume!below!VIdeal!will! result! in! excessive!dilution!of! the! luminal!drug!concentration!(Figure!4.17D),!whilst!a!volume!above!VIdeal! will! result! in! the! micturition! threshold! being! reached! prematurely.! VIdeal!would!be! independent!of!drug!concentration!and!apply!to!any!concentration!of!a!drug! as! long! as! urine! production! rate,! micturition! threshold! and! intravesical!treatment!length!are!fixed.!VIdeal!was!investigated!by!calculating!urothelium!–!drug!exposure! (AUC)! over! the! instillation! period.! The! AUC! was! then! plotted! against!volume!of!drug!instillation!to!illicit!VIdeal!(Figure!4.18).!VIdeal!was!investigated!for!a!1!h!and!2!h!intravesical!regimen!(Table!4.11,!Figure!4.18).!All!other!model!inputs!were!consistent!with!table!4.8.!!Maximising! urothelium! drug! exposure! can! be! described! as! ‘instillation! time!limiting’! or! ‘micturition! threshold! limiting’.! PK! simulations! demonstrated! that,!regardless!of!the!concentration!of!drug!instilled,!a!VIdeal!of!140!ml!and!87.5!ml!was!predicted!for!the!1!h!and!2!h!regimens!respectively!(Figure!4.18).!In!the!case!of!the!1!h!instillation!the!VIdeal!corresponds!to!the!maximum!volume!of!drug!that!can!be!instilled! when! taking! into! consideration! the! instillation! time! and! assumed!micturition!threshold!of!200!ml.!For!the!2!h!regimen!this!was!not!the!case!and!a!VIdeal!of!87.5!ml,!7.5!ml!greater!than!the!maximum!volume!of!drug!that!should!be!instilled! following! the! assumption! of! the! 1! h! regimen,! was! calculated.! In! this!example!it!is!more!effective!to!instil!87.5!ml!for!a!shorter!period!of!time!(110!min,!AUC!=!1,233!mg!min!gW1)!than!it!is!to!instil!80!ml!for!the!full!2!h!(AUC!=!1,228!mg!min!gW1).!!!VIdeal! is! unique! to! the! drug! (permeability! characteristics),! patient! (micturition!threshold! and! urine! production! rate)! and! regimen! (instillation! time)! under!investigation.!Figure!4.18!shows!that!minor!changes!in!the!regimen!(1!h!versus!2!h)! lead! to! significant! variation! in! VIdeal.! The! concept! of! there! being! an! optimal!volume! for! a! given! instillation! is! not! considered! in! practice,! rather! the! same!
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and! 20! mg! mlE1! drug! solution! (volume! of! drug! instillation! varied).! For! all! concentrations! of! drug! instillation! the! maximum! AUC! was! achieved! with! an!
instillation!volume!of!140!ml!and!87.5!ml!for!the!1!h!and!2!h!regimens!respectively.!










Concentration of drug instillation
VIdeal = 140 ml

































































Concentration of drug instillation
VIdeal = 87.5 ml
VIdeal 

























































4.3.2.4.% Instillation%time%Instillation!time!refers!to!the!time!difference!between!the!point!of!instillation!and!the! point! at! which! the! instilled! dose! is! voided.! ! Interestingly,! regardless! of! the!therapy,! recommended! instillation! times! are! usually! 1! h.! The! recommended!instillation!time!for!MMC!is!1!h53.!Similarly!intravesical!gemcitabine!is!retained!for!1!h54!as!is!intravesical!oxybutynin55,56.!There!are!examples!where!instillations!are!retained! for! shorter! periods! of! time! such! as! DMSO! (30! N! 40!min)57.! Intravesical!Bacillus!Calmette!–!Guérin!(BCG)! is!a!notable!exception!with!a! longer! instillation!time! of! 2! h58.! Based! on! this! information! the! effect! of! varying! instillation! time!between!30!and!90!min!was!investigated.!An!overview!of!the!intravesical!regimen!is! provided! in! table!4.12.!With! the! exception!of! instillation! time,! all! other!model!inputs!are!consistent!with!table!4.8.!!Results! from!PK!simulations! show! that!prolonging! instillation! time! increases! the!bladder!wall!drug!exposure! for! all! tissue! layers! (Figure!4.20A! N!C).!Owing! to! the!narrow!range!of!realistic!instillation!times,!variations!in!AUC!are!not!as!significant!as! they!are! for!other!variables! such!as! instillation!concentration! (Section!4.3.2.2,!Figure!4.15).!Interestingly!final!drug!concentrations!in!the!urothelium!and!lamina!propria! are! higher! after! 30!min! than! they! are! after! 90!min! (Figure! 4.19A).! The!prolonged!instillation!time!results!in!increased!dilution!of!the!instilled!dose,!which!in! turn! means! the! permeation! rate! of! drug! into! the! urothelium,! and! hence! the!lamina! propria,! is! superseded! by! drug! clearance! from! the! bladder! wall! (tissue!concentration! N! time! curve! plateaus! and! declines! (Figure! 4.20A! N! B).! Although!cumulative! exposure! continues! to! increase! in! these! layers,! drug! tissue!concentration! decreases.! This! observation! is! counterintuitive! and! not! something!that! is! considered! clinically;!patients! are!often! told! to!hold! the! instillation! for! as!long!as!possible.!There!may!be!scenarios!where!a!longer!instillation!time!is!of!no!additional!clinical!benefit.!For!example!if!the!aim!of!this!intravesical!regimen!was!to! reach! therapeutic! concentrations! in! the! urothelium! and! the! disease! N! specific!IC50! for! the!drug! is!0.45!mg!gN1,! a! therapeutic! tissue! concentration! is! established!after!6!min!but!is!lost!by!58!min!(Figure!4.21).!After!this!point!the!concentration!of!drug!in!the!urothelium!is!sub!N! therapeutic!and!of!no!clinical!benefit.!The!60!min!instillation!is!equally!as!effective!as!the!longer!90!min!regimen!but!is!more!efficient!
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(e.g.! less! clinic! time! and! resources)! and! less! uncomfortable! for! the! patient.! This!may! not! be! the! case! for! the! detrusor! muscle! where! after! 90! min! drug!concentrations! are! only! just! beginning! to! plateau! and! have! not! yet! started! to!decline! (Figure!4.20C).! It! is! important! therefore!when!designing! the! length!of!an!instillation!to!consider! the!drugs!site!of!action! in! the!bladder!wall!and!the! target!concentrations!desired.!































































































30 min, AUC - 15.88 mg min ml-1
60 min, AUC - 31.31 mg min ml-1 



























30 min, AUC - 0.53 mg min ml-1
60 min, AUC - 1.88 mg min ml-1




























30 min, AUC - 0.001 mg min ml-1
60 min, AUC - 0.016 mg min ml-1






















































30 min, AUC - 15.88 mg min ml-1
60 min, AUC - 31.31 mg min ml-1 




































Figure& 4.22.& Results& of& PK&model& simulations& showing& average& drug& concentrations& in& the&
different&layers&of&the&bladder&wall&(A)&and&full&concentration&E&depth&profiles&(B)&following&
60&min&intravesical&instillation&with&a&urine&production&rate&of&1,&5&and&10&ml&minE1.&!






























































































1 ml min-1, AUC - 31.31 mg min g-1
5 ml min-1, AUC - 16.39 mg min g-1






























5 ml min-1, AUC - 0.010 mg min g-1
10 ml min-1, AUC - 0.008 mg min g-1
































5 ml min-1, AUC - 1.07 mg min g-1
10 ml min-1, AUC - 0.75 mg min g-1




































































Figure& 4.24.& Results& of& PK&model& simulations& showing& average& drug& concentrations& in& the&
different&layers&of&the&bladder&wall&(A)&and&full&concentration&C&depth&profiles&(B)&following&a&
2&h&standard&and&double&dosing&regimen.&!
































































































































Double dosing, AUC - 66.0 mg min g-1
Standard dosing, AUC - 51.9 mg min g-1






4.3.3.$Using$the$PK$model$to$optimise$an$IDD$regimen$Having!investigated!the!key!physiological!/!clinical!variables!associated!with!IDD,!the! possible! advantages! such! modelling! could! have! in! the! clinical! setting! was!explored.! Using! a! study! sourced! from! the! literature,! the! PK!model! was! used! to!optimise!an!intravesical!regimen.!!!Beiko!et#al! conducted! a! double! J! blind! randomised! controlled! trial! assessing! the!safety! and! efficacy! of! intravesical! agents! in! reducing! ureteral! stent! J! related!discomfort!(SRD)!(Section!2.1.1)63.!One!of!the!drugs!investigated!was!oxybutynin.!The! reported! /! estimated! parameters! of! the! study! and! the! suggested! optimised!regimen! are! listed! in! table! 4.15.! Other!model! inputs! such! as! bladder! blood! flow!rate!and!drug!partition!coefficients! in! the!different! layers!of! the!bladder!wall!are!reported!in!table!4.8.!These!parameters!were!kept!constant!between!the!reported!and!optimised!IDD!regimens.!!Three!adjustments!were!made;!the!single!120!min!instillation!was!changed!to!two!60!min!instillations!(double!dosing);!urine!production!rate!was!reduced!by!30!%!from!2!ml!minJ1!to!1.4!ml!minJ1!by!asking!the!patient!to!fast!on!the!morning!of!their!treatment61;! finally! using! VIdeal! theory,! the! volume! of! instillation! was! increased!from!9!ml!to!115!ml.!The!concentration!of!drug!instillation!was!not!altered.!!Increasing!the! instilled!drug!volume,!reducing!urine!output!and!using!the!double!dosing! technique! resulted! in! markedly! higher! luminal! drug! concentrations!throughout!the!treatment!period!(Figure!4.26A).!As!a!result!the!optimised!regimen!significantly! increased! oxybutynin! concentrations! achieved! at! all! depths! of! the!bladder!wall! (Figure!4.27B).!Final!drug! concentrations! in! the!urothelium,! lamina!propria! and! detrusor!muscle!were! increased! by! 1,967!%,! 1,757!%! and! 1,329!%!respectively! after! instillation! of! the! optimised! regimen.! Maximum! drug!concentrations! in! the! urothelium,! lamina! propria! and! detrusor! muscle! were!increased! by! 116!%,! 253!%! and! 307!%! (Figure! 4.26B! J! D).! Over! the! treatment!period,! drug! exposure! (AUC)! of! the! urothelium,! lamina! propria! and! detrusor!muscle! was! greatly! increased! (Figure! 4.26B! J! D).! Changes! to! the! reported!intravesical!regimen!are!simple!and!practically!easy!to!implement.!The!treatment!
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, AUC - 2.5 mg min g-1



























, AUC - 13.6 mg min g-1


































, AUC - 0.18 mg min g-1




























Figure' 4.27.' Results' of' PK'model' simulations' showing' average' drug' concentrations' in' the'
different'layers'of'the'bladder'wall'(A)'and'full'concentration'A'depth'profiles'(B)'following'a'
2'h'instillation'with'the'original'(grey)'and'optimised'(pink)'IDD'regimen.'! '








































































4.4.! Conclusions! !A!PK!model!of!IDD!has!been!developed.!The!model!is!highly!flexible,!allowing!key!variables! to! be! altered! in! order! to! explore! their! role! in! the! IDD! process.! Novel!modelling! techniques! and!dosing! concepts! such! as!VIdeal! and!double! dosing!have!been! identified! and! their! usefulness! investigated.! Additionally,! counterintuitive!realisations,! such! as! the!marginal! benefits! associated!with! extending! instillation!time,!have!been!elicited.!The!model!has!many!potential!applications!including!but!not! limited!to! the!design!of! future! IDD!regimens!and!the!optimisation!of!existing!ones! and! may! be! valuable! to! investigators! wishing! to! explore! different!permutations!of!IDD!dosing!regimens!in!the!future.!! !
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Figure' 5.1.' Overview' of' the' EAU' UTUC' treatment' pathway3.' Strict' tumour' characteristics'




















It! has! been! proposed! that! recurrence! after! endoscopic! management! may! be!reduced!by!post!b!operative,!adjuvant!topical!administration!of!chemotherapeutic!agents! such! as!mitomycin!C! (MMC)10–13! or!Bacillus! Calmette! b! Guérin! (BCG)14–18.!The!rationale!behind!this!stems!from!the!established!efficacy!of!these!agents!in!the!management! of! bladder! cancer19,20.! There! are! three! main! techniques! used! to!deliver! drugs! to! the! upper! urinary! tract:! Firstly,! drug! can! be! delivered! in! an!antegrade!fashion!percutaneously!via!a!nephrostomy!tube.!This!delivery!method!is!often! used! following! percutaneous! resection! when! access! is! already! available.!Secondly,!drug!can!be!administered!in!a!retrograde!manner!using!an!open!b!ended!ureteric! catheter;! this! technique! is! favoured! after! ureteroscopic! ablation3,9.!Thirdly,!although!less!b!common,!drug!can!be!administered!intravesically!through!an!indwelling!double!b!J!stent.!This!technique!relies!on!vesicoureteral!reflux!of!the!drug! solution! from! the! bladder! up! into! the! ureter! and! renal! pelvis21.! The! renal!pelvis! is! the!central,!hollow!structure!of! the!kidney!where!urine!collects!prior! to!passage!down!the!ureter!(Figure!5.2).!!
'
Figure'5.2.'Bird’s'–'eye'view'(A)'and'cross'–'sectional'tunnel'view'(B)'of'the'renal'pelvis'from'










The!efficacy!of! topical! chemotherapy! in!UTUC! is!not!proven.!The!poor!quality!of!the! studies! (small,! retrospective! studies! with! limited! follow! up! and! no! control!arms)!prevents!results! from!demonstrating!unequivocal!benefit3,9.! If! topical!drug!delivery! is! to! be! of! benefit! in! reducing! the! recurrence! of! UTUC,! then! efficacious!concentrations!of!drug!must!be!achieved!in!the!target!tissue9.!!!The! urothelium! forms! a! continual! lining! of! the! renal! pelvis,! ureter,! bladder! and!proximal!urethra22.!Currently,! the!accepted!dogma! is! that!urothelial!permeability!is!consistent!throughout!the!urinary!tract.!This!is!largely!based!on!the!assumption!that! histologically! the! urothelium! is! unchanged! in! the! upper! and! lower! urinary!tract23.!To!date,!no!study!has!sought!to!investigate!the!relative!permeability!of!the!bladder,! ureter! and! renal! pelvis! urothelium.! However! evidence! suggests! that!despite! apparent!histological!homology,!protein!expression!on! the! surface!of! the!urothelial! umbrella! cells! is! not! consistent24,25.! Given! the! important! role! the!umbrella!cells!play! in!maintaining!barrier! function,!we!hypothesise!that!this!may!give! rise! to! varying! transurothelial! permeation! at! these! distinct! locations.! This!chapter! investigated! the! relative! permeability! and! drug! b! tissue! concentrations!achieved!in!the!bladder,!ureter!and!kidney!following!topical!instillation!with!MMC.!! !
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5.2.1.## Materials#All! chemicals!were!purchased! from!Sigma! b!Aldrich,!Poole,!UK!and!were!used!as!received! unless! otherwise! stated.! All! organic! solvents! were! of! HPLC! grade! and!were!obtained!from!Fisher!Scientific,!Loughborough,!UK!unless!otherwise!stated.!
5.2.2.#Topical#instillation#of#MMC#to#isolated#porcine#bladder,#ureter#
and#kidney#
En!bloc!porcine!urinary!tracts,!from!pigs!weighing!70!b!90!kg,!were!obtained!fresh!from! a! local! abattoir! as! described! (Section! 2.2.5).! Working! in! a! shallow! bed! of!Krebs,! excess! perivesical! fat! was! trimmed! and! the! bladder,! ureters! and! kidneys!dissected!out.!Ureters!(~!10!cm)!were!dissected!out!so!as!to!leave!~!2!cm!attached!to!the!bladder!and!kidney.!Organs!were!rinsed!with!saline!to!remove!any!residual!urine!and!then!filled!using!an!open!b!ended!ureteral!catheter!(Section!3.2.5)!with!MMC! solution! (1! mg! mlb1! in! normal! saline)! (mitomycin! b! C! 40! mg! powder! for!solution!for!injection,!Prostrakan,!UK).!The!bladder,!kidney!and!ureter!were!filled!through!the!urethra,!ureteral!orifice!and!directly!into!the!ureter!respectively.!Since!the!volume!of!the!renal!pelvis!is!variable,!pre!b!experimental!test!instillations!with!methylene!blue!(1!mg!mlb1!in!normal!saline)!were!carried!out!to!ensure!adequate!contact! with! the! renal! pelvis! urothelium!was! achieved.! Post! b! instillation,! entry!orifices!were!sutured!and!the!organs!submerged!in!oxygenated!Krebs!maintained!at! 37! °C! in! a! waterbath! for! 60! min! (Section! 3.2.5).! Four! experiments,! each!representing!a!different!ex!vivo!porcine!urinary!tract,!were!performed.!! !
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5.2.3.# Investigating# total# permeation# of# MMC# into# the# bladder,#
ureter#and#kidney#wall:#Preliminary#studies#Following!60!min! instillation,!organs!were! removed,! emptied!and!opened!with!a!single! vertical! incision.! To! remove! surface! b! adsorbed! drug! the! urothelium!was!thoroughly! rinsed! with! saline.! Tissue! samples! from! areas! of! drug! contact!(observed! due! to! purple! staining! conferred! by! MMC)! were! excised! and! their!apparent!surface!area!measured.!For!kidney!samples!the!renal!pelvis!was!isolated!from!the!underlying!cortex!by!cutting!along!the!natural!plane!of!the!tissue!with!a!scalpel!(Figure!5.3).!The!separated!cortex!was!then!cut!in!half!representing!cortex!proximal! and! distal! to! the! renal! pelvis.! For! all! tissues,! samples! were! weighed,!homogenised!and!the!drug!extracted!in!1!ml!of!mobile!phase!as!described!(Section!2.2.6.1).!Extracted!drug!was!quantified!using!HPLC!(Section!5.2.3.1).!Average!drug!concentrations!were!calculated!by!dividing!the!total!amount!of!drug!recovered!by!the! total! weight! of! tissue.! Transurothelial! permeation! was! calculated! by!normalising!the!total!amount!of!drug!extracted!from!the!tissue!to!the!surface!area!of!the!tissue!sample.!!
!
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5.2.3.1.& Analysis&of&MMC&MMC!was!analysed!by!HPLC!(Section!2.2.2).!The!mobile!phase!consisted!of!80!%!5!mM! phosphate! buffer! (pH! 7)! :! 20! %! ACN,! with! UV! detection! at! 365! nm.! The!injection!volume!was!20!µl!and!flow!rate!1ml!minR1.!!
5.2.4.&Investigating&the&distribution&of&MMC&into&the&bladder,&ureter&
and&kidney&wall:&Concentration&B&depth&studies&Following! 60!min! instillation,! organs!were! removed,! instilled! drug! emptied! and!tissue!samples!taken!as!described!(Section!5.2.3).!In!this!instance!the!renal!pelvis!was! not! isolated! from! the! underlying! renal! cortex.! Tissue! samples! were!immediately!snap!frozen!and!the!tissue!sectioned!using!a!cryostat!(Section!2.2.6.1).!Samples! were! serially! sectioned! parallel! to! the! urothelial! surface! at! 50! µm!thickness!and!sections!collected!in!pre!R!weighed!1.5!ml!eppendorf!tubes.!Two!50!
µm!tissue!sections!between!0!and!100!µm!were!grouped!for!analysis,!as!were!the!two!50!µm!sections!between!100!and!200!µm.!Groups!of!six!50!µm!tissue!sections!between!200!and!1,400!µm!and!groups!of! twelve!50!µm!tissue!sections!between!1,400!and!7,400!µm!were!also!grouped.!MMC!was!extracted!and!quantified!using!HPLC! (Section! 5.2.3.1).! Average! drug! concentrations! at! different! tissue! depths!were! calculated! as! described! (Section! 2.2.7.2).! Transurothelial! permeation! was!calculated! by! normalising! the! total! amount! of! drug! extracted! from! all! tissue!sections!to!the!surface!area!of!the!tissue!sample.!
5.2.4.1.& Validating&extraction&of&MMC&Deionised!water!(0.5!ml)!was!added!to!the!tissue!homogenate!of!sectioned!urinary!tract! tissue! (previously!extracted!according! to!Section!5.2.3).! Samples!were! then!immediately! vortexed,! centrifuged! and! the! supernatant! discarded.! Ethyl! acetate!(0.25!ml)!was!added!to!the!homogenate!and!MMC!extracted!for!24!h!with!10!min!sonication! per! sample.! Samples! were! then! centrifuged! and! the! supernatant!isolated!for!analysis!by!HPLC!(Section!5.2.3.1).!!
5.2.4.2.& Quantifying& tissue& layers&depths&of& the&ureter,&bladder&and&
kidney&wall&Samples! of! ureter,! bladder! and! kidney! were! taken! from! porcine! urinary! tracts!excised! immediately! post! R! sacrifice! on! site! at! the! abattoir.! Samples! were! fixed,!
! Chapter!Five:!Upper!and!Lower!Tract!Permeability!to!MMC!!!
! 225!
sectioned! and! stained! with! Masson’s! trichrome! prior! to! examination! by! light!microscopy!(Section!3.2.6).!The!mean!depths!of!the!different!tissue!layers!for!the!ureter,!bladder!and!kidney!were!measured!directly!from!photomicrographs!using!NIS! M!Elements!Basic!Research! imaging!software!(Nikon! Instruments!Europe!B.V,!Amsterdam,!Netherlands).!!
5.2.5.$Statistical$analysis$All! statistical! analyses! were! performed! using! GraphPad! Prism! version! 6.0c!(GraphPad! Software,! Inc,! San!Diego,! California,! USA).! For! all! comparisons,! one! –!way!ANOVA!with!Tukey’s!post!–!hoc!test!for!multiple!comparisons!was!used.!!
5.3.! Results'and'Discussion! !
5.3.1.$Investigating$ total$ permeation$ of$ MMC$ into$ the$ bladder,$




Prelim'Studies Organ Weight'(g) Size'(cm) Instillation'(ml)
Bladder 37.3 Whole 12
Ureters 2.22/23.4 10.62/210.6 22/22
Kidneys 109.32/2108.1 Whole 72/27
Bladder 23.4 Whole 10
Ureters 2.92/22.7 122/213 42/24
Kidneys 128.52/2119.3 Whole 152/212
Bladder 35.2 Whole 10
Ureters 2.22/22.5 122/213 2.52/23
Kidneys 106.42/2104.2 Whole 52/26
Bladder 35.9 Whole 14
Ureters 2.12/21.7 13.42/213 3.52/23.5


























Figure' 5.5.' Ex# vivo' porcine' bladder' (A),' kidney' (B)' and' ureter' (C)' following' 60' min'

























Figure'5.6.' External' standard' calibration' curve'used' in' the'HPLC'analysis' of'MMC.' Inset,' a'
clearer'plot'of'the'calibration'values'between'0'and'0.1'µg'mlA1.''




















































Figure!5.7.!Example!HPLC!chromatograms!showing! the!analysis!of!MMC!calibration! standards! (A! C!C)! and!drug! recovered! from!bladder! (D)!and!kidney! (E)!
tissue!samples!near!the!LLOQ.!




























































Considering!the!large!variation!in!thickness!of!the!bladder,!ureter!and!kidney,!drug!recovered!from!the!tissue!was!normalised!to!surface!area!allowing!a!more!accurate!comparison!of! permeation.! For! the!kidney,! amounts!of!MMC! recovered! from! the!renal!cortex!were!frequently!below!the!LLOQ!and!as!such!permeation!represents!drug!recovered!from!the!renal!pelvis!only.!Interestingly,!after!60!min,!permeation!of!MMC!across!ureteral! urothelium! (4.29!µg! cmM2)!was! significantly! greater! than!bladder!urothelium!(0.66!µg!cmM2)!or!kidney!urothelium!(0.84!µg!cmM2)!(p!<!0.001)!(Figure!5.8B).!There!was!no!significant!difference!between!permeation!across!the!kidney! and! bladder! urothelium! (p! >! 0.05).! This! pattern! of! increased! ureteral!permeability! was! observed! consistently! in! each! of! the! four! urinary! tracts!investigated! (Figure! 5.8A).! When! expressing! drug! recovered! as! a! total!concentration!per!weight!of!the!tissue,!concentrations!of!MMC!in!the!ureter!(20.44!










<! 0.01! for! the! ureter! versus! the! bladder! and! the! ureter! versus! the! kidney,! calculated! by! one! –! way! ANOVA! with! Tukey’s! post! –! hoc! test! for! multiple!
comparisons).! !













































































































































5.3.1.2.& Quantifying& tissue& layers&depths&of& the&ureter,&bladder&and&




























and#kidney#wall:#Concentration#@#depth#studies#Preliminary!studies!looked!only!at!total!MMC!permeated!(Figure!5.8),!treating!the!urothelium,! lamina! propria! and! detrusor! muscle! as! a! single! compartment.!Consequently!results!report!average!concentrations!across!the!whole!of!the!tissue!wall! (Figure! 5.9B).! When! comparing! drug! penetration! into! tissues! of! differing!thickness,! average! drug! concentrations! can! misrepresent! the! data.! The! bladder!wall!is!considerably!thicker!than!the!ureteral!wall!(Table!5.2);!consequently!areas!deep!in!the!bladder!wall!(where!drug!may!not!have!not!reached)!will!drive!down!the! average! tissue! concentration! expressed! as!microgram!per! gram!of! tissue.!To!extend!and!improve!upon!these!preliminary!studies,!concentration!N!depth!profiles!were! constructed! to!more! closely! examine!MMC! permeation! and! concentrations!achieved!in!the!different!layers!of!the!urinary!tract!tissues!(Figure!5.11A!and!5.12).!!Again! the! volume! of! MMC! instilled! varied! (Table! 5.3),! however! organ! weights,!dimensions!and!instillation!volumes!were!similar!to!the!preliminary!study!(Table!5.1).!! !
Urothelium Lamina.propria Smooth.muscle Cortex Adventitia Whole.wall
Ureter 186.9 355.8 652.9 N/A 1,104.1 2,299.7
Bladder 182.6 1,252.0 3,433.8 N/A 357.9 5,226.3









!Figure!5.11A!shows!average!concentration!N!depth!profiles!for!MMC!in!the!different!urinary!tract!tissues.!Profiles!resembled!those!constructed!for!other!molecules!in!this! thesis! (Sections! 2.3.3.2,! 3.3.2.2)! with! drug! concentrations! highest! in! the!superficial! (urothelial)! tissue!sections,! followed!by!a!comparatively!steep!decline!in!concentration!as!tissue!depth!increased.!Average!concentrations!of!MMC!in!the!ureter!and!kidney!were!markedly!higher!than!those!achieved!in!the!bladder!at!all!tissue! depths! investigated! (Figure! 5.11A).! This!was! the! case! in! each! of! the! four!urinary!tracts! investigated!(Figure!5.12).!Variation!in!the!relative!proportion!and!composition! of! tissue! layers! of! the! upper! and! lower! urinary! tract! makes!comparison! of! drug! concentrations! in! the! lamina! propria! and! detrusor! muscle!difficult.!The!urothelium!of!the!upper!and!lower!porcine!urinary!tract!however!is!of! a! similar! thickness! (Table! 5.2).! Urothelial! MMC! concentrations! (calculated! at!150!µm!tissue!depth)!were!>!6.5!fold!higher!in!the!ureter!and!kidney!compared!to!the!bladder!(Figure!5.11B,!p!<!0.01).!!To!validate!the!MMC!extraction!protocol,!a!second!extraction!in!ethyl!acetate!was!carried!out!on! samples! from!each! tissue! type! (two!50!µm!sections!between!100!and!200!µm!tissue!depth!for!each!of!the!four!urinary!tracts).!Prior!to!the!addition!of!ethyl!acetate,!a!washing!step!was!included!to!remove!any!adsorbed!MMC!from!the! surface!of! the! tissue!homogenate.!MMC! is!highly! soluble! in!ethyl!acetate!and!the!solvent!has!been!used!to!extract!MMC!from!bladder!tissue!by!other!groups26.!For! all! tissue! sections! the! amount! of! MMC! extracted! in! the! secondary! step!was!
CDP$Studies Organ Weight$(g) Size$(cm) Instillation$(ml)
Bladder 26.32 Whole 16.5
Ureters 0.876/61.13 56/66 16/61.9
Kidneys 147.56/6151.5 Whole 8.56/69.5
Bladder 29.13 Whole 17
Ureters 1.646/62.22 106/610 1.86/62.0
Kidneys 104.946/6103.86 Whole 7.16/610.9
Bladder 40.56 Whole 24.3
Ureters 2.246/62.31 106/610 2.256/62.75
Kidneys 159.56/6143.9 Whole 146/614.5
Bladder 32.9 Whole 26
Ureters 2.26/62.3 106/610 26/63.3







below!the!LLOD,!suggesting!complete!extraction!of!MMC!had!been!achieved!in!the!analytical!extraction.!!MMC! permeation! across! ureteral! urothelium! (9.07! µg! cmN2)! was! significantly!greater!than!that!across!bladder!urothelium!(0.94!µg!cmN2,!p!<!0.001,!Figure!5.11C).!Transurothelial!permeation!across!kidney!urothelium!(3.61!µg!cmN2)!was!greater!than! bladder! urothelium! (~! 4! fold! higher)! however! this! was! not! statistically!significant!(p!=!0.086,!Figure!5.11C).!Ureteral!permeation!was!significantly!greater!than!kidney!urothelium!(p!<!0.01,!Figure!5.11C)!and!at!tissue!depths!beyond!350!
µm! MMC! concentrations! in! the! ureter! were! greater! than! those! in! the! kidney!(Figure!5.11A,!5.12).!Although!results!from!the!concentration!N!depth!study!yielded!higher!transurothelial!permeation!results!that!those!in!the!preliminary!studies,!the!pattern! of! the! ureter! exhibiting! significantly! increased! MMC! permeability!remained!consistent.!!Bladder! wall! concentrations! are! similar! to! those! reported! by! other! groups26!(Figure! 5.13A),! especially! when! comparing! median! bladder! wall! concentrations!(4.3!versus!5.6!µg!gN1!in!the!urothelium!for!this!data!and!that!reported!by!Wientjes!











































































































































































































































































































values! ±! SD! and! figure! B! shows! median! values! from! the! same! data.! (n! =! 4! bladders! ±! SD! and! 7! bladders! ±! SD! for! this! work! and! that! of! Wientjes! et# al!
respectively).!







































































The! greater! permeability! of! porcine! ureter! might! be! explained! by! the! relative!uroplakin! (UP)! content! of! the! different! regions! of! the! urinary! tract24.! It! was!generally! believed! that! the! upper! and! lower! urinary! tracts! were! lined! by! one!homogenous! urothelium24.! Urothelia! at! these! different! regions! are!morphologically! similar! in! terms! of! thickness! and!were! presumed! to! perform! a!similar! barrier! function23.! Indeed,! histology! of! the! ex# vivo! porcine! urinary! tract!showed!no!discernable!difference!in!the!thickness!of!the!urothelium!of!the!upper!or!lower!urinary!tract!(Table!5.2).!However!recently!it!has!been!shown!that,!based!on!ultrastructure!and!UP!content,!the!urothelium!of!the!mammalian!urinary!tract!can! be! divided! into! at! least! three! different! cell! lineages:! renal! pelvis! /! ureter,!bladder!/! trigone!and!proximal!urethra24.! Immunofluorescence!and! transmission!electron!microscopy!of!bovine!urothelium!indicates!urothelial!cells!of!the!bladder!contain! more! UP! than! those! of! the! ureter24.! Immunoblotting! analysis! of! these!isolated!urothelia! indicated!the!bladder!UP!content! to!be!~!10!times!higher!than!that!of!the!ureter24.!Additionally,!immunoblot!analysis!of!bovine!urothelia!cultured!
in#vitro#showed!the!bladder!to!contain!~!10!times!more!UP!than!either!the!ureter!or! renal! pelvis.! When! maintained! under! identical! in# vitro! conditions,! bovine!urothelia! from! the! bladder! and! ureter! exhibited! very! different! proliferative!potential! and! formed! morphologically! distinct! colonies24.! Conversely,! in# vitro!cultured!urothelia!from!the!renal!pelvis!showed!indistinguishable!growth!potential!from!that!of!the!ureter.!Preliminary!work!by!the!same!group!suggested!the!concept!of!urothelial!heterogeneity!also!extended!to!monkey!and!human24.!!Following! on! from! this! work! Riedel! et# al! showed! that,! with! respect! to! UP!composition,! urothelial! heterogeneity! was! indeed! more! prominent! in! umbrella!cells! of! the! human! ureter! than! those! of! the! bladder25! (the! renal! pelvis! was! not!investigated).! Immunohistochemical! staining! revealed! that! 15! of! the! 18! ureters!investigated! possessed! a! significant! subpopulation! of! ureteral! umbrella! cells!lacking!UPIII!and!UPIb.!The!authors!concluded! that! the!UPIII!/!UPIb!pair!may! in!fact!be!completely!absent!from!the!ureters.!In!comparison,!only!2!of!the!10!bladder!samples!investigated!lacked!UPIII!and!UP1B!and!both!of!these!samples!were!taken!from!the!ureteral!orifice!or!its!immediate!surrounding;!suggesting!the!urothelium!may!have!been!of!ureteral!origin.!UPIII!is!integral!to!the!formation!of!an!effective!urothelial!barrier24,27.!UPIII!knockout!mice!exhibit! a!more!permeable!urothelium!
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• Immunohistochemical! analysis! of! porcine! urinary! tract! to! determine! UP!content!!
• Comparing!upper! and! lower!urinary! tract!permeability! to!MMC! in!human!tissue.!!!
• Further! investigations! to! ascertain! whether! the! urothelium! of! the! renal!pelvis!is!more!permeable!than!that!of!the!bladder!to!MMC.!!
• Additional! studies! to! investigate!whether! this! pattern! of! increased! upper!tract! permeability! is! seen! for! other! clinically! relevant! molecules! such! as!BCG17.!!
• Investigating! the! homogeneity! of! the! GAG! layer! throughout! upper! and!lower! urinary! tract! urothelia.! The! GAG! layer! is! crucial! to! the! barrier!function! of! the! urothelium! (1.1.2.1.c)43,44,! however! no! groups! have!investigated!its!relative!distribution!at!the!different!anatomical!sites!of!the!urinary!tract.!!!! !
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!Intravesical!drug!delivery!(IDD)!offers!a!unique!opportunity!to!target!pathology!of!the! lower!urinary! tract.!High! concentrations!of!drug! can!be!delivered!directly! to!the!bladder!with!minimal!systemic!absorption!and!significantly!improved!adverse!effect! profiles! compared! to! alternative! administration! routes1.! Despite! its!advantages,!IDD!has!several!inherent!limitations!including!the!low!permeability!of!the! urothelium2,! the! continual! dilution! of! the! instilled! dose! by! urine! and! the!limited!capacity!of!the!bladder!and!hence!low!residence!time!of!the!dose3.!IDD!has!been! used! successfully! to! manage! a! wide! range! of! conditions! such! as! bladder!cancer4,! interstitial! cystitis! /! painful! bladder! syndrome5! and! overactive! bladder!(OAB)6! and! continues! to! be! investigated! for! novel! indications7.! Despite! this! the!majority!of!IDD!regimens!remain!empirically!designed!and!as!a!result!its!potential!largely!unfulfilled.!!!When! researching! this! project! it! became! apparent! that! there! was! limited!information!available!in!the!literature!regarding!bladder!wall!drug!concentrations!achieved!following!IDD.!Although!there!were!many!IDD!clinical!studies,!there!was!no! information!detailing!desired! target! tissue!concentrations! in! the!bladder!wall.!There! continues! to! be! very! few! groups!working! in! this! field.! Such! shortcomings!underpinned! the!motivation! for! Boston! Scientific! Corporation! (BSC)! to! instigate!this! research! project.! BSCs! ketorolac! –! eluting! ureteral! stent! (Lexington™)!unexpectedly!failed!to!meet!its!primary!clinical!endpoint8,!despite!preliminary!IDD!studies! showing! the! agent! was! effective! in! the! management! of! ureteral! stent! –!related!discomfort9.! It!was! theorised! that! drug! release! from! the! stent!was! likely!insufficient! to! establish! effective! target! tissue! concentrations.! Subsequently! BSC!decided!a!bottom!–!up!approach!to!investigate!the!viability!of!delivering!ketorolac!locally!to!the!urinary!tract!was!necessary.!The!original!aims!of!this!project!were!to!investigate! the! local! delivery! of! ketorolac! to! the! urinary! tract,! determine! drug!release! characteristics! from! the! Lexington™! stent! and! investigate! /! suggest!improved!techniques!for!stent!formulation.!!Chapter!two!of!this!thesis!focused!on!the!development!of!an!ex#vivo!porcine!model!to! investigate! the! transurothelial! permeability! and! bladder! wall! distribution! of!
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drugs! after! their! local! application! to! the! urothelium.! This! research! group! had!limited! experience! in! the! urology! area! and! subsequently! new! experimental!techniques! and! procedures! were! devised.! This! provided! many! challenges!including:!how!to!obtain!and!efficiently!transport!the!porcine!tissue,!how!to!ensure!and! evaluate! that! the! barrier! function! of! urothelium! was! maintained! during!experimental! conditions,! how! to! generate!drug!permeability! parameters,! how! to!investigate!drug!distribution! in! the!bladder!wall! and!how! to! extract! and!analyse!low!concentrations!of!drug!in!complex!tissue!medium.!Ex#vivo!porcine!tissue!was!chosen!owing! to! the!history!of!pigs!being!used!as! animal!models! in!urology10.!A!wide! range! of! techniques! were! used! to! validate! the! integrity! of! the! urothelial!barrier! including:! investigating!markers!of!permeation,!measuring!transepithelial!resistance! (TEER)! and! examining! the! urothelial! surface! using! scanning! electron!microscopy!(SEM).! In! line!with!similar!work!carried!out! in! the!transdermal! field,!early! transurothelial! permeation! studies! were! performed! on! isolated! bladder!mucosa!(urothelium!and!lamina!propria).!Ideally,!isolated!urothelium!would!be!the!tissue!of!choice,!however!owing!to!the!thickness!of!the!urothelium!(~!200!µm)!and!the!delicate!nature!of!the!single!layer!of!umbrella!cells,!this!was!not!feasible.!The!mucosal! protocol! was! then! superseded! by! a! simpler! technique! that! used! full!thickness! bladder!wall! followed! by!washing! of! the! urothelial! surface.! Using! this!technique!any!remaining!surface!Z!adsorbed!drug!was!within!error!of!the!amount!of! drug! extracted! from! the! tissue.! It! also! negated! the! need! to! manipulate! and!potentially!damage!the!urothelium!that!was!necessary!to!isolate!the!mucosa.!This!then! lead! to! further! experimental! development! focused! on! drug! extraction! and!analysis!from!the!bladder!wall.!Extracting!and!quantifying!drug!in!tissue!medium!is!inherently! more! complicated! and! challenging! than! doing! so! in! ‘clean’!environments!such!as!saline!or!Krebs.!Potential!problems!include!incomplete!drug!extraction!and!interfering!peaks!/!reduced!sensitivity!during!HPLC!–!UV!analysis.!Consequently!significant!time!and!effort!went!into!the!design!and!optimisation!of!HPLC!methods! during! this! thesis.! At! this! time! a! concentration! –! depth! profiling!technique!was! optimised! that! allowed! the! determination! of! drug! concentrations!throughout! the! bladder! wall.! Although! this! technique! had! been! reported! in! the!literature,!it!had!only!been!used!by!a!small!number!of!groups!and!was!new!to!this!research! group.! Mimicking! the! dosing! concentration! of! ketorolac! shown! to! be!clinically! effective! in# vivo,# concentration! –! depth! profiles! were! generated! in! the!
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bladder! wall! and! compared! to! literature! sourced! IC50! values.! Results! suggested!intravesical! ketorolac! would! result! in! efficacious! target! concentrations! in! the!bladder!wall11.!Considering!this,!it!is!likely!that!the!Lexington™!stent!failed!owing!to! poor! drug! release! from! the! device! rather! than! an! incorrect! choice! of! drug.!Follow! up! studies! planned! to! investigate! different! techniques! of! drug! –! stent!loading!and!determine!drug!release!profiles!over!the!course!of!stent!use.!!!Approximately! one! year! into! this! project! the! focus! of! BSC’s! research! and!development!division!shifted!and!drug!release!studies!from!the!Lexington™!stent!were! postponed.! The! overarching! aim! of! this! project! evolved! to! focus! on!investigating! the! transurothelial! delivery! of! clinically! relevant! molecules! and!developing!strategies!to!maximise!the!potential!of!IDD.!!In! chapter! three! ex# vivo! work! was! extended! to! include! a! whole! bladder! setup!allowing! the! incorporation! of! urine! dilution.! This! was! the! first! time! urine!production! had! been! incorporated! into! ex# vivo! IDD! studies.! ! Artificial! urine!was!added! to! the! bladder! at! a! physiological! rate! and! concentration! –! depth! profiles!determined! following! the! IDD!of!oxybutynin.!A! significant! challenge! in! this!work!concerned! the!analysis!of!oxybutynin.!Originally!HPLC!was!used!as! the!detection!method,! however! oxybutynin! has! a! poor! chromophore! and! shows! maximum!absorbance!at!210!nm12.!At!this!wavelength!there!is!significant!interference!from!other! molecules! in! homogenised! tissue! and! consequently! UV! detection! was!unsuitable! for!sensitive!quantification12.!Consequently!oxybutynin!was!measured!by!HPLC!–!MS,!which!significantly!increased!the!sensitivity!at!which!the!drug!could!be! quantified! (LLOQ! of! 3! ng! mlY1! compared! to! ~! 250! ng! mlY1! using! HPLC! –! UV!detection).!!Intravesical!oxybutynin!is!highly!efficacious!in!the!management!of!OAB!in!patients!refractory!to!oral!treatment13!and!is!used!extensively!for!this!indication14.!Despite!this,! the! mechanism! of! action! (MOA)! is! unclear.! Originally! believed! to! act! by!directly! inhibiting!M3!muscarinic! receptors! in! the! detrusor!muscle,! there! is! now!significant! evidence! that! antimuscarinics! activate! muscarinic! receptors! at! the!urothelial! and! /! or! suburothelial! level! to! modulate! the! afferent! arc! of! the!micturition!cycle15.!Ex#vivo!studies!showed!that!despite!permeating!the!urothelium!at!a!high!rate! in!comparison! to!ketorolac,!oxybutynin!concentrations!achieved! in!
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the!detrusor!muscle!were!significantly!lower!than!reported!IC50!values!suggesting!target! concentrations! achieved! post! –! IDD! would! not! be! sufficient! to! directly!inhibit! detrusor! contraction.! Unfortunately! this! work! did! not! concomitantly!investigate!detrusor!muscle!contractility!with!drug!concentrations!achieved!in!the!bladder! wall.! This! was! a! real! shame! and! had! it! been! feasible! would! have!contributed! to! the! impact! of! this! work.! Looking! forward,! the! incorporation! of!concomitant! pharmacology! studies,! whether! performed! in! H! house! or! in!collaboration! with! partners,! is! essential! to! eliciting! the! MOA! in! studies! such! as!these.!!!Chapter!four!documented!the!design!of!a!computer!–!based!pharmacokinetic!(PK)!model! of! IDD.! Originally! the!model! was! designed! to! incorporate! drug! clearance!from! the!bladder!wall! into! the!ex#vivo! studies.!However! it! became! clear! that! the!usefulness!of!the!model!was!actually!its!ability!to!compare!the!efficacy!of!different!IDD! regimens.! It! was! evident! from! the! literature! that! the! majority! of! regimens!were!designed!without!consideration!of!the!variables!associated!with!IDD!such!as!instillation! volume,! concentration! or! length.! The!model! provided! a! platform! for!these! variables! to! be! investigated.! The! model! was! built! using! STELLA®!which!allows!mathematical!models!to!be!designed!diagrammatically!rather!than!by!high!–!level! programming! code.! This! work! was! in! part! assisted! by! Yuri! Anissimov,! a!mathematician! who! has! published! extensively! in! the! field! of! mathematical!modelling! of! biological! processes16–20.! This! collaboration! was! initiated! after! the!original!design!of!the!PK!model.!It!was!deemed!important!to!consult!the!expertise!of!a!mathematician!who!is!at!the!forefront!of!this!niche!area!of!research.!Yuri!was!able! assist! with! the! choice! of! the! underlying! diffusion! equations! and! validate!outputs! generated! by! the! STELLA®! model! using! PYTHON™,! a! widely! used!programming! language.! Using! the!model,! the! key! variables! associated! with! IDD!were! investigated! and! their! contribution! to! the! efficacy! of! the! IDD! process!evaluated.!To!demonstrate! the!usefulness!of! the!model!an! IDD!regimen! from!the!literature!was!optimised!using!techniques!highlighted!by!the!model!and!significant!improvements!predicted.!Currently!the!value!of!the!model!lies!not!in!its!ability!to!predict! in#vivo!bladder!concentrations!achieved!after! IDD,!but! rather! to!highlight!comparative! differences! between! regimens! and! dosing! variables.! In! the! future,!validation!of!the!models!ability!to!predict!in#vivo!bladder!wall!concentrations!could!
! Chapter!Six:!General!Discussion!!!
! 253!
only!be!achieved!through! in#vivo!pig!studies.!Urine!concentrations!however!could!be!validated!clinically!using!patient!urine!samples!from!IDD!regimens.!!The!final!chapter!of!this!thesis!extended!transurothelial!permeability!studies!to!the!upper! urinary! tract.! In! addition! to! treating! urothelial! carcinoma! of! the! bladder,!topical! mitomycin! C! (MMC)! is! suggested! to! be! efficacious! in! reducing! the!recurrence!of! upper! tract! urothelial! carcinoma! (UTUC)21–24.! Interestingly!despite!evidence!that!protein!expression!on!the!surface!of!the!urothelial!umbrella!cells!is!not! consistent25,26,! no! groups! had! previously! investigated! the! hypothesis! that!urothelium! barrier! function! differs! at! these! distinct! locations.! Ex# vivo! studies!showed! conclusively! that! the! urothelium! of! the! ureter! was! significantly! more!permeable!to!MMC!than!the!bladder!and!that!urothelial!concentrations!achieved!in!the!upper!urinary!tract!were!significantly!higher.!The!reasoning!for!this!disparity!might!be!explained!by!the!relative!distribution!and!density!of!uroplakin!plaques!in!the!upper!and!lower!porcine!urinary!tract!as!has!been!shown!in!other!mammals.!This! research! is! particularly! interesting! as! a! more! permeable! urothelium! may!provide!higher!target!tissue!concentrations!after!local!delivery!and!subsequently!a!significant!opportunity!to!manage!UTUC!conservatively.!Ideally!future!work!would!mirror! these! studies! in! human! tissue,! however! owing! to! the! ethical! approval!necessary!and! the! limited! supply!of!whole!urinary! tract!organs! this! is! extremely!unlikely.! In# vivo! studies! in! large! mammals! such! as! pigs! require! substantial!resources,!however!if!feasible!they!would!be!an!exciting!next!step!in!which!to!take!this!research.!!!The!bladder!offers!a!unique!opportunity!for!the!local!delivery!of!therapies.!It!is!one!of! a! small! number! of! organs! that! can! conveniently! and!minimally! invasively! be!accessed.! IDD! is! seemingly! well! placed! as! a! method! for! delivering! high!concentrations!of!drug!directly!to!the!bladder!and!has!been!used!to!manage!a!wide!range!of!bladder!conditions.!!It!was!therefore!surprising!to!discover!that!very!little!was! known! about! the! permeability! and! tissue! distribution! of! drugs! following!topical!application.!Whereas!other!significant!barriers!to!drug!delivery,!such!as!the!stratum! corneum! and! blood! brain! barrier,! had! been! extensively! studied,!information!on!the!urothelium!was!extremely! limited.! !This!project!originally!set!out! to! evaluate! the! potential! of! drug! eluting! ureteral! stents! for! delivering! drugs!
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out! to! evaluate! the! potential! of! drug! eluting! ureteral! stents! for! delivering! drugs!directly! to! the! urinary! tract.! However! it! soon! became! clear! that! rational! device!design,!in!particular!drug!loading!and!release!rates,!was!hampered!by!the!paucity!of! information! defining! the! urothelial! barrier.! Therefore! the! project! naturally!evolved!to!explore!the!fundamental!issues!of!transurothelial!permeability!and!drug!distribution! following! topical! delivery.! ! From! here! several! novel! ex# vivo! and! in#
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